metformin has been researched along with Inflammation in 324 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin has anti-inflammatory effects through multiple routes, which provides potential therapeutic targets for certain inflammatory diseases, such as neuroinflammation and rheumatoid arthritis." | 9.41 | Role of metformin in inflammation. ( Feng, YY; Pang, H; Wang, Z, 2023) |
| " This study aimed to evaluate the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin on the biomarkers of inflammation, thrombosis, and atherosclerosis in T2DM patients with symptomatic coronary artery disease (CAD)." | 9.34 | Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease. ( Kabel, M; Mostafa, T; Omran, G; Shokry, A; Werida, R, 2020) |
| "The objective was to determine the effect of metformin on the concentrations of resistin and other markers of insulin resistance or inflammation (C-reactive protein, cytokines, body weight, HbA1c, among others) in minors with glucose intolerance." | 9.16 | Metformin decreases plasma resistin concentrations in pediatric patients with impaired glucose tolerance: a placebo-controlled randomized clinical trial. ( Aguilar-Salinas, CA; Cruz, M; Gómez-Díaz, RA; Mondragón-González, R; Ortiz-Navarrete, FV; Pool, EC; Solórzano-Santos, F; Talavera, JO; Valladares-Salgado, A; Wacher, NH, 2012) |
| "We plan to prospectively investigate the effects of dipeptidyl peptidase-4 inhibition with vildagliptin on a number of atherothrombotic markers and adipokines in patients with proven atherosclerosis and type 2 diabetes." | 9.16 | Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease. ( Fisman, EZ; Goldenberg, I; Klempfner, R; Leor, J; Tenenbaum, A, 2012) |
| " This study investigates the impact of a pioglitazone plus metformin therapy on biomarkers of inflammation and platelet activation in comparison to a treatment with glimepiride plus metformin." | 9.15 | The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study. ( Forst, T; Fuchs, W; Hohberg, C; Lehmann, U; Löbig, M; Müller, J; Musholt, PB; Pfützner, A; Schöndorf, T, 2011) |
| "The aim of this study was to evaluate the effect of exenatide compared to glimepiride on body weight, glycemic control and insulin resistance in type 2 diabetic patients taking metformin." | 9.15 | Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. ( Bonaventura, A; Bossi, AC; Derosa, G; Fogari, E; Franzetti, IG; Guazzini, B; Maffioli, P; Putignano, P; Querci, F; Testori, G, 2011) |
| "To compare the effect of addition of pioglitazone and acarbose to sulphonylureas and metformin therapy on metabolic parameters and on markers of endothelial dysfunction and vascular inflammation in type 2 diabetic patients." | 9.14 | Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Gravina, A; Maffioli, P; Mereu, R; Palumbo, I; Randazzo, S; Salvadeo, SA, 2010) |
| "To study the effect of simvastatin and metformin on insulin sensitivity and inflammatory markers." | 9.12 | Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. ( Bulcão, C; Ribeiro-Filho, FF; Roberta Ferreira, SG; Sañudo, A, 2007) |
| "We compared the vascular effects of rosiglitazone versus glyburide and evaluated asymmetric dimethylarginine (ADMA) and oxidative stress as potential mechanisms associated with changes in vascular health in patients with type 2 diabetes mellitus (T2DM)." | 9.12 | Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus. ( Bank, AJ; Gonzalez-Campoy, JM; Kaiser, DR; Kelly, AS; Thelen, AM, 2007) |
| " The Diabetes Prevention Program (DPP) clinical trial studied the effect of an intensive lifestyle intervention or metformin on progression to diabetes relative to placebo in 3,234 adults with impaired glucose tolerance." | 9.11 | Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. ( Barrett-Connor, E; Crandall, J; Fowler, S; Goldberg, R; Haffner, S; Horton, E; Marcovina, S; Mather, K; Orchard, T; Ratner, R; Temprosa, M, 2005) |
| "To discussing metformin effects on rheumatoid arthritis complications." | 9.01 | Metformin one in a Million Efficient Medicines for Rheumatoid Arthritis Complications: Inflammation, Osteoblastogenesis, Cardiovascular Disease, Malignancies. ( Haybar, H; Mowla, K; Rajaei, E; Zayeri, ZD, 2019) |
| "Observational studies show a beneficial effect of adjuvant metformin therapy on breast cancer survivals, but data from randomized clinical trials are lacking." | 9.01 | The effect of metformin on biomarkers and survivals for breast cancer- a systematic review and meta-analysis of randomized clinical trials. ( Bi, Y; Liu, Y; Wang, C; Yuan, J; Zhang, ZJ, 2019) |
| " In this context, metformin has been shown to not only contribute to a better glycaemic control but also to induce some weight loss (especially in the visceral depot) which may contribute to the improvement of the features of the metabolic syndrome." | 8.82 | Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. ( Després, JP, 2003) |
| "This study aimed to characterize aging-induced tendinopathy in mouse Achilles tendon and also to assess the treatment effects of metformin (Met) on aging tendon." | 8.31 | Metformin improves tendon degeneration by blocking translocation of HMGB1 and suppressing tendon inflammation and senescence in aging mice. ( Brown, R; Hogan, MV; Onishi, K; Wang, JH; Zhang, J, 2023) |
| " Although several pharmacological interventions, including melatonin and metformin, have been reported to protect against various cardiovascular diseases, their potential roles in trastuzumab-induced cardiotoxicity remain elusive." | 8.31 | Melatonin and metformin ameliorated trastuzumab-induced cardiotoxicity through the modulation of mitochondrial function and dynamics without reducing its anticancer efficacy. ( Arinno, A; Arunsak, B; Chattipakorn, N; Chattipakorn, SC; Chunchai, T; Kerdphoo, S; Khuanjing, T; Maneechote, C; Nawara, W; Prathumsap, N; Shinlapawittayatorn, K, 2023) |
| "This study showed that some pathological changes occurring in the lungs of aged rats, such as hemorrhage, edema, and inflammation, improved after metformin treatment; the number of hepatocyte death increased in the AgCLP group, and decreased in the AgMET group." | 8.31 | Effect of metformin on sepsis-associated acute lung injury and gut microbiota in aged rats with sepsis. ( Duo, B; Liu, Y; Lu, Z; Niu, Y; Wan, Y; Wang, S; Zhu, R, 2023) |
| " The potential protective outcome of the antidiabetic and pleiotropic drug metformin against TAA-induced chronic kidney disease in association with the modulation of AMP-activated protein kinase (AMPK), oxidative stress, inflammation, dyslipidemia, and systemic hypertension has not been investigated before." | 8.31 | Metformin Suppresses Thioacetamide-Induced Chronic Kidney Disease in Association with the Upregulation of AMPK and Downregulation of Oxidative Stress and Inflammation as Well as Dyslipidemia and Hypertension. ( Al-Ani, B; Albawardi, A; Alqahtani, SM; Alshahrani, MY; Bayoumy, NM; Ebrahim, HA; Haidara, MA; Kamar, SS; ShamsEldeen, AM, 2023) |
| " Metformin (MET) is an oral hypoglycemic agent that activates AMPK-regulated signaling pathways and inhibits inflammation and oxidative stress responses." | 8.31 | Protective role of metformin in preeclampsia via the regulation of NF-κB/sFlt-1 and Nrf2/HO-1 signaling pathways by activating AMPK. ( He, L; Li, X; Wu, J; Wu, X; Zhan, F, 2023) |
| "Twelve-month metformin treatment reduced fat content, waist circumference, glycated hemoglobin, glucose and triglycerides, as well as improved insulin sensitivity." | 8.12 | Impaired metabolic effects of metformin in men with early-onset androgenic alopecia. ( Kowalcze, K; Krysiak, R; Okopień, B, 2022) |
| " Consequently, we aimed to investigate the effects of metformin, letrozole, and atorvastatin on inflammation and apoptosis in experimentally induced ovarian and peritoneal endometriosis in rat models." | 8.12 | Effects of metformin, letrozole and atorvastatin on inflammation and apoptosis in experimental peritoneal and ovarian endometriosis in the rat. ( Coskun, G; Efendic, F; Erdem, E; Hayretdag, C; Irkorucu, O; Keles, P; Kuras, S; Pence, HH; Polat, S; Saker, D; Sapmaz, E; Sapmaz, T; Sevgin, K; Tekayev, M; Topkaraoglu, S, 2022) |
| " The present study compared the impact of low-grade systemic inflammation and insulin resistance on levothyroxine action in subjects with this disorder." | 8.12 | Thyroid Antibody Titers and Hypothalamic-Pituitary-Thyroid Axis Activity in Levothyroxine-Treated Women With Autoimmune Subclinical Hypothyroidism Receiving Atorvastatin or Metformin. ( Kowalcze, K; Krysiak, R; Okopień, B, 2022) |
| "The results showed that CGA decreased body weight and improved glucose tolerance and insulin resistance, and these effects were similar to those of metformin." | 8.12 | Chlorogenic acid improves glucose tolerance, lipid metabolism, inflammation and microbiota composition in diabetic db/db mice. ( Guo, K; Li, Q; Shen, L; Yan, Y; Zhou, X, 2022) |
| "Metformin, traditionally regarded as a hypoglycemic drug, has been studied in other various fields including inflammation." | 8.02 | Metformin alleviates inflammation through suppressing FASN-dependent palmitoylation of Akt. ( Sun, KY; Xiong, W; Zhang, X; Zhou, YH; Zhu, Y; Zou, X, 2021) |
| "The present study evaluated the effects of dapagliflozin, a SGLT2 inhibitor, or dapagliflozin plus metformin versus metformin monotherapy in patients with metabolic syndrome." | 8.02 | Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome. ( Cheng, L; Fan, Y; Fu, Q; Lin, W; Liu, F; Wu, X; Zhang, X; Zhou, L, 2021) |
| "The present study aimed to investigate the possible effects of metformin on the olanzapine-induced insulin resistance in rats." | 8.02 | Metformin ameliorates olanzapine-induced insulin resistance via suppressing macrophage infiltration and inflammatory responses in rats. ( Guo, C; Li, H; Liu, J, 2021) |
| "Our findings suggest that in CLP induced sepsis model, metformin can improve the function of blood and cardiac cells through alleviating inflammation, improvement of anti-inflammation properties, and enhancement of blood profile, and all these effects are more pronounced after 24 h in comparison with 12 h after induction of sepsis." | 8.02 | Short-term Effects of Metformin on Cardiac and Peripheral Blood Cells Following Cecal Ligation and Puncture-induced Sepsis. ( Abdollahi, M; Baeeri, M; Didari, T; Gholami, M; Haghi-Aminjan, H; Hassan, FI; Hassani, S; Mojtahedzadeh, M; Navaei-Nigjeh, M; Nejad, SM; Rahimifard, M, 2021) |
| " Metformin has potential effects on improving asthma airway inflammation." | 8.02 | Metformin alleviates allergic airway inflammation and increases Treg cells in obese asthma. ( Chen, M; Guo, Y; Hong, L; Jiang, S; Liu, S; Shi, J; Wang, Q; Yuan, X, 2021) |
| "It is revealed that metformin alleviated inflammation and underlying mechanism may result from inhibition of SPHK1/S1P signaling pathway." | 8.02 | Metformin alleviates inflammation in oxazolone induced ulcerative colitis in rats: plausible role of sphingosine kinase 1/sphingosine 1 phosphate signaling pathway. ( Abu-Risha, SE; El-Kadem, AH; El-Mahdy, NA; El-Sayad, ME, 2021) |
| " Based on metformin and other anti-diabetic agent prescriptions, we categorized all patients with autoimmune diseases into either the metformin group (metformin administration for at least 28 days) or the non-metformin group." | 8.02 | Reduced Mortality Associated With the Use of Metformin Among Patients With Autoimmune Diseases. ( Chen, TH; Hsu, CY; Lin, CY; Lin, MS; Lin, YS; Su, YJ; Wu, CH, 2021) |
| "Although the beneficial effects of metformin (MET) and genistein in ameliorating inflammation have been elucidated, their combined impacts on skeletal muscle inflammation have not been clearly understood." | 8.02 | Metformin in combination with genistein ameliorates skeletal muscle inflammation in high-fat diet fed c57BL/6 mice. ( Aliabadi, M; Meshkani, R; Panahi, G; Tehrani, SS; Zamani-Garmsiri, F, 2021) |
| " We aimed to confirm the correlation between SFRP5, metabolic inflammation and PCOS, investigate the predictive value of SFRP5 for PCOS and the involvement of SFRP5 in metformin treated PCOS." | 8.02 | Decreased SFRP5 correlated with excessive metabolic inflammation in polycystic ovary syndrome could be reversed by metformin: implication of its role in dysregulated metabolism. ( Chen, Y; Geng, L; Hu, J; Huang, H; Kong, L; Qi, H; Ran, Y; Zhang, H; Zhang, Y, 2021) |
| "We found a possible mechanism that metformin could reduce inflammation and apoptosis, and promote functional recovery of SCI rats through activating Wnt/β-catenin signaling pathway." | 7.96 | Therapeutic effect of metformin on inflammation and apoptosis after spinal cord injury in rats through the Wnt/β-catenin signaling pathway. ( Gao, K; Li, K; Lv, C; Wang, F; Zhang, T, 2020) |
| "Metformin beneficially impacts several aspects of metabolic syndrome including dysglycemia, obesity, and liver dysfunction, thus making it a widely used frontline treatment for early-stage type 2 diabetes, which is associated with these disorders." | 7.91 | Amelioration of metabolic syndrome by metformin associates with reduced indices of low-grade inflammation independently of the gut microbiota. ( Adeshirlarijaney, A; Chassaing, B; Gewirtz, AT; Tran, HQ; Zou, J, 2019) |
| " We found that, in ultra-high-molecular-weight polyethylene particle-induced osteolysis mouse models, metformin had bone protect property and reduced the negative regulator of bone formation sclerostin (SOST) and Dickkopf-related protein 1 (DKK1), and increased osteoprotegerin (OPG) secretion and the ratio of OPG/Receptor Activator for Nuclear Factor-κB Ligand (RANKL)." | 7.91 | Metformin protects bone mass in ultra-high-molecular-weight polyethylene particle-induced osteolysis by regulating osteocyte secretion. ( Cao, X; Lu, Z; Tian, X; Wei, D; Yan, Z; Ye, Z; Zhai, D; Zhu, Q; Zhu, S; Zhu, Z, 2019) |
| "The present study aimed to investigate the possible effects of metformin on the progression of atherosclerosis in a rabbit model." | 7.88 | Metformin ameliorates the progression of atherosclerosis via suppressing macrophage infiltration and inflammatory responses in rabbits. ( Chen, J; Chen, M; Qu, J; Ren, W; Sun, S; Tang, X; Wang, H; Yang, Q; Yu, B; Yuan, H, 2018) |
| " Metformin (MET) is a potent combination drug to elevate anti-TB efficacy and able to regulate inflammation." | 7.88 | Metformin associated inflammation levels regulation in type 2 diabetes mellitus-tuberculosis coinfection patients - A case report. ( Novita, BD; Nugraha, J; Soediono, EI, 2018) |
| "To evaluate the effects of metformin (Met) on inflammation, oxidative stress, and bone loss in a rat model of ligature-induced periodontitis." | 7.85 | Effects of metformin on inflammation, oxidative stress, and bone loss in a rat model of periodontitis. ( Araújo Júnior, RF; Araújo, AA; Araújo, LS; Brito, GAC; Guedes, PMM; Hiyari, S; Leitão, RFC; Medeiros, CACX; Pereira, ASBF; Pirih, FQ, 2017) |
| " This study investigated the effects of scopoletin on hepatic steatosis and inflammation in a high-fat diet fed type 1 diabetic mice by comparison with metformin." | 7.85 | Scopoletin Supplementation Ameliorates Steatosis and Inflammation in Diabetic Mice. ( Cho, HW; Choi, MS; Choi, RY; Ham, JR; Kim, MJ; Lee, HI; Lee, J; Lee, MK; Park, SK; Seo, KI, 2017) |
| "Oral administration of metformin or resveratrol prevented hypoxia and reduced HIF-1α accumulation with dephosphorylation of inositol-requiring enzyme 1α and eukaryotic initiation factor 2α, indicative of suppression of hypoxic HIF-1α activation and endoplasmic reticulum stress." | 7.83 | The role of metformin and resveratrol in the prevention of hypoxia-inducible factor 1α accumulation and fibrosis in hypoxic adipose tissue. ( Huang, F; Kou, J; Li, A; Li, J; Li, X; Liu, B; Liu, K; Qi, LW; Qiu, Z; Wang, L, 2016) |
| "This study aims to investigate the effects of metformin and resveratrol on muscle insulin resistance with emphasis on the regulation of lipolysis in hypoxic adipose tissue." | 7.83 | Metformin and resveratrol ameliorate muscle insulin resistance through preventing lipolysis and inflammation in hypoxic adipose tissue. ( Feng, X; Hou, T; Li, A; Liu, B; Liu, K; Zhang, N; Zhao, W, 2016) |
| "We investigated the effects of metformin and celecoxib on obesity-induced adipose tissue inflammation, insulin resistance (IR), fatty liver, and high blood pressure in high-fat (HF) fed rats." | 7.83 | Additional effect of metformin and celecoxib against lipid dysregulation and adipose tissue inflammation in high-fat fed rats with insulin resistance and fatty liver. ( Hsieh, PS; Hung, YJ; Lu, CH, 2016) |
| "Accumulating evidence suggests that chronic metformin preconditioning offers potent neuroprotective effects against ischemic stroke." | 7.81 | Chronic Metformin Preconditioning Provides Neuroprotection via Suppression of NF-κB-Mediated Inflammatory Pathway in Rats with Permanent Cerebral Ischemia. ( Cao, L; Ding, ZZ; Jiang, T; Tan, L; Tan, MS; Wang, HF; Yu, JT; Zhang, QQ; Zhu, XC, 2015) |
| " Inflammation and coagulation are closely associated pathological processes, therefore the potential effects of metformin on key steps in activation of the coagulation system were further investigated in endotoxic hepatitis induced by lipopolysaccharide/D‑galactosamine (LPS/D‑Gal)." | 7.81 | Metformin suppresses intrahepatic coagulation activation in mice with lipopolysaccharide/D‑galactosamine‑induced fulminant hepatitis. ( Ai, Q; Ao, JE; Duan, R; Ge, P; Gong, X; Lin, L; Zhang, L, 2015) |
| " To better understand the pathophysiology of obesity-associated NAFLD, the present study examined the involvement of liver and adipose tissues in metformin actions on reducing hepatic steatosis and inflammation during obesity." | 7.80 | Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity. ( An, X; Botchlett, R; Chen, L; Guo, T; Guo, X; Hu, X; Huo, Y; Li, H; Li, Q; Pei, Y; Qi, T; Woo, SL; Wu, C; Xiao, X; Xu, H; Xu, Y; Zhao, J; Zhao, Y; Zheng, J, 2014) |
| "Diet induced-obesity/metabolic syndrome during pregnancy significantly enhanced fetal and placental cytokine production; maternal metformin reduced fetal cytokine levels." | 7.79 | Maternal metformin treatment decreases fetal inflammation in a rat model of obesity and metabolic syndrome. ( Chatterjee, PK; Desai, N; Gupta, M; Metz, CN; Rochelson, B; Roman, A; Tam Tam, H; Xue, X, 2013) |
| "Metformin is widely used for treatment of type 2 diabetes and has a potential application on the treatment of inflammation and cancer." | 7.79 | Blockade of reactive oxygen species and Akt activation is critical for anti-inflammation and growth inhibition of metformin in phosphatase and tensin homolog-deficient RAW264.7 cells. ( Bai, CH; Chien, YC; Lai, HW; Liao, CS; Lin, CF; Ma, CT; Su, HC; Tsao, CW; Wang, HY; Young, KC; Yu, BC, 2013) |
| " The AMP-activated protein kinase (AMPK) activator metformin reverses obesity-associated insulin resistance (IR) and inhibits different types of inflammatory responses." | 7.79 | Metformin attenuates the exacerbation of the allergic eosinophilic inflammation in high fat-diet-induced obesity in mice. ( André, DM; Anhê, GF; Antunes, E; Bordin, S; Calixto, MC; Ferreira, D; Landgraf, RG; Leiria, LO; Lellis-Santos, C; Lintomen, L, 2013) |
| " The aim of this study was to evaluate the effects of rosuvastatin and metformin on inflammation and oxidative stress in patients with hypertension and dyslipidemia." | 7.74 | [Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia]. ( Alvarez-Aguilar, C; Gómez-García, A; Martínez Torres, G; Ortega-Pierres, LE; Rodríguez-Ayala, E, 2007) |
| "Metformin and placebo were administered orally for 12 weeks in escalating doses: 850 mg/day for the first 5 days, 850 mg twice a day for the next 5 days, and 850 mg three times a day subsequently." | 6.94 | Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial. ( Ajjan, R; Ajodha, S; Akanle, O; Bestwick, JP; Christ-Crain, M; Fraser, W; Gabrovska, P; Grossman, AB; Kelly, S; Kola, B; Korbonits, M; Pernicova, I; Pitzalis, C; Sahdev, A; Stadler, M, 2020) |
| "Inflammation is one biological mechanism hypothesized to mediate these associations." | 6.94 | Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial. ( Abrams, TA; Brown, JC; Campbell, N; Cartmel, B; Douglas, PS; Fuchs, CS; Harrigan, M; Hu, FB; Irwin, ML; Jones, LW; Ligibel, JA; Meyerhardt, JA; Ng, K; Pollak, MN; Sanft, T; Sorrentino, A; Tolaney, SM; Winer, EP; Zhang, S, 2020) |
| "Chronic low-grade inflammation is a common feature of insulin resistant states, including obesity and type 2 diabetes." | 6.78 | Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment. ( Aroda, V; Ciaraldi, TP; Henry, RR; Mudaliar, SR, 2013) |
| "Pioglitazone has demonstrated a favorable CV profile relative to other oral antidiabetic drugs (OADs) in outcome and observational studies." | 6.75 | Effects of pioglitazone and metformin fixed-dose combination therapy on cardiovascular risk markers of inflammation and lipid profile compared with pioglitazone and metformin monotherapy in patients with type 2 diabetes. ( Arora, V; Jacks, R; Perez, A; Spanheimer, R, 2010) |
| "Metformin is an oral hypoglycemic agent which is most widely used as first-line therapy for type 2 diabetes." | 6.52 | Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect. ( Saisho, Y, 2015) |
| "Metformin and aspirin have been explored as two emerging cancer chemoprevention agents for different types of cancers, including pancreatic cancer." | 6.50 | Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment. ( DiPaola, RS; Tan, XL; Yang, CS; Yue, W, 2014) |
| " Future clinical trials are necessary to study the nephroprotective effects of the combined treatment at a low dosage in patients with diabetes." | 6.44 | Dapagliflozin and metformin in combination ameliorates diabetic nephropathy by suppressing oxidative stress, inflammation, and apoptosis and activating autophagy in diabetic rats. ( Htun, KT; Jaikumkao, K; Kothan, S; Lungkaphin, A; Montha, N; Pengrattanachot, N; Phengpol, N; Promsan, S; Sriburee, S; Sutthasupha, P; Thongnak, L, 2024) |
| "Metformin (MET) has been demonstrated to have favorable impact on nonalcoholic fatty liver disease (NAFLD); however, the combined effect of this drug with p-coumaric acid (PCA) on liver steatosis is unclear." | 5.91 | Combination therapy of metformin and p-coumaric acid mitigates metabolic dysfunction associated with obesity and nonalcoholic fatty liver disease in high-fat diet obese C57BL/6 mice. ( Bahramzadeh, A; Goodarzi, G; Meshkani, R; Panahi, G; Tehrani, SS, 2023) |
| "Metformin, a clinical agent of type 2 diabetes, is reported as a potential geroprotector." | 5.72 | Metformin Protects Against Inflammation, Oxidative Stress to Delay Poly I:C-Induced Aging-Like Phenomena in the Gut of an Annual Fish. ( Hou, Y; Li, G; Li, S; Liu, K; Qiao, M; Sun, X; Zhu, H, 2022) |
| "Metformin is an oral hypoglycemic drug widely used in the management of type 2 diabetes mellitus." | 5.72 | Metformin effect in models of inflammation is associated with activation of ATP-dependent potassium channels and inhibition of tumor necrosis factor-α production. ( Augusto, PSA; Batista, CRA; Bertollo, CM; Braga, AV; Coelho, MM; Costa, SOAM; Dutra, MMGB; Machado, RR; Matsui, TC; Melo, ISF; Morais, MI; Rodrigues, FF, 2022) |
| "Metformin has potential anti-inflammatory properties and accelerates wound healing by enhancing vascular development." | 5.72 | Metformin regulates macrophage polarization via the Shh signaling pathway to improve pulmonary vascular development in bronchopulmonary dysplasia. ( Chen, Y; Lin, Z; Qu, X; Xia, H; Xiang, X; Zhou, L, 2022) |
| "Metformin alone reduced hyperinsulinemia and circulating c-reactive protein, but exacerbated nephropathy." | 5.72 | Rapamycin/metformin co-treatment normalizes insulin sensitivity and reduces complications of metabolic syndrome in type 2 diabetic mice. ( Calcutt, NA; Doty, R; Flurkey, K; Harrison, DE; Koza, RA; Reifsnyder, PC, 2022) |
| "Cardiac fibrosis is a major structural change observed in the heart of patients with type 2 diabetes mellitus (T2DM), ultimately resulting in heart failure (HF)." | 5.72 | Gentiopicroside alleviates cardiac inflammation and fibrosis in T2DM rats through targeting Smad3 phosphorylation. ( Hu, XP; Huang, P; Huang, ZJ; Liu, T; Pan, ZF; Shi, JN; Sun, ZY; Xu, YN; Yuan, MN; Zhang, YW; Zou, XZ, 2022) |
| "Metformin is increasingly used to treat gestational diabetes (GDM) and pregnancies complicated by pregestational type 2 diabetes or polycystic ovary syndrome but data regarding long-term offspring outcome are lacking in both human studies and animal models." | 5.72 | Sex-specific effects of maternal metformin intervention during glucose-intolerant obese pregnancy on body composition and metabolic health in aged mouse offspring. ( Aiken, CE; Ashmore, TJ; Blackmore, HL; Dearden, L; Fernandez-Twinn, DS; Ozanne, SE; Pantaleão, LC; Pellegrini Pisani, L; Schoonejans, JM; Tadross, JA, 2022) |
| "Metformin has anti-inflammatory effects, but its role in the mechanism of treatment in intestinal injury caused by 5-Fu remains unclear." | 5.72 | Metformin ameliorates 5-fluorouracil-induced intestinalinjury by inhibiting cellular senescence, inflammation, and oxidative stress. ( Chen, J; Dai, Q; Ge, Y; He, S; Shi, YL; Vashisth, MK; Wang, XB; Xia, J, 2022) |
| "As metformin has multiple therapeutic effects in many autoimmune diseases, we explored the effects of metformin on TAO in an in vitro fibroblast model." | 5.72 | Metformin Attenuates Inflammation and Fibrosis in Thyroid-Associated Ophthalmopathy. ( Sha, X; Sun, A; Xiao, W; Xu, Z; Yang, H; Yang, S; Ye, H; Zhang, T, 2022) |
| "Metformin (MET) is a widely used hypoglycemic drug that exhibits anti-inflammatory properties." | 5.72 | Effects of metformin on lipopolysaccharide induced inflammation by activating fibroblast growth factor 21. ( Alataş, Ö; Kar, E; Öz, S; Şahıntürk, V, 2022) |
| "To compare body composition, visceral adiposity, adipocytokines, and low-grade inflammation markers in prepubertal offspring of mothers who were treated with metformin or insulin for gestational diabetes mellitus (GDM)." | 5.69 | Metformin versus insulin for gestational diabetes: Adiposity variables and adipocytokines in offspring at age of 9 years. ( Koskensalo, K; Loo, BM; Niinikoski, H; Nikkinen, H; Paavilainen, E; Parkkola, R; Rönnemaa, T; Tertti, K; Tossavainen, P; Vääräsmäki, M; Veijola, R, 2023) |
| "Metformin treatment markedly reduced postinfarction fibrotic remodeling and CD68-positive cell population in mice." | 5.62 | Metformin Attenuates Postinfarction Myocardial Fibrosis and Inflammation in Mice. ( Boal, F; Cussac, D; Korda, M; Kramar, S; Kunduzova, O; Laborde, C; Loi, H; Marsal, D; Oleshchuk, O; Pizzinat, N; Roncalli, J; Tronchere, H, 2021) |
| "Metformin is a kind of hypoglycemic drugs widely used in clinical practice, which has anti-inflammatory and antioxidant effects." | 5.62 | Metformin alleviates high glucose-induced ER stress and inflammation by inhibiting the interaction between caveolin1 and AMPKα in rat astrocytes. ( Chen, S; Cui, W; Li, J; Li, Y; Mao, L; Mei, X; Shao, Z; Wang, G; Wang, W, 2021) |
| "Non-alcoholic fatty liver disease (NAFLD) has become an important health problem in the world." | 5.62 | Combination of metformin and chlorogenic acid attenuates hepatic steatosis and inflammation in high-fat diet fed mice. ( Aliabadi, M; Emamgholipour, S; Ghasempour, G; Hashemnia, SMR; Meshkani, R; Zamani-Garmsiri, F, 2021) |
| "Metformin has exhibited anti-inflammatory and neuroprotective properties in numerous studies." | 5.62 | Metformin ameliorates the status epilepticus- induced hippocampal pathology through possible mTOR modulation. ( Anand, S; Bhatia, A; Bojja, SL; Joshi, R; Medhi, B; Minz, RW, 2021) |
| " We concluded that PD-CSNPs and PD ameliorate diabetic liver damage by modulating glucose transporter 2 expression, affecting the activity of carbohydrate metabolism enzymes, and suppressing oxidative stress and inflammation, PD-CSNPs being more efficient than PD, probably due to higher bioavailability and prolonged release." | 5.62 | Hepatoprotective Effects of Polydatin-Loaded Chitosan Nanoparticles in Diabetic Rats: Modulation of Glucose Metabolism, Oxidative Stress, and Inflammation Biomarkers. ( Abd El-Hameed, AM; Abd El-Twab, SM; Abdel-Moneim, A; El-Shahawy, AAG; Yousef, AI, 2021) |
| "Non-alcoholic fatty liver disease (NAFLD) is one of the primary causes of chronic liver disease and is closely linked to insulin resistance, type 2 diabetes mellitus (T2DM), and dyslipidemia." | 5.62 | Metformin in Combination with Malvidin Prevents Progression of Non-Alcoholic Fatty Liver Disease via Improving Lipid and Glucose Metabolisms, and Inhibiting Inflammation in Type 2 Diabetes Rats. ( Gu, X; Li, X; Zhang, C; Zhu, H; Zou, W, 2021) |
| "Inflammation is the first stage of this progression, becoming an appealing target of early therapeutic intervention." | 5.62 | Pharmacological activation of SIRT1 by metformin prevented trauma-induced heterotopic ossification through inhibiting macrophage mediated inflammation. ( Fan, C; He, Y; Li, J; Liu, W; Luo, G; Qian, Y; Sun, Z; Wang, F, 2021) |
| "Treatment with dapsone and metformin reversed the effects of testosterone in the DAP and MET groups." | 5.62 | The effect of dapsone in testosterone enanthate-induced polycystic ovary syndrome in rat. ( Dehpour, AR; Khaledi, E; Khazaei, M; Noori, T; Sadeghi, F; Shirooie, S; Sobarzo-Sánchez, E, 2021) |
| "Low-grade inflammation is often higher in older adults and remains a key risk factor of aging-related morbidities and mortalities." | 5.56 | Metformin Reduces Aging-Related Leaky Gut and Improves Cognitive Function by Beneficially Modulating Gut Microbiome/Goblet Cell/Mucin Axis. ( Ahmadi, S; Ding, J; Jain, S; Justice, J; Kitzman, D; Kritchevsky, SB; McClain, DA; Mishra, SP; Nagpal, R; Razazan, A; Wang, B; Wang, S; Yadav, H, 2020) |
| "Olanzapine treatment also altered the mRNA expression of hypothalamic appetite-regulating and nutrient-sensing factors, inflammatory genes and TRPV1/TRPV3, which were reversed with ruthenium red and capsazepine treatment." | 5.56 | Role of TRPV1/TRPV3 channels in olanzapine-induced metabolic alteration: Possible involvement in hypothalamic energy-sensing, appetite regulation, inflammation and mesolimbic pathway. ( Bansal, Y; Bishnoi, M; Khare, P; Kondepudi, KK; Kuhad, A; Medhi, B; Singh, R; Sodhi, RK, 2020) |
| "Metformin has been shown to have potential anti-inflammatory activity, but the underlying mechanisms remain obscure." | 5.56 | Metformin improves depressive-like symptoms in mice via inhibition of peripheral and central NF-κB-NLRP3 inflammation activation. ( Bu, WG; Du, RW, 2020) |
| "Despite being the frontline therapy for type 2 diabetes, the mechanisms of action of the biguanide drug metformin are still being discovered." | 5.56 | AMPK regulation of Raptor and TSC2 mediate metformin effects on transcriptional control of anabolism and inflammation. ( Dayn, A; Dayn, Y; Hellberg, K; Luo, EC; Shaw, RJ; Shokhirev, MN; Van Nostrand, EL; Van Nostrand, JL; Yeo, GW; Yu, J, 2020) |
| "The addition of metformin to standard ATT did not hasten sputum culture conversion but diminished excess inflammation, thus reducing lung tissue damage as seen by faster clearance on X-ray and reduced inflammatory markers." | 5.51 | Randomized Trial of Metformin With Anti-Tuberculosis Drugs for Early Sputum Conversion in Adults With Pulmonary Tuberculosis. ( Devi, P; Gomathy, NS; Guleria, R; Jawahar, S; Kadam, A; Kumar, H; Mamulwar, M; Mane, A; Menon, J; Mohan, A; Padmapriydarsini, C; Pavankumar, N; Ramesh, PM; Reddy, D; Sekar, L; Shandil, RK; Shanmugam, P; Singh, M; Singh, UB; Suresh, C, 2022) |
| "Oral metformin supplementation once daily for 24 weeks as an adjuvant therapy to intensive insulin in pediatric T1DM was safe and effective in improving glycemic control, dyslipidemia and Nrg-4 levels; hence, it decreased inflammation, microvascular complications and subclinical atherosclerosis." | 5.51 | Effect of metformin as an add-on therapy on neuregulin-4 levels and vascular-related complications in adolescents with type 1 diabetes: A randomized controlled trial. ( Elbarbary, NS; Ghallab, MA; Ismail, EAR, 2022) |
| "Systemic inflammation was induced by injecting LPS (1." | 5.51 | Possible involvement of metformin in downregulation of neuroinflammation and associated behavioural changes in mice. ( Anoopkumar-Dukie, S; Arora, D; Basu Mallik, S; Grant, G; Hall, S; Kinra, M; Mudgal, J; Nampoothiri, M; Rao, CM, 2019) |
| "This pilot study suggests that the serum inflammatory markers at the average normal values point to the sufficiency of metformin-single therapy in inflammation control in non-obese T2DM patients with NAFLD." | 5.51 | Effects of Metformin-Single Therapy on the Level of Inflammatory Markers in Serum of Non-Obese T2DM Patients with NAFLD. ( Gluvic, Z; Isenovic, ER; Macut, D; Mitrovic, B; Obradovic, M; Soskic, S; Stajic, D; Sudar-Milovanovic, E, 2022) |
| "Treatment with metformin altered macrophage polarization, reduced liver size and reduced micronuclei formation in NAFLD/NASH-associated HCC larvae." | 5.51 | Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish. ( de Oliveira, S; Golenberg, N; Graves, AL; Houseright, RA; Huttenlocher, A; Korte, BG; Miskolci, V, 2019) |
| "Gout is the most common inflammatory arthritis worldwide, and patients experience a heavy burden of cardiovascular and metabolic diseases." | 5.51 | mTOR inhibition by metformin impacts monosodium urate crystal-induced inflammation and cell death in gout: a prelude to a new add-on therapy? ( Broen, JCA; Jansen, M; Merriman, T; Ottria, A; Phipps-Green, A; Radstake, TRDJ; Schuiveling, M; van der Linden, M; van Lochem, E; Vazirpanah, N; Wichers, CGK; Zimmermann, M, 2019) |
| "Metformin was administered for 7 weeks to high fat-fed C57/6J male mice in vivo." | 5.48 | Metformin improves obesity-associated inflammation by altering macrophages polarization. ( Jing, Y; Li, D; Li, Q; Li, R; Wu, F; Yang, L, 2018) |
| "Metformin has been the most prescribed glucose-lowering medicine worldwide, and its potential for many other therapeutic applications is also being explored intensively." | 5.48 | Metformin attenuates folic-acid induced renal fibrosis in mice. ( Cao, Q; Chen, J; Chen, XM; Huang, C; Pollock, CA; Shi, Y; Yi, H; Zhang, L; Zhao, Y, 2018) |
| "Esophageal squamous cell carcinoma (ESCC) is an intractable digestive organ cancer that has proven difficult to treat despite multidisciplinary therapy, and a new treatment strategy is demanded." | 5.48 | Antitumor effects of metformin are a result of inhibiting nuclear factor kappa B nuclear translocation in esophageal squamous cell carcinoma. ( Akimoto, AK; Akutsu, Y; Hanari, N; Hoshino, I; Iida, K; Kano, M; Matsubara, H; Matsumoto, Y; Murakami, K; Okada, K; Otsuka, R; Sakata, H; Sekino, N; Shiraishi, T; Takahashi, M; Toyozumi, T; Yokoyama, M, 2018) |
| "Overall, MET reduced liver NAFLD but promoted hepatocyte increase in pro-inflammatory cytokines, thus, leading to liver inflammation." | 5.48 | Short-term treatment with metformin reduces hepatic lipid accumulation but induces liver inflammation in obese mice. ( Alves, MJ; Araujo, AP; Batatinha, HA; Biondo, LA; Curi, R; de Souza Teixeira, AA; Hirabara, SM; Lima, EA; Neto, JCR; Sanches Silveira, L; Souza, CO, 2018) |
| "Treatment with metformin reversed LPS-induced decline of AMPK phosphorylation." | 5.48 | Metformin alleviated endotoxemia-induced acute lung injury via restoring AMPK-dependent suppression of mTOR. ( Dai, J; Huang, J; Jiang, R; Tian, R; Wu, K; Yang, Y; Zhang, L, 2018) |
| "Pretreatment of metformin dose dependently suppressed the expression of TNF-α mRNA induced by LPS (2 mM, p = 0." | 5.43 | The suppressive effects of metformin on inflammatory response of otitis media model in human middle ear epithelial cells. ( Chae, SW; Cho, JG; Choi, J; Im, GJ; Jung, HH; Song, JJ, 2016) |
| "Metformin has anti-inflammatory effects through multiple routes, which provides potential therapeutic targets for certain inflammatory diseases, such as neuroinflammation and rheumatoid arthritis." | 5.41 | Role of metformin in inflammation. ( Feng, YY; Pang, H; Wang, Z, 2023) |
| "In addition to the anti-diabetic effect of metformin, a growing number of studies have shown that metformin has some exciting properties, such as anti-oxidative capabilities, anticancer, genomic stability, anti-inflammation, and anti-fibrosis, which have potent, that can treat other disorders other than diabetes mellitus." | 5.41 | Metformin beyond an anti-diabetic agent: A comprehensive and mechanistic review on its effects against natural and chemical toxins. ( Askari, VR; Bahari, H; Baradaran Rahimi, V; Heidari, R; Karbasforoushan, S; Malaekeh-Nikouei, A; Shokri-Naei, S, 2023) |
| " These results indicated that chronic administration of Met regulated pancreatic inflammation generation, ion and hormone homeostasis and improved β cell function of diabetic KKAy mice." | 5.40 | [Metformin ameliorates β-cell dysfunction by regulating inflammation production, ion and hormone homeostasis of pancreas in diabetic KKAy mice]. ( Hou, SC; Liu, Q; Liu, SN; Shen, ZF; Sun, SJ; Wang, Y, 2014) |
| "Metformin treatment decreases serum ASAA in these women." | 5.37 | The anti-atherogenic aspect of metformin treatment in insulin resistant women with the polycystic ovary syndrome: role of the newly established pro-inflammatory adipokine Acute-phase Serum Amyloid A; evidence of an adipose tissue-monocyte axis. ( Adya, R; Aghilla, M; Keay, SD; Lehnert, H; Randeva, HS; Shan, X; Tan, BK, 2011) |
| " This study aimed to evaluate the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin on the biomarkers of inflammation, thrombosis, and atherosclerosis in T2DM patients with symptomatic coronary artery disease (CAD)." | 5.34 | Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease. ( Kabel, M; Mostafa, T; Omran, G; Shokry, A; Werida, R, 2020) |
| " Patients also underwent a combined euglycemic, hyperinsulinemic, and hyperglycemic clamp with subsequent arginine stimulation to assess insulin sensitivity and insulin secretion." | 5.17 | Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial. ( Carbone, A; Ciccarelli, L; Derosa, G; Fogari, E; Franzetti, IG; Maffioli, P; Piccinni, MN; Querci, F, 2013) |
| "The objective was to determine the effect of metformin on the concentrations of resistin and other markers of insulin resistance or inflammation (C-reactive protein, cytokines, body weight, HbA1c, among others) in minors with glucose intolerance." | 5.16 | Metformin decreases plasma resistin concentrations in pediatric patients with impaired glucose tolerance: a placebo-controlled randomized clinical trial. ( Aguilar-Salinas, CA; Cruz, M; Gómez-Díaz, RA; Mondragón-González, R; Ortiz-Navarrete, FV; Pool, EC; Solórzano-Santos, F; Talavera, JO; Valladares-Salgado, A; Wacher, NH, 2012) |
| "We plan to prospectively investigate the effects of dipeptidyl peptidase-4 inhibition with vildagliptin on a number of atherothrombotic markers and adipokines in patients with proven atherosclerosis and type 2 diabetes." | 5.16 | Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease. ( Fisman, EZ; Goldenberg, I; Klempfner, R; Leor, J; Tenenbaum, A, 2012) |
| " This study investigates the impact of a pioglitazone plus metformin therapy on biomarkers of inflammation and platelet activation in comparison to a treatment with glimepiride plus metformin." | 5.15 | The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study. ( Forst, T; Fuchs, W; Hohberg, C; Lehmann, U; Löbig, M; Müller, J; Musholt, PB; Pfützner, A; Schöndorf, T, 2011) |
| "The aim of this study was to evaluate the effect of exenatide compared to glimepiride on body weight, glycemic control and insulin resistance in type 2 diabetic patients taking metformin." | 5.15 | Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. ( Bonaventura, A; Bossi, AC; Derosa, G; Fogari, E; Franzetti, IG; Guazzini, B; Maffioli, P; Putignano, P; Querci, F; Testori, G, 2011) |
| "To evaluate subclinical inflammation and fibrinolysis in low-risk type 2 diabetic subjects and to assess the efficacy of metformin and rosiglitazone in this group." | 5.14 | Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone. ( Akinci, B; Bayraktar, F; Comlekci, A; Demir, T; Ozcan, MA; Yener, S; Yesil, S; Yuksel, F, 2009) |
| "The aim of the study was to compare the effects of the addition of sitagliptin or metformin to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients on body weight, glycemic control, beta-cell function, insulin resistance, and inflammatory state parameters." | 5.14 | Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. ( Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Franzetti, IG; Gadaleta, G; Maffioli, P; Piccinni, MN; Querci, F; Ragonesi, PD; Salvadeo, SA, 2010) |
| "To compare the effect of addition of pioglitazone and acarbose to sulphonylureas and metformin therapy on metabolic parameters and on markers of endothelial dysfunction and vascular inflammation in type 2 diabetic patients." | 5.14 | Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Gravina, A; Maffioli, P; Mereu, R; Palumbo, I; Randazzo, S; Salvadeo, SA, 2010) |
| "To study the effect of simvastatin and metformin on insulin sensitivity and inflammatory markers." | 5.12 | Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. ( Bulcão, C; Ribeiro-Filho, FF; Roberta Ferreira, SG; Sañudo, A, 2007) |
| "We compared the vascular effects of rosiglitazone versus glyburide and evaluated asymmetric dimethylarginine (ADMA) and oxidative stress as potential mechanisms associated with changes in vascular health in patients with type 2 diabetes mellitus (T2DM)." | 5.12 | Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus. ( Bank, AJ; Gonzalez-Campoy, JM; Kaiser, DR; Kelly, AS; Thelen, AM, 2007) |
| " The Diabetes Prevention Program (DPP) clinical trial studied the effect of an intensive lifestyle intervention or metformin on progression to diabetes relative to placebo in 3,234 adults with impaired glucose tolerance." | 5.11 | Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. ( Barrett-Connor, E; Crandall, J; Fowler, S; Goldberg, R; Haffner, S; Horton, E; Marcovina, S; Mather, K; Orchard, T; Ratner, R; Temprosa, M, 2005) |
| "To discussing metformin effects on rheumatoid arthritis complications." | 5.01 | Metformin one in a Million Efficient Medicines for Rheumatoid Arthritis Complications: Inflammation, Osteoblastogenesis, Cardiovascular Disease, Malignancies. ( Haybar, H; Mowla, K; Rajaei, E; Zayeri, ZD, 2019) |
| "Observational studies show a beneficial effect of adjuvant metformin therapy on breast cancer survivals, but data from randomized clinical trials are lacking." | 5.01 | The effect of metformin on biomarkers and survivals for breast cancer- a systematic review and meta-analysis of randomized clinical trials. ( Bi, Y; Liu, Y; Wang, C; Yuan, J; Zhang, ZJ, 2019) |
| " In breast cancer, TGF-β effect on EMT could be potentiated by Fos-related antigen, oncogene HER2, epidermal growth factor, or mitogen-activated protein kinase kinase 5 - extracellular-regulated kinase signaling." | 5.01 | Epithelial mesenchymal transition and resistance in endocrine-related cancers. ( Culig, Z, 2019) |
| " In this context, metformin has been shown to not only contribute to a better glycaemic control but also to induce some weight loss (especially in the visceral depot) which may contribute to the improvement of the features of the metabolic syndrome." | 4.82 | Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. ( Després, JP, 2003) |
| "This study aimed to characterize aging-induced tendinopathy in mouse Achilles tendon and also to assess the treatment effects of metformin (Met) on aging tendon." | 4.31 | Metformin improves tendon degeneration by blocking translocation of HMGB1 and suppressing tendon inflammation and senescence in aging mice. ( Brown, R; Hogan, MV; Onishi, K; Wang, JH; Zhang, J, 2023) |
| " Although several pharmacological interventions, including melatonin and metformin, have been reported to protect against various cardiovascular diseases, their potential roles in trastuzumab-induced cardiotoxicity remain elusive." | 4.31 | Melatonin and metformin ameliorated trastuzumab-induced cardiotoxicity through the modulation of mitochondrial function and dynamics without reducing its anticancer efficacy. ( Arinno, A; Arunsak, B; Chattipakorn, N; Chattipakorn, SC; Chunchai, T; Kerdphoo, S; Khuanjing, T; Maneechote, C; Nawara, W; Prathumsap, N; Shinlapawittayatorn, K, 2023) |
| "This study showed that some pathological changes occurring in the lungs of aged rats, such as hemorrhage, edema, and inflammation, improved after metformin treatment; the number of hepatocyte death increased in the AgCLP group, and decreased in the AgMET group." | 4.31 | Effect of metformin on sepsis-associated acute lung injury and gut microbiota in aged rats with sepsis. ( Duo, B; Liu, Y; Lu, Z; Niu, Y; Wan, Y; Wang, S; Zhu, R, 2023) |
| " The potential protective outcome of the antidiabetic and pleiotropic drug metformin against TAA-induced chronic kidney disease in association with the modulation of AMP-activated protein kinase (AMPK), oxidative stress, inflammation, dyslipidemia, and systemic hypertension has not been investigated before." | 4.31 | Metformin Suppresses Thioacetamide-Induced Chronic Kidney Disease in Association with the Upregulation of AMPK and Downregulation of Oxidative Stress and Inflammation as Well as Dyslipidemia and Hypertension. ( Al-Ani, B; Albawardi, A; Alqahtani, SM; Alshahrani, MY; Bayoumy, NM; Ebrahim, HA; Haidara, MA; Kamar, SS; ShamsEldeen, AM, 2023) |
| "Metformin, a first-line drug for type-2 diabetes, displays pleiotropic effects on inflammation, aging, and cancer." | 4.31 | Metformin potentiates immunosuppressant activity and adipogenic differentiation of human umbilical cord-mesenchymal stem cells. ( Bajetto, A; Barbieri, F; Florio, T; Pattarozzi, A; Sirito, R, 2023) |
| " Metformin (MET) is an oral hypoglycemic agent that activates AMPK-regulated signaling pathways and inhibits inflammation and oxidative stress responses." | 4.31 | Protective role of metformin in preeclampsia via the regulation of NF-κB/sFlt-1 and Nrf2/HO-1 signaling pathways by activating AMPK. ( He, L; Li, X; Wu, J; Wu, X; Zhan, F, 2023) |
| " We tested the drugs metformin (AMPK activator) and baicalin (CPT1A activator) in different experimental models mimicking COVID-19 associated inflammation in lung and kidney." | 4.31 | Enhanced fatty acid oxidation through metformin and baicalin as therapy for COVID-19 and associated inflammatory states in lung and kidney. ( Alcalde-Estévez, E; Castillo, C; Castro, A; Costa, IG; Fernández, L; Herrero, JI; Jansen, J; Kramann, R; Lamas, S; Miguel, V; Nagai, J; Ranz, I; Reimer, KC; Rey-Serra, C; Rodríguez González-Moro, JM; Sancho, D; Sevilla, L; Sirera, B; Tituaña, J, 2023) |
| "Twelve-month metformin treatment reduced fat content, waist circumference, glycated hemoglobin, glucose and triglycerides, as well as improved insulin sensitivity." | 4.12 | Impaired metabolic effects of metformin in men with early-onset androgenic alopecia. ( Kowalcze, K; Krysiak, R; Okopień, B, 2022) |
| " This research used in vivo and in vitro experiments to explore the therapeutic potential of metformin in kidney injury from LN-induced inflammation." | 4.12 | Metformin improves renal injury of MRL/lpr lupus-prone mice via the AMPK/STAT3 pathway. ( An, N; Chen, XC; Huang, LF; Huang, XR; Li, HY; Liu, HF; Liu, ZJ; Lu, X; Pan, QJ; Su, HY; Wu, D; Wu, HL; Yang, C; Zhu, SP, 2022) |
| " Consequently, we aimed to investigate the effects of metformin, letrozole, and atorvastatin on inflammation and apoptosis in experimentally induced ovarian and peritoneal endometriosis in rat models." | 4.12 | Effects of metformin, letrozole and atorvastatin on inflammation and apoptosis in experimental peritoneal and ovarian endometriosis in the rat. ( Coskun, G; Efendic, F; Erdem, E; Hayretdag, C; Irkorucu, O; Keles, P; Kuras, S; Pence, HH; Polat, S; Saker, D; Sapmaz, E; Sapmaz, T; Sevgin, K; Tekayev, M; Topkaraoglu, S, 2022) |
| " To assess the relationship between PDIA4, adiponectin, and metformin, we used the palmitate-induced inflammation in hypertrophic adipocytes and the high-fat diet-induced obesity mouse model." | 4.12 | PDIA4, a novel ER stress chaperone, modulates adiponectin expression and inflammation in adipose tissue. ( Chen, YC; Chiang, CF; Chien, CY; Ho, LJ; Hsieh, CH; Huang, CL; Hung, YJ; Kuo, FC; Lee, CH; Li, PF; Lin, FH; Liu, JS; Lu, CH; Shieh, YS; Su, SC, 2022) |
| " The present study compared the impact of low-grade systemic inflammation and insulin resistance on levothyroxine action in subjects with this disorder." | 4.12 | Thyroid Antibody Titers and Hypothalamic-Pituitary-Thyroid Axis Activity in Levothyroxine-Treated Women With Autoimmune Subclinical Hypothyroidism Receiving Atorvastatin or Metformin. ( Kowalcze, K; Krysiak, R; Okopień, B, 2022) |
| "5 % cholic acid and 60 % cocoa butter for 6 weeks causing a number of metabolic and hepatic alterations including insulin resistance, dyslipidemia, systemic inflammation, increased hepatic oxidative stress and lipid peroxidation, hepatic steatosis, lobular inflammation, as well as increased markers of liver inflammation and hepatocyte apoptosis." | 4.12 | Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms. ( Aly, RG; Alzaim, I; El-Mallah, A; El-Yazbi, AF; Shaaban, HH; Wahid, A, 2022) |
| "The results showed that CGA decreased body weight and improved glucose tolerance and insulin resistance, and these effects were similar to those of metformin." | 4.12 | Chlorogenic acid improves glucose tolerance, lipid metabolism, inflammation and microbiota composition in diabetic db/db mice. ( Guo, K; Li, Q; Shen, L; Yan, Y; Zhou, X, 2022) |
| " The effect of HFD on maternal rats was alleviated by prenatal metformin, which also ameliorated inflammation and apoptosis in the fetal liver and intestines." | 4.02 | Metformin ameliorates maternal high-fat diet-induced maternal dysbiosis and fetal liver apoptosis. ( Hou, CY; Huang, LT; Huang, SW; Lin, IC; Ou, YC; Sheen, JM; Tain, YL; Tang, KS; Tiao, MM; Tsai, CC; Yu, HR, 2021) |
| "Metformin, traditionally regarded as a hypoglycemic drug, has been studied in other various fields including inflammation." | 4.02 | Metformin alleviates inflammation through suppressing FASN-dependent palmitoylation of Akt. ( Sun, KY; Xiong, W; Zhang, X; Zhou, YH; Zhu, Y; Zou, X, 2021) |
| "The present study evaluated the effects of dapagliflozin, a SGLT2 inhibitor, or dapagliflozin plus metformin versus metformin monotherapy in patients with metabolic syndrome." | 4.02 | Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome. ( Cheng, L; Fan, Y; Fu, Q; Lin, W; Liu, F; Wu, X; Zhang, X; Zhou, L, 2021) |
| "The present study aimed to investigate the possible effects of metformin on the olanzapine-induced insulin resistance in rats." | 4.02 | Metformin ameliorates olanzapine-induced insulin resistance via suppressing macrophage infiltration and inflammatory responses in rats. ( Guo, C; Li, H; Liu, J, 2021) |
| "Our findings suggest that in CLP induced sepsis model, metformin can improve the function of blood and cardiac cells through alleviating inflammation, improvement of anti-inflammation properties, and enhancement of blood profile, and all these effects are more pronounced after 24 h in comparison with 12 h after induction of sepsis." | 4.02 | Short-term Effects of Metformin on Cardiac and Peripheral Blood Cells Following Cecal Ligation and Puncture-induced Sepsis. ( Abdollahi, M; Baeeri, M; Didari, T; Gholami, M; Haghi-Aminjan, H; Hassan, FI; Hassani, S; Mojtahedzadeh, M; Navaei-Nigjeh, M; Nejad, SM; Rahimifard, M, 2021) |
| " Metformin has potential effects on improving asthma airway inflammation." | 4.02 | Metformin alleviates allergic airway inflammation and increases Treg cells in obese asthma. ( Chen, M; Guo, Y; Hong, L; Jiang, S; Liu, S; Shi, J; Wang, Q; Yuan, X, 2021) |
| "It is revealed that metformin alleviated inflammation and underlying mechanism may result from inhibition of SPHK1/S1P signaling pathway." | 4.02 | Metformin alleviates inflammation in oxazolone induced ulcerative colitis in rats: plausible role of sphingosine kinase 1/sphingosine 1 phosphate signaling pathway. ( Abu-Risha, SE; El-Kadem, AH; El-Mahdy, NA; El-Sayad, ME, 2021) |
| " Based on metformin and other anti-diabetic agent prescriptions, we categorized all patients with autoimmune diseases into either the metformin group (metformin administration for at least 28 days) or the non-metformin group." | 4.02 | Reduced Mortality Associated With the Use of Metformin Among Patients With Autoimmune Diseases. ( Chen, TH; Hsu, CY; Lin, CY; Lin, MS; Lin, YS; Su, YJ; Wu, CH, 2021) |
| "Although the beneficial effects of metformin (MET) and genistein in ameliorating inflammation have been elucidated, their combined impacts on skeletal muscle inflammation have not been clearly understood." | 4.02 | Metformin in combination with genistein ameliorates skeletal muscle inflammation in high-fat diet fed c57BL/6 mice. ( Aliabadi, M; Meshkani, R; Panahi, G; Tehrani, SS; Zamani-Garmsiri, F, 2021) |
| " We aimed to confirm the correlation between SFRP5, metabolic inflammation and PCOS, investigate the predictive value of SFRP5 for PCOS and the involvement of SFRP5 in metformin treated PCOS." | 4.02 | Decreased SFRP5 correlated with excessive metabolic inflammation in polycystic ovary syndrome could be reversed by metformin: implication of its role in dysregulated metabolism. ( Chen, Y; Geng, L; Hu, J; Huang, H; Kong, L; Qi, H; Ran, Y; Zhang, H; Zhang, Y, 2021) |
| "The current results suggest that exenatide is equivalent to metformin in controlling insulin resistance, body weight gain, improving liver function, suppressing inflammation, and attenuating NAFLD progression in male rats." | 3.96 | Exenatide ameliorates experimental non-alcoholic fatty liver in rats via suppression of toll-like receptor 4/NFκB signaling: Comparison to metformin. ( Ahmed, AAM; Khodeer, DM; Moustafa, YM; Saad, ZA; Zaitone, SA, 2020) |
| " The protective effect of metformin pretreatment against alterations to the articular cartilage ultrastructure induced by type 2 diabetes mellitus (T2DM) associated with the inhibition of oxidative stress and inflammation has not been investigated before." | 3.96 | Metformin pretreatment suppresses alterations to the articular cartilage ultrastructure and knee joint tissue damage secondary to type 2 diabetes mellitus in rats. ( Abdel Kader, DH; Al-Ani, B; Alzamil, N; Dawood, AF; Ebrahim, HA; Haidara, MA; Kamar, SS, 2020) |
| "We found a possible mechanism that metformin could reduce inflammation and apoptosis, and promote functional recovery of SCI rats through activating Wnt/β-catenin signaling pathway." | 3.96 | Therapeutic effect of metformin on inflammation and apoptosis after spinal cord injury in rats through the Wnt/β-catenin signaling pathway. ( Gao, K; Li, K; Lv, C; Wang, F; Zhang, T, 2020) |
| " Insulin and the insulin sensitizers rosiglitazone and metformin prevent in part the RD-induced cone loss in vivo, despite the persistence of inflammation CONCLUSION: Our results describe a new mechanism by which inflammation induces cone death in RD, likely through cone starvation due to the downregulation of RdCVF that could be reversed by insulin." | 3.96 | Insulin inhibits inflammation-induced cone death in retinal detachment. ( Augustin, S; Beguier, F; Berrod, JP; Blot, G; Charles-Messance, H; Conart, JB; Delarasse, C; Guillonneau, X; Léveillard, T; Millet-Puel, G; Roubeix, C; Sahel, JA; Sennlaub, F; Touhami, S, 2020) |
| "Metformin beneficially impacts several aspects of metabolic syndrome including dysglycemia, obesity, and liver dysfunction, thus making it a widely used frontline treatment for early-stage type 2 diabetes, which is associated with these disorders." | 3.91 | Amelioration of metabolic syndrome by metformin associates with reduced indices of low-grade inflammation independently of the gut microbiota. ( Adeshirlarijaney, A; Chassaing, B; Gewirtz, AT; Tran, HQ; Zou, J, 2019) |
| " We found that, in ultra-high-molecular-weight polyethylene particle-induced osteolysis mouse models, metformin had bone protect property and reduced the negative regulator of bone formation sclerostin (SOST) and Dickkopf-related protein 1 (DKK1), and increased osteoprotegerin (OPG) secretion and the ratio of OPG/Receptor Activator for Nuclear Factor-κB Ligand (RANKL)." | 3.91 | Metformin protects bone mass in ultra-high-molecular-weight polyethylene particle-induced osteolysis by regulating osteocyte secretion. ( Cao, X; Lu, Z; Tian, X; Wei, D; Yan, Z; Ye, Z; Zhai, D; Zhu, Q; Zhu, S; Zhu, Z, 2019) |
| "The present study aimed to investigate the possible effects of metformin on the progression of atherosclerosis in a rabbit model." | 3.88 | Metformin ameliorates the progression of atherosclerosis via suppressing macrophage infiltration and inflammatory responses in rabbits. ( Chen, J; Chen, M; Qu, J; Ren, W; Sun, S; Tang, X; Wang, H; Yang, Q; Yu, B; Yuan, H, 2018) |
| "Metformin could be considered as an alternative therapeutic agent for SCI, as it potentially attenuates neuroinflammation, sensory and locomotor complications of cord injury." | 3.88 | Anti-inflammatory effects of Metformin improve the neuropathic pain and locomotor activity in spinal cord injured rats: introduction of an alternative therapy. ( Afshari, K; Dehdashtian, A; Dehpour, AR; Ebrahimi, MA; Faghir-Ghanesefat, H; Haddadi, NS; Haj-Mirzaian, A; Iranmehr, A; Javidan, AN; Mohammadi, F; Rahimi, N; Tavangar, SM, 2018) |
| " Metformin (MET) is a potent combination drug to elevate anti-TB efficacy and able to regulate inflammation." | 3.88 | Metformin associated inflammation levels regulation in type 2 diabetes mellitus-tuberculosis coinfection patients - A case report. ( Novita, BD; Nugraha, J; Soediono, EI, 2018) |
| "To evaluate the effects of metformin (Met) on inflammation, oxidative stress, and bone loss in a rat model of ligature-induced periodontitis." | 3.85 | Effects of metformin on inflammation, oxidative stress, and bone loss in a rat model of periodontitis. ( Araújo Júnior, RF; Araújo, AA; Araújo, LS; Brito, GAC; Guedes, PMM; Hiyari, S; Leitão, RFC; Medeiros, CACX; Pereira, ASBF; Pirih, FQ, 2017) |
| " This study investigated the effects of scopoletin on hepatic steatosis and inflammation in a high-fat diet fed type 1 diabetic mice by comparison with metformin." | 3.85 | Scopoletin Supplementation Ameliorates Steatosis and Inflammation in Diabetic Mice. ( Cho, HW; Choi, MS; Choi, RY; Ham, JR; Kim, MJ; Lee, HI; Lee, J; Lee, MK; Park, SK; Seo, KI, 2017) |
| "Oral administration of metformin or resveratrol prevented hypoxia and reduced HIF-1α accumulation with dephosphorylation of inositol-requiring enzyme 1α and eukaryotic initiation factor 2α, indicative of suppression of hypoxic HIF-1α activation and endoplasmic reticulum stress." | 3.83 | The role of metformin and resveratrol in the prevention of hypoxia-inducible factor 1α accumulation and fibrosis in hypoxic adipose tissue. ( Huang, F; Kou, J; Li, A; Li, J; Li, X; Liu, B; Liu, K; Qi, LW; Qiu, Z; Wang, L, 2016) |
| "This study aims to investigate the effects of metformin and resveratrol on muscle insulin resistance with emphasis on the regulation of lipolysis in hypoxic adipose tissue." | 3.83 | Metformin and resveratrol ameliorate muscle insulin resistance through preventing lipolysis and inflammation in hypoxic adipose tissue. ( Feng, X; Hou, T; Li, A; Liu, B; Liu, K; Zhang, N; Zhao, W, 2016) |
| "We investigated the effects of metformin and celecoxib on obesity-induced adipose tissue inflammation, insulin resistance (IR), fatty liver, and high blood pressure in high-fat (HF) fed rats." | 3.83 | Additional effect of metformin and celecoxib against lipid dysregulation and adipose tissue inflammation in high-fat fed rats with insulin resistance and fatty liver. ( Hsieh, PS; Hung, YJ; Lu, CH, 2016) |
| "Neither diabetes mellitus nor preadmission insulin or metformin use are associated with altered disease presentation, outcome or host response in patients with sepsis requiring intensive care." | 3.83 | Association of diabetes and diabetes treatment with the host response in critically ill sepsis patients. ( Bonten, MM; Cremer, OL; Hoogendijk, AJ; Horn, J; Klein Klouwenberg, PM; Nürnberg, P; Schultz, MJ; Scicluna, BP; van der Poll, T; van Vught, LA; Wiewel, MA, 2016) |
| "Accumulating evidence suggests that chronic metformin preconditioning offers potent neuroprotective effects against ischemic stroke." | 3.81 | Chronic Metformin Preconditioning Provides Neuroprotection via Suppression of NF-κB-Mediated Inflammatory Pathway in Rats with Permanent Cerebral Ischemia. ( Cao, L; Ding, ZZ; Jiang, T; Tan, L; Tan, MS; Wang, HF; Yu, JT; Zhang, QQ; Zhu, XC, 2015) |
| " Glucose-induced inflammation was partially reversed by metformin." | 3.81 | Glucose and metformin modulate human first trimester trophoblast function: a model and potential therapy for diabetes-associated uteroplacental insufficiency. ( Abrahams, VM; Flannery, CA; Han, CS; Herrin, MA; Mulla, MJ; Pettker, CM; Pitruzzello, MC; Werner, EF, 2015) |
| " In this study, the effect of metformin on senescence and antisenescence mediators (SirT1-7, p53, and p16(INK4a)) mRNA expression in white blood cells (WBCs) following lipopolysaccharides (LPS)-induced inflammation in mice was examined." | 3.81 | Lipopolysaccharides-Induced Inflammatory Response in White Blood Cells Is Associated with Alterations in Senescence Mediators: Modulation by Metformin. ( Aljada, A, 2015) |
| "We explored if known risk factors for pancreatic cancer such as type II diabetes and chronic inflammation, influence the pathophysiology of an established primary tumor in the pancreas and if administration of metformin has an impact on tumor growth." | 3.81 | Impact of diabetes type II and chronic inflammation on pancreatic cancer. ( Albert, AC; Amme, J; Bürtin, F; Partecke, LI; Radecke, T; Vollmar, B; Zechner, D, 2015) |
| " Inflammation and coagulation are closely associated pathological processes, therefore the potential effects of metformin on key steps in activation of the coagulation system were further investigated in endotoxic hepatitis induced by lipopolysaccharide/D‑galactosamine (LPS/D‑Gal)." | 3.81 | Metformin suppresses intrahepatic coagulation activation in mice with lipopolysaccharide/D‑galactosamine‑induced fulminant hepatitis. ( Ai, Q; Ao, JE; Duan, R; Ge, P; Gong, X; Lin, L; Zhang, L, 2015) |
| " To better understand the pathophysiology of obesity-associated NAFLD, the present study examined the involvement of liver and adipose tissues in metformin actions on reducing hepatic steatosis and inflammation during obesity." | 3.80 | Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity. ( An, X; Botchlett, R; Chen, L; Guo, T; Guo, X; Hu, X; Huo, Y; Li, H; Li, Q; Pei, Y; Qi, T; Woo, SL; Wu, C; Xiao, X; Xu, H; Xu, Y; Zhao, J; Zhao, Y; Zheng, J, 2014) |
| "Diet induced-obesity/metabolic syndrome during pregnancy significantly enhanced fetal and placental cytokine production; maternal metformin reduced fetal cytokine levels." | 3.79 | Maternal metformin treatment decreases fetal inflammation in a rat model of obesity and metabolic syndrome. ( Chatterjee, PK; Desai, N; Gupta, M; Metz, CN; Rochelson, B; Roman, A; Tam Tam, H; Xue, X, 2013) |
| "Metformin is widely used for treatment of type 2 diabetes and has a potential application on the treatment of inflammation and cancer." | 3.79 | Blockade of reactive oxygen species and Akt activation is critical for anti-inflammation and growth inhibition of metformin in phosphatase and tensin homolog-deficient RAW264.7 cells. ( Bai, CH; Chien, YC; Lai, HW; Liao, CS; Lin, CF; Ma, CT; Su, HC; Tsao, CW; Wang, HY; Young, KC; Yu, BC, 2013) |
| "Telmisartan acts beneficially against diabetes-induced inflammation and improves insulin resistance in pre-diabetes OLETF rats fed with HFD." | 3.79 | Angiotensin II receptor blocker telmisartan prevents new-onset diabetes in pre-diabetes OLETF rats on a high-fat diet: evidence of anti-diabetes action. ( Li, LY; Luo, R; Sun, LT; Tian, FS; Xiong, HL; Zhao, ZQ; Zheng, XL, 2013) |
| " The AMP-activated protein kinase (AMPK) activator metformin reverses obesity-associated insulin resistance (IR) and inhibits different types of inflammatory responses." | 3.79 | Metformin attenuates the exacerbation of the allergic eosinophilic inflammation in high fat-diet-induced obesity in mice. ( André, DM; Anhê, GF; Antunes, E; Bordin, S; Calixto, MC; Ferreira, D; Landgraf, RG; Leiria, LO; Lellis-Santos, C; Lintomen, L, 2013) |
| "Metformin, the first-line drug for treating diabetes, inhibits cellular transformation and selectively kills cancer stem cells in breast cancer cell lines." | 3.79 | Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. ( Hirsch, HA; Iliopoulos, D; Struhl, K, 2013) |
| "The pharmacological action of metformin goes beyond mere glycemic control, decreasing markers of inflammation and contributing to the reduction of oxidative stress." | 3.78 | [Effect of metformin on the expression of tumor necrosis factor-α, Toll like receptors 2/4 and C reactive protein in obese type-2 diabetic patients]. ( Andrews, M; Arredondo, M; Soto, N, 2012) |
| " Systemic inflammation markers (fibrinogen, CRP), higher in DM, decreased following both treatments." | 3.74 | Intensification of oxidative stress and inflammation in type 2 diabetes despite antihyperglycemic treatment. ( Farah, R; Lapin, O; Shurtz-Swirski, R, 2008) |
| " In impaired glucose tolerance subjects, these procedures were performed before and after treatment with pioglitazone or metformin." | 3.74 | Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. ( Bodles, AM; Fried, SK; Kern, LM; Kern, PA; Lee, MJ; McGehee, RE; Phanavanh, B; Rasouli, N; Spencer, HJ; Starks, T; Varma, V; Yao-Borengasser, A, 2007) |
| "ESCs derived from ovarian endometriomas were cultured with various concentrations of metformin." | 3.74 | Metformin suppresses interleukin (IL)-1beta-induced IL-8 production, aromatase activation, and proliferation of endometriotic stromal cells. ( Harada, M; Hasegawa, A; Hirata, T; Hirota, Y; Koga, K; Morimoto, C; Nose, E; Osuga, Y; Tajima, T; Takemura, Y; Taketani, Y; Yano, T; Yoshino, O, 2007) |
| " The aim of this study was to evaluate the effects of rosuvastatin and metformin on inflammation and oxidative stress in patients with hypertension and dyslipidemia." | 3.74 | [Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia]. ( Alvarez-Aguilar, C; Gómez-García, A; Martínez Torres, G; Ortega-Pierres, LE; Rodríguez-Ayala, E, 2007) |
| "Chronic low-grade inflammation has emerged as a key contributor to the pathogenesis of Polycystic Ovary Syndrome (PCOS)." | 3.11 | Effect of aerobic exercise on inflammatory markers in polycystic ovary syndrome: a randomized controlled trial. ( Abdelbasset, WK; Eid, MM; Elbandrawy, AM; Elkholi, SM; Ewais, NF; Morgan, EN; Yousef, AM, 2022) |
| "Metformin and placebo were administered orally for 12 weeks in escalating doses: 850 mg/day for the first 5 days, 850 mg twice a day for the next 5 days, and 850 mg three times a day subsequently." | 2.94 | Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial. ( Ajjan, R; Ajodha, S; Akanle, O; Bestwick, JP; Christ-Crain, M; Fraser, W; Gabrovska, P; Grossman, AB; Kelly, S; Kola, B; Korbonits, M; Pernicova, I; Pitzalis, C; Sahdev, A; Stadler, M, 2020) |
| "Inflammation is one biological mechanism hypothesized to mediate these associations." | 2.94 | Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial. ( Abrams, TA; Brown, JC; Campbell, N; Cartmel, B; Douglas, PS; Fuchs, CS; Harrigan, M; Hu, FB; Irwin, ML; Jones, LW; Ligibel, JA; Meyerhardt, JA; Ng, K; Pollak, MN; Sanft, T; Sorrentino, A; Tolaney, SM; Winer, EP; Zhang, S, 2020) |
| "Metformin treatment reduced the concentrations of NET components independently from glucose control." | 2.87 | The antidiabetic drug metformin blunts NETosis in vitro and reduces circulating NETosis biomarkers in vivo. ( Albiero, M; Avogaro, A; Bonora, BM; Bortolozzi, M; Cappellari, R; Ceolotto, G; Fadini, GP; Menegazzo, L; Romanato, F; Scattolini, V; Vigili de Kreutzeberg, S, 2018) |
| "Metformin has shown its effectiveness in treating obesity in adults." | 2.84 | Metformin for Obesity in Prepubertal and Pubertal Children: A Randomized Controlled Trial. ( Aguilera, CM; Bueno, G; Caballero-Villarraso, J; Cañete, MD; Cañete, R; Gil, Á; Hoyos, R; Latorre, M; Leis, R; Maldonado, J; Pastor-Villaescusa, B; Plaza-Díaz, J; Vázquez-Cobela, R, 2017) |
| "Metformin is a widely used classic antidiabetic drug." | 2.80 | Metformin ameliorates the proinflammatory state in patients with carotid artery atherosclerosis through sirtuin 1 induction. ( Deng, YY; Gao, S; Liu, J; Maharjan, P; Tian, Y; Wang, L; Wu, Y; Xu, W; Yang, L; Yuan, Z; Zhao, S; Zhao, Y; Zhao, Z; Zhou, J; Zhuo, X, 2015) |
| "Chronic low-grade inflammation is a common feature of insulin resistant states, including obesity and type 2 diabetes." | 2.78 | Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment. ( Aroda, V; Ciaraldi, TP; Henry, RR; Mudaliar, SR, 2013) |
| "Pioglitazone-treated patients were found to have statistically significantly larger decreases in mean CRP levels (-0." | 2.78 | Effect of pioglitazone versus metformin on cardiovascular risk markers in type 2 diabetes. ( Ceriello, A; De Berardis, G; Evangelista, V; Genovese, S; Mannucci, E; Nicolucci, A; Pellegrini, F; Totani, L, 2013) |
| "Vildagliptin treatment was associated with a stronger decrease in nitrotyrosine (P < 0." | 2.77 | Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. ( Barbieri, M; Marfella, R; Paolisso, G; Rizzo, MR, 2012) |
| "A total of 2368 patients with type 2 diabetes mellitus and clinically stable, angiographically documented coronary artery disease were randomized to treatment with 1 of the 2 strategies and followed for an average of 5 years." | 2.76 | Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. ( Brooks, MM; Frye, RL; Genuth, S; Hardison, RM; Huber, K; Krishnaswami, A; McBane, RD; Pratley, RE; Schneider, DJ; Sobel, BE; Wolk, R, 2011) |
| "Treatment with metformin significantly reduced IL-6, especially in PCOS patients with IRS-2 homozygous Asp variant." | 2.76 | Interleukin-6 as an early chronic inflammatory marker in polycystic ovary syndrome with insulin receptor substrate-2 polymorphism. ( Huang, MF; Lin, MW; Lin, YS; Tsai, SJ; Wu, MH; Yang, CT, 2011) |
| "Pioglitazone has demonstrated a favorable CV profile relative to other oral antidiabetic drugs (OADs) in outcome and observational studies." | 2.75 | Effects of pioglitazone and metformin fixed-dose combination therapy on cardiovascular risk markers of inflammation and lipid profile compared with pioglitazone and metformin monotherapy in patients with type 2 diabetes. ( Arora, V; Jacks, R; Perez, A; Spanheimer, R, 2010) |
| " A prospective, randomized, double-blind study enrolled 55 patients with type 2 diabetes mellitus, which were randomly assigned to receive either metformin SR or RR (at a maximal dosage of 2000 mg/d for 12 weeks)." | 2.73 | Both slow-release and regular-form metformin improve glycemic control without altering plasma visfatin level in patients with type 2 diabetes mellitus. ( He, CT; Hsieh, CH; Hung, YJ; Lee, CH; Wu, LY, 2007) |
| "Metformin is a biguanide drug widely used as the initial treatment of type 2 diabetes." | 2.72 | Metformin as an anti-inflammatory agent: a short review. ( Eriksson, JW; Kristófi, R, 2021) |
| "However, strategies for the treatment of inflammation should focus on metformin in patients with T2D." | 2.72 | Effect of Metformin on Circulating Levels of Inflammatory Markers in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. ( Eskandari, M; Hosseini, H; Karbalaee-Hasani, A; Khadive, T; Khalkhali, L; Khodabandehloo, H; Koushki, M; Mohammadi, D; Mosavi, M; Nejadebrahimi, Z; Sangdari, A; Shahidi, S; Soltani, A, 2021) |
| "Skin aging is aggravated by the fact that the skin is in direct contact with extrinsic factors, such as ultraviolet irradiation." | 2.66 | Shedding Light on the Effects of Calorie Restriction and its Mimetics on Skin Biology. ( Choi, YJ, 2020) |
| "Inflammation is implicated in the development and severity of the coronavirus disease 2019 (COVID-19), as well as in the pathophysiology of diabetes." | 2.66 | Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era? ( Ferrannini, E; Katsiki, N, 2020) |
| "The pandemic of coronavirus disease 2019 (COVID-19), a disease which causes severe lung injury and multiple organ damage, presents an urgent need for new drugs." | 2.66 | Immunomodulatory and Antiviral Activity of Metformin and Its Potential Implications in Treating Coronavirus Disease 2019 and Lung Injury. ( Chen, X; Deng, Q; Guo, H; Leng, Q; Qiu, L; Zhang, C, 2020) |
| "Depression is a common comorbidity in diabetes but conventional antidepressant treatments do not consistently improve outcomes." | 2.58 | Repositioning of diabetes treatments for depressive symptoms: A systematic review and meta-analysis of clinical trials. ( Hopkins, CWP; Ismail, K; Moulton, CD; Stahl, D, 2018) |
| " Qualitative synthesis also suggests an apparently dose-response relationship and increased benefit when administered alone." | 2.58 | Protective effects of metformin, statins and anti-inflammatory drugs on head and neck cancer: A systematic review. ( Estrugo Devesa, A; Jané-Salas, E; López-López, J; Saka Herrán, C, 2018) |
| "Although current therapies in chronic obstructive pulmonary disease (COPD) improve the quality of life, they do not satisfactorily reduce disease progression or mortality." | 2.55 | Geroprotectors as a therapeutic strategy for COPD - where are we now? ( Białas, AJ; Górski, P; Makowska, J; Miłkowska-Dymanowska, J; Piotrowski, WJ; Wardzynska, A, 2017) |
| "The link between NAFLD/NASH and PCOS is not just a coincidence." | 2.53 | Hepatic manifestations of women with polycystic ovary syndrome. ( Chen, MJ; Ho, HN, 2016) |
| "Obesity is now a major international health concern." | 2.52 | Obesity and polycystic ovary syndrome. ( Boyle, J; De Courten, B; Joham, A; Naderpoor, N; Shorakae, S; Teede, HJ, 2015) |
| "Maternal obesity is associated with adverse perinatal outcome." | 2.52 | Placental dysfunction in obese women and antenatal surveillance strategies. ( Doshani, A; Jeve, YB; Konje, JC, 2015) |
| "Metformin is an oral hypoglycemic agent which is most widely used as first-line therapy for type 2 diabetes." | 2.52 | Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect. ( Saisho, Y, 2015) |
| "Diabetes and obesity are associated with nonalcoholic fatty liver disease (NAFLD) and an increased incidence of hepatocellular carcinoma (HCC)." | 2.52 | Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. ( Noureddin, M; Rinella, ME, 2015) |
| "Chemoprevention in Barrett's esophagus is currently applied only in research settings." | 2.52 | Chemoprevention in Barrett's Esophagus: Current Status. ( Baruah, A; Buttar, NS; Kossak, SK; Zeb, MH, 2015) |
| "Metformin and aspirin have been explored as two emerging cancer chemoprevention agents for different types of cancers, including pancreatic cancer." | 2.50 | Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment. ( DiPaola, RS; Tan, XL; Yang, CS; Yue, W, 2014) |
| "Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease of the lungs, which progresses very slowly and the majority of patients are therefore elderly." | 2.50 | STOP accelerating lung aging for the treatment of COPD. ( Ito, K; Mercado, N, 2014) |
| "Interestingly, Alzheimer's disease (AD) is associated with several abnormalities in neuronal energy metabolism, for example, decline in glucose uptake, mitochondrial dysfunctions and defects in cholesterol metabolism, and in addition, with problems in maintaining Ca(2+) homeostasis." | 2.47 | AMP-activated protein kinase: a potential player in Alzheimer's disease. ( Haapasalo, A; Hiltunen, M; Kaarniranta, K; Salminen, A; Soininen, H, 2011) |
| "This inflammation is characterized by infiltration with macrophages, alterations of adipokine secretion, development of insulin resistance." | 2.45 | [Adipose tissue inflammation and atherosclerosis]. ( Shwarts, V, 2009) |
| " Future clinical trials are necessary to study the nephroprotective effects of the combined treatment at a low dosage in patients with diabetes." | 2.44 | Dapagliflozin and metformin in combination ameliorates diabetic nephropathy by suppressing oxidative stress, inflammation, and apoptosis and activating autophagy in diabetic rats. ( Htun, KT; Jaikumkao, K; Kothan, S; Lungkaphin, A; Montha, N; Pengrattanachot, N; Phengpol, N; Promsan, S; Sriburee, S; Sutthasupha, P; Thongnak, L, 2024) |
| "Although insulin resistance is not part of the diagnostic criteria for PCOS, its importance in the pathogenesis of PCOS can not be denied." | 2.43 | Insulin resistance in polycystic ovarian disease. ( Bhatia, V, 2005) |
| "Metformin (MET) has been demonstrated to have favorable impact on nonalcoholic fatty liver disease (NAFLD); however, the combined effect of this drug with p-coumaric acid (PCA) on liver steatosis is unclear." | 1.91 | Combination therapy of metformin and p-coumaric acid mitigates metabolic dysfunction associated with obesity and nonalcoholic fatty liver disease in high-fat diet obese C57BL/6 mice. ( Bahramzadeh, A; Goodarzi, G; Meshkani, R; Panahi, G; Tehrani, SS, 2023) |
| "Chronic inflammation is a risk factor for diabetes, but it can also be a complication of diabetes, leading to severe diabetes and causing many other clinical manifestations." | 1.91 | Molecular insights of anti-diabetic compounds and its hyaluronic acid conjugates against aldose reductase enzyme through molecular modeling and simulations study-a novel treatment option for inflammatory diabetes. ( Jayabal, D; Jayanthi, S; Shimu, MSS; Thirumalaisamy, R, 2023) |
| "Metformin, a clinical agent of type 2 diabetes, is reported as a potential geroprotector." | 1.72 | Metformin Protects Against Inflammation, Oxidative Stress to Delay Poly I:C-Induced Aging-Like Phenomena in the Gut of an Annual Fish. ( Hou, Y; Li, G; Li, S; Liu, K; Qiao, M; Sun, X; Zhu, H, 2022) |
| "Metformin is an oral hypoglycemic drug widely used in the management of type 2 diabetes mellitus." | 1.72 | Metformin effect in models of inflammation is associated with activation of ATP-dependent potassium channels and inhibition of tumor necrosis factor-α production. ( Augusto, PSA; Batista, CRA; Bertollo, CM; Braga, AV; Coelho, MM; Costa, SOAM; Dutra, MMGB; Machado, RR; Matsui, TC; Melo, ISF; Morais, MI; Rodrigues, FF, 2022) |
| "Metformin has potential anti-inflammatory properties and accelerates wound healing by enhancing vascular development." | 1.72 | Metformin regulates macrophage polarization via the Shh signaling pathway to improve pulmonary vascular development in bronchopulmonary dysplasia. ( Chen, Y; Lin, Z; Qu, X; Xia, H; Xiang, X; Zhou, L, 2022) |
| "Metformin (Met) is a glucose-lowering drug that shows a good effect for the treatment of SCI." | 1.72 | Glutathione-modified macrophage-derived cell membranes encapsulated metformin nanogels for the treatment of spinal cord injury. ( Jiang, X; Liu, X; Mei, X; Shen, W; Tian, H; Wu, C; Yu, Q, 2022) |
| "Nonalcoholic fatty liver disease (NAFLD) is a common cause of clinical liver dysfunction and an important prepathological change of liver cirrhosis." | 1.72 | Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice. ( Cui, W; Kong, L; Yang, X; Zhou, ST, 2022) |
| "Metformin alone reduced hyperinsulinemia and circulating c-reactive protein, but exacerbated nephropathy." | 1.72 | Rapamycin/metformin co-treatment normalizes insulin sensitivity and reduces complications of metabolic syndrome in type 2 diabetic mice. ( Calcutt, NA; Doty, R; Flurkey, K; Harrison, DE; Koza, RA; Reifsnyder, PC, 2022) |
| "Cardiac fibrosis is a major structural change observed in the heart of patients with type 2 diabetes mellitus (T2DM), ultimately resulting in heart failure (HF)." | 1.72 | Gentiopicroside alleviates cardiac inflammation and fibrosis in T2DM rats through targeting Smad3 phosphorylation. ( Hu, XP; Huang, P; Huang, ZJ; Liu, T; Pan, ZF; Shi, JN; Sun, ZY; Xu, YN; Yuan, MN; Zhang, YW; Zou, XZ, 2022) |
| "Metformin is increasingly used to treat gestational diabetes (GDM) and pregnancies complicated by pregestational type 2 diabetes or polycystic ovary syndrome but data regarding long-term offspring outcome are lacking in both human studies and animal models." | 1.72 | Sex-specific effects of maternal metformin intervention during glucose-intolerant obese pregnancy on body composition and metabolic health in aged mouse offspring. ( Aiken, CE; Ashmore, TJ; Blackmore, HL; Dearden, L; Fernandez-Twinn, DS; Ozanne, SE; Pantaleão, LC; Pellegrini Pisani, L; Schoonejans, JM; Tadross, JA, 2022) |
| "Neuroinflammation is a common feature during the development of neurological disorders and neurodegenerative diseases, where glial cells, such as microglia and astrocytes, play key roles in the activation and maintenance of inflammatory responses in the central nervous system." | 1.72 | Early effects of LPS-induced neuroinflammation on the rat hippocampal glycolytic pathway. ( Bobermin, LD; Fróes, F; Gonçalves, CA; Quincozes-Santos, A; Roginski, AC; Seady, M; Vizuete, AFK; Wajner, M; Zanotto, C, 2022) |
| "Metformin has anti-inflammatory effects, but its role in the mechanism of treatment in intestinal injury caused by 5-Fu remains unclear." | 1.72 | Metformin ameliorates 5-fluorouracil-induced intestinalinjury by inhibiting cellular senescence, inflammation, and oxidative stress. ( Chen, J; Dai, Q; Ge, Y; He, S; Shi, YL; Vashisth, MK; Wang, XB; Xia, J, 2022) |
| "As metformin has multiple therapeutic effects in many autoimmune diseases, we explored the effects of metformin on TAO in an in vitro fibroblast model." | 1.72 | Metformin Attenuates Inflammation and Fibrosis in Thyroid-Associated Ophthalmopathy. ( Sha, X; Sun, A; Xiao, W; Xu, Z; Yang, H; Yang, S; Ye, H; Zhang, T, 2022) |
| "Metformin (MET) is a widely used hypoglycemic drug that exhibits anti-inflammatory properties." | 1.72 | Effects of metformin on lipopolysaccharide induced inflammation by activating fibroblast growth factor 21. ( Alataş, Ö; Kar, E; Öz, S; Şahıntürk, V, 2022) |
| "Metformin treatment markedly reduced postinfarction fibrotic remodeling and CD68-positive cell population in mice." | 1.62 | Metformin Attenuates Postinfarction Myocardial Fibrosis and Inflammation in Mice. ( Boal, F; Cussac, D; Korda, M; Kramar, S; Kunduzova, O; Laborde, C; Loi, H; Marsal, D; Oleshchuk, O; Pizzinat, N; Roncalli, J; Tronchere, H, 2021) |
| "Metformin is a first-line drug in the treatment of type-2 diabetes mellitus (T2DM)." | 1.62 | Metformin selectively dampens the acute inflammatory response through an AMPK-dependent mechanism. ( Bhatt, DM; Ghosh, S; Peng, V; Postler, TS, 2021) |
| "Metformin could inhibit the growth of tumor under the condition of diabetes and play a role in the intestinal homeostasis in mice." | 1.62 | Metformin inhibits tumor growth and affects intestinal flora in diabetic tumor-bearing mice. ( Chen, C; Gao, X; Kang, J; Li, C; Liu, Z; Luo, D, 2021) |
| "Metformin (MET) is an anti-diabetic drug, opposes malignancies, inhibits cellular transformation, and promotes cardiovascular protection." | 1.62 | P53 mediates the protective effects of metformin in inflamed lung endothelial cells. ( Akhter, MS; Barabutis, N; Kubra, KT; Leo, AJ; Siejka, A; Uddin, MA, 2021) |
| "Metformin is a kind of hypoglycemic drugs widely used in clinical practice, which has anti-inflammatory and antioxidant effects." | 1.62 | Metformin alleviates high glucose-induced ER stress and inflammation by inhibiting the interaction between caveolin1 and AMPKα in rat astrocytes. ( Chen, S; Cui, W; Li, J; Li, Y; Mao, L; Mei, X; Shao, Z; Wang, G; Wang, W, 2021) |
| "Non-alcoholic fatty liver disease (NAFLD) has become an important health problem in the world." | 1.62 | Combination of metformin and chlorogenic acid attenuates hepatic steatosis and inflammation in high-fat diet fed mice. ( Aliabadi, M; Emamgholipour, S; Ghasempour, G; Hashemnia, SMR; Meshkani, R; Zamani-Garmsiri, F, 2021) |
| "Metformin has exhibited anti-inflammatory and neuroprotective properties in numerous studies." | 1.62 | Metformin ameliorates the status epilepticus- induced hippocampal pathology through possible mTOR modulation. ( Anand, S; Bhatia, A; Bojja, SL; Joshi, R; Medhi, B; Minz, RW, 2021) |
| " We concluded that PD-CSNPs and PD ameliorate diabetic liver damage by modulating glucose transporter 2 expression, affecting the activity of carbohydrate metabolism enzymes, and suppressing oxidative stress and inflammation, PD-CSNPs being more efficient than PD, probably due to higher bioavailability and prolonged release." | 1.62 | Hepatoprotective Effects of Polydatin-Loaded Chitosan Nanoparticles in Diabetic Rats: Modulation of Glucose Metabolism, Oxidative Stress, and Inflammation Biomarkers. ( Abd El-Hameed, AM; Abd El-Twab, SM; Abdel-Moneim, A; El-Shahawy, AAG; Yousef, AI, 2021) |
| " This study is designed to explore the therapeutic potential of metformin and montelukast, in combination with Lactobacillus, for modulation of intestinal flora and suppression of oxidative stress in testicular and liver damage in diabetic male rats." | 1.62 | The therapeutic role of lactobacillus and montelukast in combination with metformin in diabetes mellitus complications through modulation of gut microbiota and suppression of oxidative stress. ( El-Baz, AM; El-Sokkary, MMA; Hassan, HM; Khodir, AE; Shata, A, 2021) |
| " This model provides a simple but unique platform to evaluate aspects of an individual factor's contribution to NAFLD development and mechanisms as well as evaluate preclinical drug efficacy and reassess human dosing regimens." | 1.62 | Validation of an adipose-liver human-on-a-chip model of NAFLD for preclinical therapeutic efficacy evaluation. ( Boone, R; Cai, Y; Hickman, JJ; Lambert, S; Long, CJ; Malik, D; McAleer, CW; Rumsey, JW; Shuler, ML; Slaughter, VL; Sriram, NN, 2021) |
| "Non-alcoholic fatty liver disease (NAFLD) is one of the primary causes of chronic liver disease and is closely linked to insulin resistance, type 2 diabetes mellitus (T2DM), and dyslipidemia." | 1.62 | Metformin in Combination with Malvidin Prevents Progression of Non-Alcoholic Fatty Liver Disease via Improving Lipid and Glucose Metabolisms, and Inhibiting Inflammation in Type 2 Diabetes Rats. ( Gu, X; Li, X; Zhang, C; Zhu, H; Zou, W, 2021) |
| "Inflammation is the first stage of this progression, becoming an appealing target of early therapeutic intervention." | 1.62 | Pharmacological activation of SIRT1 by metformin prevented trauma-induced heterotopic ossification through inhibiting macrophage mediated inflammation. ( Fan, C; He, Y; Li, J; Liu, W; Luo, G; Qian, Y; Sun, Z; Wang, F, 2021) |
| "Treatment with dapsone and metformin reversed the effects of testosterone in the DAP and MET groups." | 1.62 | The effect of dapsone in testosterone enanthate-induced polycystic ovary syndrome in rat. ( Dehpour, AR; Khaledi, E; Khazaei, M; Noori, T; Sadeghi, F; Shirooie, S; Sobarzo-Sánchez, E, 2021) |
| "Low-grade inflammation is often higher in older adults and remains a key risk factor of aging-related morbidities and mortalities." | 1.56 | Metformin Reduces Aging-Related Leaky Gut and Improves Cognitive Function by Beneficially Modulating Gut Microbiome/Goblet Cell/Mucin Axis. ( Ahmadi, S; Ding, J; Jain, S; Justice, J; Kitzman, D; Kritchevsky, SB; McClain, DA; Mishra, SP; Nagpal, R; Razazan, A; Wang, B; Wang, S; Yadav, H, 2020) |
| "Metformin has a protective effect on DA neurons against rotenone-induced neurotoxicity through inhibiting neuroinflammation and ER stress in PD mouse model." | 1.56 | Protective effect of metformin against rotenone-induced parkinsonism in mice. ( Chen, AD; Jing, YH; Wang, DX; Wang, QJ; Xin, YY; Yin, J, 2020) |
| "Cellular starvation is typically a consequence of tissue injury that disrupts the local blood supply but can also occur where cell populations outgrow the local vasculature, as observed in solid tumors." | 1.56 | Starvation and antimetabolic therapy promote cytokine release and recruitment of immune cells. ( Chevet, E; Eldering, E; Favaro, F; Iurlaro, R; Lucendo, E; Majem, B; Marchetti, S; Muñoz-Pinedo, C; Nadal, E; Püschel, F; Redondo-Pedraza, J; Ricci, JE, 2020) |
| "Olanzapine treatment also altered the mRNA expression of hypothalamic appetite-regulating and nutrient-sensing factors, inflammatory genes and TRPV1/TRPV3, which were reversed with ruthenium red and capsazepine treatment." | 1.56 | Role of TRPV1/TRPV3 channels in olanzapine-induced metabolic alteration: Possible involvement in hypothalamic energy-sensing, appetite regulation, inflammation and mesolimbic pathway. ( Bansal, Y; Bishnoi, M; Khare, P; Kondepudi, KK; Kuhad, A; Medhi, B; Singh, R; Sodhi, RK, 2020) |
| "Metformin is an old antidiabetic drug with anti-inflammatory and neuroprotective effects." | 1.56 | The possible role of progranulin on anti-inflammatory effects of metformin in temporal lobe epilepsy. ( Khanizadeh, AM; Mojarad, TB; Nikbakht, F; Vazifehkhah, S, 2020) |
| "In this study, mice with type 2 diabetes mellitus (T2DM) induced by high-fat diet were used to investigate the antidiabetic effect and mechanism of action of peanut skin extract (PSE)." | 1.56 | Peanut skin extract ameliorates the symptoms of type 2 diabetes mellitus in mice by alleviating inflammation and maintaining gut microbiota homeostasis. ( Osada, H; Pan, W; Qi, J; Wu, Q; Xiang, L; Yoshida, M, 2020) |
| "Metformin has been shown to have potential anti-inflammatory activity, but the underlying mechanisms remain obscure." | 1.56 | Metformin improves depressive-like symptoms in mice via inhibition of peripheral and central NF-κB-NLRP3 inflammation activation. ( Bu, WG; Du, RW, 2020) |
| "Despite being the frontline therapy for type 2 diabetes, the mechanisms of action of the biguanide drug metformin are still being discovered." | 1.56 | AMPK regulation of Raptor and TSC2 mediate metformin effects on transcriptional control of anabolism and inflammation. ( Dayn, A; Dayn, Y; Hellberg, K; Luo, EC; Shaw, RJ; Shokhirev, MN; Van Nostrand, EL; Van Nostrand, JL; Yeo, GW; Yu, J, 2020) |
| "Systemic inflammation was induced by injecting LPS (1." | 1.51 | Possible involvement of metformin in downregulation of neuroinflammation and associated behavioural changes in mice. ( Anoopkumar-Dukie, S; Arora, D; Basu Mallik, S; Grant, G; Hall, S; Kinra, M; Mudgal, J; Nampoothiri, M; Rao, CM, 2019) |
| "Metformin was used as positive control." | 1.51 | Eugenol ameliorates insulin resistance, oxidative stress and inflammation in high fat-diet/streptozotocin-induced diabetic rat. ( Al-Trad, B; Al-Zoubi, M; Alkhateeb, H; Alsmadi, W, 2019) |
| "Psoriasis is a prevalent, chronic inflammatory skin disease that arises from rapid and excessive growth of keratinocytes induced by abnormal inflammatory responses." | 1.51 | Metformin inhibits pro-inflammatory responses via targeting nuclear factor-κB in HaCaT cells. ( Ba, W; Chi, S; Li, C; Wang, R; Wang, Y; Xu, Y; Yang, J; Yin, G, 2019) |
| "Treatment with metformin altered macrophage polarization, reduced liver size and reduced micronuclei formation in NAFLD/NASH-associated HCC larvae." | 1.51 | Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish. ( de Oliveira, S; Golenberg, N; Graves, AL; Houseright, RA; Huttenlocher, A; Korte, BG; Miskolci, V, 2019) |
| "Gout is the most common inflammatory arthritis worldwide, and patients experience a heavy burden of cardiovascular and metabolic diseases." | 1.51 | mTOR inhibition by metformin impacts monosodium urate crystal-induced inflammation and cell death in gout: a prelude to a new add-on therapy? ( Broen, JCA; Jansen, M; Merriman, T; Ottria, A; Phipps-Green, A; Radstake, TRDJ; Schuiveling, M; van der Linden, M; van Lochem, E; Vazirpanah, N; Wichers, CGK; Zimmermann, M, 2019) |
| "15 obese patients with type 2 diabetes were studied, all using metformin (1-2 g/day) and sulfonylurea (glimiperide)." | 1.51 | Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes. ( Digtiar, NI; Kaidashev, IP; Kaidasheva, EI; Savchenko, LG; Selikhova, LG; Shlykova, OA; Vesnina, LE, 2019) |
| "The pathophysiology of type 2 diabetes (T2DM) is associated with perturbation of innate immune response." | 1.51 | Analysis of Inflammatory Gene Expression Profile of Peripheral Blood Leukocytes in Type 2 Diabetes. ( Azim, MK; Baloch, AA; Inayat, H, 2019) |
| " Long-term use of OCPs needs to be considered carefully for PCOS patients who are already burdened with associated risk factors." | 1.51 | Oral contraceptive use increases risk of inflammatory and coagulatory disorders in women with Polycystic Ovarian Syndrome: An observational study. ( Amin, S; Bhat, IA; Fatima, Q; Ganie, MA; Jeelani, H; Kawa, IA; Manzoor, S; Rashid, F; Shah, ZA; Yousuf, SD, 2019) |
| "Metformin was administered for 7 weeks to high fat-fed C57/6J male mice in vivo." | 1.48 | Metformin improves obesity-associated inflammation by altering macrophages polarization. ( Jing, Y; Li, D; Li, Q; Li, R; Wu, F; Yang, L, 2018) |
| "Metformin has been the most prescribed glucose-lowering medicine worldwide, and its potential for many other therapeutic applications is also being explored intensively." | 1.48 | Metformin attenuates folic-acid induced renal fibrosis in mice. ( Cao, Q; Chen, J; Chen, XM; Huang, C; Pollock, CA; Shi, Y; Yi, H; Zhang, L; Zhao, Y, 2018) |
| "Esophageal squamous cell carcinoma (ESCC) is an intractable digestive organ cancer that has proven difficult to treat despite multidisciplinary therapy, and a new treatment strategy is demanded." | 1.48 | Antitumor effects of metformin are a result of inhibiting nuclear factor kappa B nuclear translocation in esophageal squamous cell carcinoma. ( Akimoto, AK; Akutsu, Y; Hanari, N; Hoshino, I; Iida, K; Kano, M; Matsubara, H; Matsumoto, Y; Murakami, K; Okada, K; Otsuka, R; Sakata, H; Sekino, N; Shiraishi, T; Takahashi, M; Toyozumi, T; Yokoyama, M, 2018) |
| "The degree of complexity of a cancer system could be vast involving multiple endogenous and exogenous agents interacting with the over 10 trillion cells comprising the body." | 1.48 | A complex systems approach to cancer prevention. ( Jupp, PW, 2018) |
| "Overall, MET reduced liver NAFLD but promoted hepatocyte increase in pro-inflammatory cytokines, thus, leading to liver inflammation." | 1.48 | Short-term treatment with metformin reduces hepatic lipid accumulation but induces liver inflammation in obese mice. ( Alves, MJ; Araujo, AP; Batatinha, HA; Biondo, LA; Curi, R; de Souza Teixeira, AA; Hirabara, SM; Lima, EA; Neto, JCR; Sanches Silveira, L; Souza, CO, 2018) |
| "Obesity-driven Type 2 diabetes (T2D) is a systemic inflammatory condition associated with cardiovascular disease." | 1.48 | Inflammatory signatures distinguish metabolic health in African American women with obesity. ( Andrieu, G; Bertrand, KA; Denis, GV; Medina, ND; Palmer, JR; Sebastiani, P; Slama, J; Strissel, KJ; Tran, AH, 2018) |
| "Treatment with metformin reversed LPS-induced decline of AMPK phosphorylation." | 1.48 | Metformin alleviated endotoxemia-induced acute lung injury via restoring AMPK-dependent suppression of mTOR. ( Dai, J; Huang, J; Jiang, R; Tian, R; Wu, K; Yang, Y; Zhang, L, 2018) |
| "Inflammation has been suggested as a critical etiologic factor." | 1.46 | Attenuation of Myeloid-Specific TGFβ Signaling Induces Inflammatory Cerebrovascular Disease and Stroke. ( Boehm, M; Hallenbeck, J; Hollander, MC; Ishii, H; Latour, LL; Lin, PC; Merchant, AS; Min, Y; Munasinghe, J; Ray-Choudhury, A; Xiao, Z; Yang, D; Yang, L, 2017) |
| "Metformin is a widely used and safe antidiabetic drug that has recently been shown to possess analgesic properties in models of inflammatory pain." | 1.46 | Metformin Synergizes With Conventional and Adjuvant Analgesic Drugs to Reduce Inflammatory Hyperalgesia in Rats. ( Micov, AM; Pecikoza, UB; Stepanović-Petrović, RM; Tomić, MA, 2017) |
| "Co-treatment with metformin significantly abrogated the AGE-mediated effects in hNSCs." | 1.46 | Metformin activation of AMPK suppresses AGE-induced inflammatory response in hNSCs. ( Chen, SJ; Chen, YL; Cheng, YC; Chiang, MC; Chung, MM; Huang, RN; Lin, CH; Lin, KH; Nicol, CJ; Pei, D; Shih, YN; Yen, CH, 2017) |
| "Pretreatment of metformin dose dependently suppressed the expression of TNF-α mRNA induced by LPS (2 mM, p = 0." | 1.43 | The suppressive effects of metformin on inflammatory response of otitis media model in human middle ear epithelial cells. ( Chae, SW; Cho, JG; Choi, J; Im, GJ; Jung, HH; Song, JJ, 2016) |
| "About 350 million people worldwide have type 2 diabetes (T2D)." | 1.42 | Increased Plasma Levels of Xanthurenic and Kynurenic Acids in Type 2 Diabetes. ( Oxenkrug, GF, 2015) |
| "Metformin has been considered a potential adjunctive therapy in treating poorly controlled type 1 diabetes with obesity and insulin resistance, owing to its potent effects on improving insulin sensitivity." | 1.42 | New Insight Into Metformin Action: Regulation of ChREBP and FOXO1 Activities in Endothelial Cells. ( Clements, MA; Heruth, DP; Jackson, K; Kover, KL; Li, X; Moore, WV; Watkins, DJ; Yan, Y; Zang, M, 2015) |
| "Metformin treatment significantly improved the glycaemic profile of HFD-fed mice." | 1.40 | An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. ( Bae, JW; Kim, MS; Lee, HY; Lee, JC; Lee, MS; Shin, NR; Whon, TW, 2014) |
| "Metformin is a cornerstone of the current therapy of type 2 diabetes." | 1.40 | Metformin affects macrophages' phenotype and improves the activity of glutathione peroxidase, superoxide dismutase, catalase and decreases malondialdehyde concentration in a partially AMPK-independent manner in LPS-stimulated human monocytes/macrophages. ( Bułdak, RJ; Bułdak, Ł; Duława-Bułdak, A; Kozłowski, M; Liber, S; Machnik, G; Okopień, B; Suchy, D; Łabuzek, K, 2014) |
| "Inflammation has been proposed as the main cause for the high risk of atherosclerotic disease in DM II." | 1.40 | Impaired fibrous repair: a possible contributor to atherosclerotic plaque vulnerability in patients with type II diabetes. ( Bengtsson, E; Björkbacka, H; Dunér, P; Edsfeldt, A; Gonçalves, I; Grufman, H; Melander, O; Mollet, IG; Nilsson, J; Nilsson, M; Nitulescu, M; Orho-Melander, M; Persson, A, 2014) |
| " These results indicated that chronic administration of Met regulated pancreatic inflammation generation, ion and hormone homeostasis and improved β cell function of diabetic KKAy mice." | 1.40 | [Metformin ameliorates β-cell dysfunction by regulating inflammation production, ion and hormone homeostasis of pancreas in diabetic KKAy mice]. ( Hou, SC; Liu, Q; Liu, SN; Shen, ZF; Sun, SJ; Wang, Y, 2014) |
| "Treatment with metformin mimics some of the benefits of calorie restriction, such as improved physical performance, increased insulin sensitivity, and reduced low-density lipoprotein and cholesterol levels without a decrease in caloric intake." | 1.39 | Metformin improves healthspan and lifespan in mice. ( Becker, KG; Bernier, M; Blouin, MJ; Bohr, VA; de Cabo, R; Gomes, AP; Ingram, DK; Martin-Montalvo, A; Mercken, EM; Minor, RK; Mitchell, SJ; Mote, PL; Palacios, HH; Pollak, M; Scheibye-Knudsen, M; Schwab, M; Sinclair, DA; Spindler, SR; Ward, TM; Wolf, NS; Yu, Y; Zhang, Y, 2013) |
| "Semecarpus anacardium nut milk extract at a dosage of 200 mg/kg orally significantly (p < 0." | 1.39 | Anti-inflammatory and anti-hyperlipidemic effect of Semecarpus anacardium in a high fat diet: STZ-induced type 2 diabetic rat model. ( Khan, HB; Moorthy, BT; Palanivelu, S; Panchanatham, S; Vinayagam, KS, 2013) |
| "Metformin treatment decreases serum ASAA in these women." | 1.37 | The anti-atherogenic aspect of metformin treatment in insulin resistant women with the polycystic ovary syndrome: role of the newly established pro-inflammatory adipokine Acute-phase Serum Amyloid A; evidence of an adipose tissue-monocyte axis. ( Adya, R; Aghilla, M; Keay, SD; Lehnert, H; Randeva, HS; Shan, X; Tan, BK, 2011) |
| "Metformin treatment significantly improved glycation, oxidative stress, CCL2 levels, NO bioavailability and insulin resistance and normalized endothelial function in aorta." | 1.37 | Metformin restores endothelial function in aorta of diabetic rats. ( Fernandes, R; Louro, T; Matafome, P; Nunes, E; Seiça, RM; Sena, CM, 2011) |
| "Metformin treatment attenuated the main components of the fibrovascular tissue, wet weight, vascularization (Hb content), macrophage recruitment (NAG activity), collagen deposition and the levels of transforming growth factor (TGF-beta1) intraimplant." | 1.36 | Metformin inhibits inflammatory angiogenesis in a murine sponge model. ( Amaral, LS; Andrade, SP; Belo, AV; Campos, PR; Cota, BD; Gomes, MA; Paiva, AM; Rocha, MA; Silva, JH; Tafuri, LS; Xavier, DO, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.31) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 21 (6.48) | 29.6817 |
| 2010's | 147 (45.37) | 24.3611 |
| 2020's | 155 (47.84) | 2.80 |
| Authors | Studies |
|---|---|
| Kristófi, R | 1 |
| Eriksson, JW | 1 |
| Huang, SW | 1 |
| Ou, YC | 1 |
| Tang, KS | 1 |
| Yu, HR | 1 |
| Huang, LT | 1 |
| Tain, YL | 1 |
| Lin, IC | 1 |
| Sheen, JM | 1 |
| Hou, CY | 1 |
| Tsai, CC | 1 |
| Tiao, MM | 1 |
| Loi, H | 1 |
| Kramar, S | 1 |
| Laborde, C | 1 |
| Marsal, D | 1 |
| Pizzinat, N | 1 |
| Cussac, D | 1 |
| Roncalli, J | 1 |
| Boal, F | 1 |
| Tronchere, H | 1 |
| Oleshchuk, O | 1 |
| Korda, M | 1 |
| Kunduzova, O | 1 |
| Postler, TS | 1 |
| Peng, V | 1 |
| Bhatt, DM | 1 |
| Ghosh, S | 2 |
| Dare, A | 1 |
| Channa, ML | 1 |
| Nadar, A | 1 |
| Li, S | 2 |
| Hou, Y | 4 |
| Liu, K | 5 |
| Zhu, H | 2 |
| Qiao, M | 1 |
| Sun, X | 4 |
| Li, G | 3 |
| Xiong, W | 1 |
| Sun, KY | 1 |
| Zhu, Y | 2 |
| Zhang, X | 10 |
| Zhou, YH | 1 |
| Zou, X | 1 |
| Abdulmalek, S | 1 |
| Eldala, A | 1 |
| Awad, D | 1 |
| Balbaa, M | 1 |
| Azemi, AK | 1 |
| Mokhtar, SS | 1 |
| Sharif, SET | 1 |
| Rasool, AHG | 1 |
| Kang, J | 2 |
| Li, C | 4 |
| Gao, X | 2 |
| Liu, Z | 4 |
| Chen, C | 1 |
| Luo, D | 1 |
| Kubra, KT | 1 |
| Uddin, MA | 1 |
| Akhter, MS | 1 |
| Leo, AJ | 1 |
| Siejka, A | 1 |
| Barabutis, N | 1 |
| Zhou, C | 1 |
| Peng, B | 1 |
| Qin, Z | 1 |
| Zhu, W | 1 |
| Guo, C | 2 |
| Padmapriydarsini, C | 1 |
| Mamulwar, M | 1 |
| Mohan, A | 1 |
| Shanmugam, P | 1 |
| Gomathy, NS | 1 |
| Mane, A | 1 |
| Singh, UB | 1 |
| Pavankumar, N | 1 |
| Kadam, A | 1 |
| Kumar, H | 1 |
| Suresh, C | 1 |
| Reddy, D | 1 |
| Devi, P | 1 |
| Ramesh, PM | 1 |
| Sekar, L | 1 |
| Jawahar, S | 1 |
| Shandil, RK | 1 |
| Singh, M | 4 |
| Menon, J | 1 |
| Guleria, R | 1 |
| Augusto, PSA | 1 |
| Matsui, TC | 1 |
| Braga, AV | 1 |
| Rodrigues, FF | 1 |
| Morais, MI | 1 |
| Dutra, MMGB | 1 |
| Batista, CRA | 1 |
| Melo, ISF | 1 |
| Costa, SOAM | 1 |
| Bertollo, CM | 1 |
| Coelho, MM | 1 |
| Machado, RR | 1 |
| Krysiak, R | 2 |
| Kowalcze, K | 2 |
| Okopień, B | 3 |
| Xiang, X | 1 |
| Zhou, L | 4 |
| Lin, Z | 1 |
| Qu, X | 1 |
| Chen, Y | 7 |
| Xia, H | 1 |
| Cheng, L | 1 |
| Fu, Q | 2 |
| Fan, Y | 3 |
| Liu, F | 1 |
| Lin, W | 2 |
| Wu, X | 5 |
| Wang, G | 2 |
| Wang, Y | 8 |
| Yang, Q | 3 |
| Xu, C | 3 |
| Zheng, Y | 3 |
| Wang, L | 7 |
| Wu, J | 3 |
| Zeng, M | 1 |
| Luo, M | 1 |
| Usman, A | 1 |
| Bliden, KP | 1 |
| Cho, A | 1 |
| Walia, N | 1 |
| Jerjian, C | 1 |
| Singh, A | 2 |
| Kundan, P | 1 |
| Duhan, S | 1 |
| Tantry, US | 1 |
| Gurbel, PA | 1 |
| Khodadadi, M | 1 |
| Jafari-Gharabaghlou, D | 1 |
| Zarghami, N | 1 |
| Yu, Q | 1 |
| Jiang, X | 2 |
| Liu, X | 3 |
| Shen, W | 1 |
| Mei, X | 3 |
| Tian, H | 2 |
| Wu, C | 2 |
| Liu, J | 4 |
| Aylor, KW | 1 |
| Chai, W | 1 |
| Barrett, EJ | 1 |
| Song, H | 3 |
| Zhai, R | 1 |
| Liang, H | 1 |
| Song, G | 1 |
| Yuan, Y | 1 |
| Xu, Y | 6 |
| Yan, Y | 6 |
| Qiu, L | 2 |
| Sun, T | 1 |
| Xiao, Y | 1 |
| Li, K | 3 |
| Bian, J | 1 |
| Liu, H | 3 |
| Zhai, X | 1 |
| El-Omar, E | 1 |
| Han, L | 1 |
| Gong, L | 1 |
| Wang, M | 1 |
| Jia, Y | 1 |
| Yang, W | 1 |
| Lin, C | 1 |
| Tao, B | 1 |
| Deng, Z | 1 |
| Gao, P | 1 |
| Yang, Y | 3 |
| Cai, K | 1 |
| Elbarbary, NS | 1 |
| Ismail, EAR | 1 |
| Ghallab, MA | 1 |
| Chen, XC | 1 |
| Wu, D | 4 |
| Wu, HL | 1 |
| Li, HY | 1 |
| Yang, C | 2 |
| Su, HY | 1 |
| Liu, ZJ | 1 |
| Huang, XR | 1 |
| Lu, X | 2 |
| Huang, LF | 1 |
| Zhu, SP | 1 |
| Pan, QJ | 1 |
| An, N | 1 |
| Liu, HF | 1 |
| Zhou, ST | 1 |
| Cui, W | 2 |
| Kong, L | 2 |
| Yang, X | 4 |
| Sapmaz, T | 1 |
| Coskun, G | 1 |
| Saker, D | 1 |
| Pence, HH | 1 |
| Keles, P | 1 |
| Hayretdag, C | 1 |
| Kuras, S | 1 |
| Topkaraoglu, S | 1 |
| Erdem, E | 1 |
| Efendic, F | 1 |
| Sevgin, K | 1 |
| Tekayev, M | 1 |
| Polat, S | 1 |
| Sapmaz, E | 1 |
| Irkorucu, O | 1 |
| Elbandrawy, AM | 1 |
| Yousef, AM | 1 |
| Morgan, EN | 1 |
| Ewais, NF | 1 |
| Eid, MM | 1 |
| Elkholi, SM | 1 |
| Abdelbasset, WK | 1 |
| Su, SC | 2 |
| Chien, CY | 1 |
| Chen, YC | 1 |
| Chiang, CF | 2 |
| Lin, FH | 2 |
| Kuo, FC | 2 |
| Huang, CL | 2 |
| Li, PF | 2 |
| Liu, JS | 2 |
| Lu, CH | 3 |
| Ho, LJ | 1 |
| Hsieh, CH | 3 |
| Hung, YJ | 4 |
| Shieh, YS | 2 |
| Lee, CH | 3 |
| Wang, X | 7 |
| Liu, Y | 8 |
| Han, D | 1 |
| Zhong, J | 1 |
| Chen, X | 4 |
| Shaaban, AA | 1 |
| Abdelhamid, AM | 1 |
| Shaker, ME | 1 |
| Cavalu, S | 1 |
| Maghiar, AM | 1 |
| Alsayegh, AA | 1 |
| Babalghith, AO | 1 |
| El-Ahwany, E | 1 |
| Amin, NA | 1 |
| Mohammed, OA | 1 |
| Eissa, H | 1 |
| Gaafar, AGA | 1 |
| Batiha, GE | 1 |
| Saber, S | 1 |
| Reifsnyder, PC | 1 |
| Flurkey, K | 1 |
| Doty, R | 1 |
| Calcutt, NA | 1 |
| Koza, RA | 1 |
| Harrison, DE | 1 |
| Zou, XZ | 1 |
| Zhang, YW | 1 |
| Pan, ZF | 1 |
| Hu, XP | 1 |
| Xu, YN | 1 |
| Huang, ZJ | 1 |
| Sun, ZY | 1 |
| Yuan, MN | 1 |
| Shi, JN | 1 |
| Huang, P | 1 |
| Liu, T | 1 |
| Song, L | 1 |
| Cui, J | 2 |
| Hu, S | 1 |
| Wang, R | 3 |
| Li, H | 7 |
| Sun, B | 2 |
| Shaaban, HH | 1 |
| Alzaim, I | 1 |
| El-Mallah, A | 1 |
| Aly, RG | 1 |
| El-Yazbi, AF | 2 |
| Wahid, A | 1 |
| Schoonejans, JM | 1 |
| Blackmore, HL | 1 |
| Ashmore, TJ | 1 |
| Pantaleão, LC | 1 |
| Pellegrini Pisani, L | 1 |
| Dearden, L | 1 |
| Tadross, JA | 1 |
| Aiken, CE | 1 |
| Fernandez-Twinn, DS | 1 |
| Ozanne, SE | 1 |
| Gorbatenko, VO | 1 |
| Goriainov, SV | 1 |
| Babenko, VA | 1 |
| Plotnikov, EY | 1 |
| Sergeeva, MG | 1 |
| Chistyakov, DV | 1 |
| Vizuete, AFK | 1 |
| Fróes, F | 1 |
| Seady, M | 1 |
| Zanotto, C | 1 |
| Bobermin, LD | 1 |
| Roginski, AC | 1 |
| Wajner, M | 1 |
| Quincozes-Santos, A | 1 |
| Gonçalves, CA | 1 |
| Eleazu, CO | 1 |
| Obeten, UN | 1 |
| Ozor, G | 1 |
| Njemanze, CC | 1 |
| Eleazu, KC | 1 |
| Egedigwe-Ekeleme, AC | 1 |
| Okorie, UC | 1 |
| Ogunwa, SC | 1 |
| Adeolu, AI | 1 |
| Okoh, PN | 1 |
| Kalu, AO | 1 |
| Onyia, CJ | 1 |
| Onyia, S | 1 |
| Ossai, P | 1 |
| Chikezie, CC | 1 |
| Odii, BC | 1 |
| Obi, V | 1 |
| Igwe, VM | 1 |
| Amobi, CA | 1 |
| Ugada, OJ | 1 |
| Kalu, WO | 1 |
| Kanu, S | 1 |
| Zhang, J | 4 |
| Brown, R | 1 |
| Hogan, MV | 1 |
| Onishi, K | 1 |
| Wang, JH | 1 |
| Feng, YY | 1 |
| Wang, Z | 4 |
| Pang, H | 1 |
| Xia, J | 1 |
| Chen, J | 4 |
| Vashisth, MK | 1 |
| Ge, Y | 1 |
| Dai, Q | 1 |
| He, S | 1 |
| Shi, YL | 1 |
| Wang, XB | 1 |
| Li, Q | 8 |
| Shen, L | 3 |
| Guo, K | 3 |
| Zhou, X | 5 |
| Arinno, A | 2 |
| Maneechote, C | 2 |
| Khuanjing, T | 2 |
| Prathumsap, N | 2 |
| Chunchai, T | 2 |
| Arunsak, B | 2 |
| Nawara, W | 2 |
| Kerdphoo, S | 2 |
| Shinlapawittayatorn, K | 2 |
| Chattipakorn, SC | 2 |
| Chattipakorn, N | 2 |
| Xu, Z | 2 |
| Ye, H | 1 |
| Xiao, W | 1 |
| Sun, A | 1 |
| Yang, S | 3 |
| Zhang, T | 4 |
| Sha, X | 1 |
| Yang, H | 2 |
| Pedrosa, AR | 1 |
| Martins, DC | 1 |
| Rizzo, M | 1 |
| Silva-Nunes, J | 1 |
| Khalafani, Z | 1 |
| Zamani-Garmsiri, F | 4 |
| Panahi, G | 4 |
| Meshkani, R | 5 |
| Wan, Y | 1 |
| Wang, S | 5 |
| Niu, Y | 1 |
| Duo, B | 1 |
| Lu, Z | 2 |
| Zhu, R | 1 |
| Alshahrani, MY | 1 |
| Ebrahim, HA | 2 |
| Alqahtani, SM | 1 |
| Bayoumy, NM | 1 |
| Kamar, SS | 3 |
| ShamsEldeen, AM | 1 |
| Haidara, MA | 3 |
| Al-Ani, B | 3 |
| Albawardi, A | 1 |
| Tehrani, SS | 3 |
| Goodarzi, G | 2 |
| Karami, F | 1 |
| Jamaati, H | 1 |
| Coleman-Fuller, N | 1 |
| Zeini, MS | 1 |
| Hayes, AW | 1 |
| Gholami, M | 2 |
| Salehirad, M | 1 |
| Darabi, M | 1 |
| Motaghinejad, M | 1 |
| Bahramzadeh, A | 1 |
| Solier, S | 1 |
| Müller, S | 1 |
| Cañeque, T | 1 |
| Versini, A | 1 |
| Mansart, A | 1 |
| Sindikubwabo, F | 1 |
| Baron, L | 1 |
| Emam, L | 1 |
| Gestraud, P | 1 |
| Pantoș, GD | 1 |
| Gandon, V | 1 |
| Gaillet, C | 1 |
| Wu, TD | 1 |
| Dingli, F | 1 |
| Loew, D | 1 |
| Baulande, S | 1 |
| Durand, S | 1 |
| Sencio, V | 1 |
| Robil, C | 1 |
| Trottein, F | 1 |
| Péricat, D | 1 |
| Näser, E | 1 |
| Cougoule, C | 1 |
| Meunier, E | 1 |
| Bègue, AL | 1 |
| Salmon, H | 1 |
| Manel, N | 1 |
| Puisieux, A | 1 |
| Watson, S | 1 |
| Dawson, MA | 1 |
| Servant, N | 1 |
| Kroemer, G | 2 |
| Annane, D | 1 |
| Rodriguez, R | 1 |
| Hambly, R | 1 |
| Kearney, N | 1 |
| Hughes, R | 1 |
| Fletcher, JM | 1 |
| Kirby, B | 1 |
| Petakh, P | 1 |
| Oksenych, V | 1 |
| Kamyshnyi, A | 1 |
| Medeiros, ML | 1 |
| Oliveira, AL | 1 |
| Mello, GC | 1 |
| Antunes, E | 2 |
| Paavilainen, E | 1 |
| Niinikoski, H | 1 |
| Parkkola, R | 1 |
| Koskensalo, K | 1 |
| Nikkinen, H | 1 |
| Veijola, R | 1 |
| Vääräsmäki, M | 1 |
| Loo, BM | 1 |
| Tossavainen, P | 1 |
| Rönnemaa, T | 1 |
| Tertti, K | 1 |
| Oikonomou, E | 1 |
| Xenou, M | 1 |
| Zakynthinos, GE | 1 |
| Tsaplaris, P | 1 |
| Lampsas, S | 1 |
| Bletsa, E | 1 |
| Gialamas, I | 1 |
| Kalogeras, K | 1 |
| Goliopoulou, A | 1 |
| Gounaridi, MI | 1 |
| Pesiridis, T | 1 |
| Tsatsaragkou, A | 1 |
| Vavouranakis, M | 1 |
| Siasos, G | 2 |
| Tousoulis, D | 2 |
| Jayabal, D | 1 |
| Jayanthi, S | 1 |
| Thirumalaisamy, R | 1 |
| Shimu, MSS | 1 |
| Petrocelli, JJ | 1 |
| McKenzie, AI | 1 |
| de Hart, NMMP | 1 |
| Reidy, PT | 1 |
| Mahmassani, ZS | 1 |
| Keeble, AR | 1 |
| Kaput, KL | 1 |
| Wahl, MP | 1 |
| Rondina, MT | 1 |
| Marcus, RL | 1 |
| Welt, CK | 1 |
| Holland, WL | 1 |
| Funai, K | 1 |
| Fry, CS | 1 |
| Drummond, MJ | 1 |
| Mohamed, EK | 1 |
| Hafez, DM | 1 |
| Sarkar, K | 1 |
| Bank, S | 1 |
| Chatterjee, A | 1 |
| Dutta, K | 1 |
| Das, A | 1 |
| Chakraborty, S | 1 |
| Paul, N | 1 |
| Sarkar, J | 1 |
| De, S | 1 |
| Acharyya, K | 1 |
| Chattopadhyay, D | 1 |
| Das, M | 1 |
| Malaekeh-Nikouei, A | 1 |
| Shokri-Naei, S | 1 |
| Karbasforoushan, S | 1 |
| Bahari, H | 1 |
| Baradaran Rahimi, V | 1 |
| Heidari, R | 1 |
| Askari, VR | 1 |
| Jaikumkao, K | 1 |
| Thongnak, L | 1 |
| Htun, KT | 1 |
| Pengrattanachot, N | 1 |
| Phengpol, N | 1 |
| Sutthasupha, P | 1 |
| Promsan, S | 1 |
| Montha, N | 1 |
| Sriburee, S | 1 |
| Kothan, S | 1 |
| Lungkaphin, A | 1 |
| Bajetto, A | 1 |
| Pattarozzi, A | 1 |
| Sirito, R | 1 |
| Barbieri, F | 1 |
| Florio, T | 1 |
| He, L | 1 |
| Zhan, F | 1 |
| Li, X | 16 |
| Inceu, AI | 1 |
| Neag, MA | 1 |
| Catinean, A | 1 |
| Bocsan, CI | 1 |
| Craciun, CI | 1 |
| Melincovici, CS | 1 |
| Muntean, DM | 1 |
| Onofrei, MM | 1 |
| Pop, RM | 1 |
| Buzoianu, AD | 1 |
| Miguel, V | 1 |
| Rey-Serra, C | 1 |
| Tituaña, J | 1 |
| Sirera, B | 1 |
| Alcalde-Estévez, E | 1 |
| Herrero, JI | 1 |
| Ranz, I | 1 |
| Fernández, L | 1 |
| Castillo, C | 1 |
| Sevilla, L | 1 |
| Nagai, J | 1 |
| Reimer, KC | 1 |
| Jansen, J | 1 |
| Kramann, R | 1 |
| Costa, IG | 1 |
| Castro, A | 1 |
| Sancho, D | 1 |
| Rodríguez González-Moro, JM | 1 |
| Lamas, S | 1 |
| Cortés, M | 1 |
| Brischetto, A | 1 |
| Martinez-Campanario, MC | 1 |
| Ninfali, C | 1 |
| Domínguez, V | 1 |
| Fernández, S | 1 |
| Celis, R | 1 |
| Esteve-Codina, A | 1 |
| Lozano, JJ | 1 |
| Sidorova, J | 1 |
| Garrabou, G | 1 |
| Siegert, AM | 1 |
| Enrich, C | 1 |
| Pintado, B | 1 |
| Morales-Ruiz, M | 1 |
| Castro, P | 1 |
| Cañete, JD | 1 |
| Postigo, A | 1 |
| Elkhatib, MAW | 1 |
| Mroueh, A | 1 |
| Rafeh, RW | 1 |
| Sleiman, F | 1 |
| Fouad, H | 1 |
| Saad, EI | 1 |
| Fouda, MA | 1 |
| Elgaddar, O | 1 |
| Issa, K | 1 |
| Eid, AH | 1 |
| Eid, AA | 1 |
| Abd-Elrahman, KS | 1 |
| Malvandi, AM | 1 |
| Loretelli, C | 1 |
| Ben Nasr, M | 1 |
| Zuccotti, GV | 1 |
| Fiorina, P | 1 |
| Mudgal, J | 1 |
| Nampoothiri, M | 1 |
| Basu Mallik, S | 1 |
| Kinra, M | 1 |
| Hall, S | 1 |
| Grant, G | 1 |
| Anoopkumar-Dukie, S | 1 |
| Rao, CM | 1 |
| Arora, D | 1 |
| Mo, D | 1 |
| Liu, S | 4 |
| Ma, H | 3 |
| Yu, H | 1 |
| Tong, N | 1 |
| Liao, J | 2 |
| Ren, Y | 2 |
| Adeshirlarijaney, A | 1 |
| Zou, J | 2 |
| Tran, HQ | 1 |
| Chassaing, B | 1 |
| Gewirtz, AT | 1 |
| Shi, W | 1 |
| SreeHarsha, N | 1 |
| Zhang, D | 3 |
| Lytrivi, M | 1 |
| Castell, AL | 1 |
| Poitout, V | 1 |
| Cnop, M | 1 |
| Han, Y | 2 |
| Yuan, F | 1 |
| Deng, C | 1 |
| He, F | 1 |
| Zhang, Y | 8 |
| Shen, H | 1 |
| Chen, Z | 1 |
| Qian, L | 1 |
| Gus, EI | 1 |
| Shahrokhi, S | 1 |
| Jeschke, MG | 1 |
| Bagheri, M | 1 |
| Mostafavinia, A | 1 |
| Abdollahifar, MA | 1 |
| Amini, A | 1 |
| Ghoreishi, SK | 1 |
| Chien, S | 1 |
| Hamblin, MR | 1 |
| Bayat, S | 1 |
| Bayat, M | 1 |
| Shen, X | 1 |
| Fan, B | 1 |
| Hu, X | 3 |
| Luo, L | 2 |
| Yang, L | 5 |
| Hao, Y | 2 |
| Meng, X | 1 |
| Pernicova, I | 1 |
| Kelly, S | 1 |
| Ajodha, S | 1 |
| Sahdev, A | 1 |
| Bestwick, JP | 1 |
| Gabrovska, P | 1 |
| Akanle, O | 1 |
| Ajjan, R | 1 |
| Kola, B | 1 |
| Stadler, M | 1 |
| Fraser, W | 1 |
| Christ-Crain, M | 2 |
| Grossman, AB | 1 |
| Pitzalis, C | 1 |
| Korbonits, M | 1 |
| Reincke, M | 1 |
| Ahmadi, S | 1 |
| Razazan, A | 1 |
| Nagpal, R | 1 |
| Jain, S | 1 |
| Wang, B | 1 |
| Mishra, SP | 1 |
| Justice, J | 1 |
| Ding, J | 1 |
| McClain, DA | 1 |
| Kritchevsky, SB | 1 |
| Kitzman, D | 1 |
| Yadav, H | 1 |
| Pålsson-McDermott, EM | 1 |
| O'Neill, LAJ | 1 |
| Ouyang, J | 2 |
| Isnard, S | 2 |
| Lin, J | 2 |
| Fombuena, B | 2 |
| Marette, A | 2 |
| Routy, B | 2 |
| Routy, JP | 2 |
| Wang, DX | 1 |
| Chen, AD | 1 |
| Wang, QJ | 1 |
| Xin, YY | 1 |
| Yin, J | 1 |
| Jing, YH | 1 |
| Püschel, F | 1 |
| Favaro, F | 1 |
| Redondo-Pedraza, J | 1 |
| Lucendo, E | 1 |
| Iurlaro, R | 1 |
| Marchetti, S | 1 |
| Majem, B | 1 |
| Eldering, E | 1 |
| Nadal, E | 1 |
| Ricci, JE | 1 |
| Chevet, E | 1 |
| Muñoz-Pinedo, C | 1 |
| Peng, X | 1 |
| Messaoudene, M | 1 |
| Saad, ZA | 1 |
| Khodeer, DM | 1 |
| Zaitone, SA | 1 |
| Ahmed, AAM | 1 |
| Moustafa, YM | 1 |
| Wei, J | 1 |
| Qi, H | 2 |
| Zhao, C | 1 |
| Bian, Y | 1 |
| Rai, RC | 1 |
| Bagul, PK | 1 |
| Banerjee, SK | 1 |
| Zitvogel, L | 1 |
| Bharath, LP | 3 |
| Agrawal, M | 1 |
| McCambridge, G | 1 |
| Nicholas, DA | 1 |
| Hasturk, H | 1 |
| Jiang, K | 1 |
| Liu, R | 1 |
| Guo, Z | 1 |
| Deeney, J | 1 |
| Apovian, CM | 1 |
| Snyder-Cappione, J | 1 |
| Hawk, GS | 1 |
| Fleeman, RM | 1 |
| Pihl, RMF | 1 |
| Thompson, K | 1 |
| Belkina, AC | 1 |
| Cui, L | 1 |
| Proctor, EA | 1 |
| Kern, PA | 3 |
| Nikolajczyk, BS | 3 |
| Dawood, AF | 1 |
| Alzamil, N | 1 |
| Abdel Kader, DH | 1 |
| Chung, E | 1 |
| Elmassry, MM | 1 |
| Kottapalli, P | 1 |
| Kottapalli, KR | 1 |
| Kaur, G | 1 |
| Dufour, JM | 1 |
| Wright, K | 1 |
| Ramalingam, L | 1 |
| Moustaid-Moussa, N | 1 |
| Hamood, AN | 1 |
| Shen, CL | 1 |
| Choi, YJ | 1 |
| Menendez, JA | 1 |
| Nyambuya, TM | 2 |
| Dludla, PV | 2 |
| Mxinwa, V | 1 |
| Mokgalaboni, K | 1 |
| Ngcobo, SR | 1 |
| Tiano, L | 1 |
| Nkambule, BB | 2 |
| Fei, Q | 1 |
| Wang, W | 3 |
| Zhu, L | 3 |
| Deng, H | 1 |
| Meng, M | 1 |
| Tan, S | 1 |
| Zhang, H | 3 |
| Xiao, X | 3 |
| Wang, N | 1 |
| Wang, K | 2 |
| Saffari, PM | 1 |
| Alijanpour, S | 1 |
| Takzaree, N | 1 |
| Sahebgharani, M | 1 |
| Etemad-Moghadam, S | 1 |
| Noorbakhsh, F | 1 |
| Partoazar, A | 1 |
| Singh, R | 1 |
| Bansal, Y | 1 |
| Sodhi, RK | 1 |
| Khare, P | 1 |
| Bishnoi, M | 1 |
| Kondepudi, KK | 1 |
| Medhi, B | 2 |
| Kuhad, A | 1 |
| Vazifehkhah, S | 1 |
| Khanizadeh, AM | 1 |
| Mojarad, TB | 1 |
| Nikbakht, F | 1 |
| Xiang, L | 1 |
| Wu, Q | 2 |
| Osada, H | 1 |
| Yoshida, M | 1 |
| Pan, W | 2 |
| Qi, J | 3 |
| Baggio, LL | 1 |
| Varin, EM | 1 |
| Koehler, JA | 1 |
| Cao, X | 3 |
| Lokhnygina, Y | 1 |
| Stevens, SR | 1 |
| Holman, RR | 1 |
| Drucker, DJ | 1 |
| Scheen, AJ | 1 |
| Kim, HS | 1 |
| Ren, G | 1 |
| Kim, T | 1 |
| Bhatnagar, S | 1 |
| Bahk, YY | 1 |
| Kim, JA | 1 |
| Huang, KY | 1 |
| Que, JQ | 1 |
| Hu, ZS | 1 |
| Yu, YW | 1 |
| Zhou, YY | 1 |
| Xue, YJ | 1 |
| Ji, KT | 1 |
| Zhang, XM | 1 |
| Brown, JC | 1 |
| Zhang, S | 3 |
| Ligibel, JA | 1 |
| Irwin, ML | 1 |
| Jones, LW | 1 |
| Campbell, N | 1 |
| Pollak, MN | 2 |
| Sorrentino, A | 1 |
| Cartmel, B | 1 |
| Harrigan, M | 1 |
| Tolaney, SM | 1 |
| Winer, EP | 1 |
| Ng, K | 1 |
| Abrams, TA | 1 |
| Sanft, T | 1 |
| Douglas, PS | 1 |
| Hu, FB | 1 |
| Fuchs, CS | 1 |
| Meyerhardt, JA | 1 |
| Nguépy Keubo, FR | 1 |
| Mboua, PC | 1 |
| Djifack Tadongfack, T | 1 |
| Fokouong Tchoffo, E | 1 |
| Tasson Tatang, C | 1 |
| Ide Zeuna, J | 1 |
| Noupoue, EM | 1 |
| Tsoplifack, CB | 1 |
| Folefack, GO | 1 |
| Kettani, M | 1 |
| Bandelier, P | 1 |
| Huo, J | 1 |
| Yu, D | 1 |
| Arulsamy, N | 1 |
| AlAbbad, S | 1 |
| Sardot, T | 1 |
| Lekashvili, O | 1 |
| Decato, D | 1 |
| Lelj, F | 1 |
| Alexander Ross, JB | 1 |
| Rosenberg, E | 1 |
| Nazir, H | 1 |
| Muthuswamy, N | 1 |
| Louis, C | 1 |
| Jose, S | 1 |
| Prakash, J | 1 |
| Buan, MEM | 1 |
| Flox, C | 1 |
| Chavan, S | 1 |
| Shi, X | 1 |
| Kauranen, P | 1 |
| Kallio, T | 1 |
| Maia, G | 1 |
| Tammeveski, K | 1 |
| Lymperopoulos, N | 1 |
| Carcadea, E | 1 |
| Veziroglu, E | 1 |
| Iranzo, A | 1 |
| M Kannan, A | 1 |
| Arunamata, A | 1 |
| Tacy, TA | 1 |
| Kache, S | 1 |
| Mainwaring, RD | 1 |
| Ma, M | 1 |
| Maeda, K | 1 |
| Punn, R | 1 |
| Noguchi, S | 1 |
| Hahn, S | 3 |
| Iwasa, Y | 3 |
| Ling, J | 2 |
| Voccio, JP | 2 |
| Kim, Y | 3 |
| Song, J | 4 |
| Bascuñán, J | 2 |
| Chu, Y | 1 |
| Tomita, M | 1 |
| Cazorla, M | 1 |
| Herrera, E | 1 |
| Palomeque, E | 1 |
| Saud, N | 1 |
| Hoplock, LB | 1 |
| Lobchuk, MM | 1 |
| Lemoine, J | 1 |
| Henson, MA | 1 |
| Unsihuay, D | 1 |
| Qiu, J | 1 |
| Swaroop, S | 1 |
| Nagornov, KO | 1 |
| Kozhinov, AN | 1 |
| Tsybin, YO | 1 |
| Kuang, S | 1 |
| Laskin, J | 1 |
| Zin, NNINM | 1 |
| Mohamad, MN | 1 |
| Roslan, K | 1 |
| Abdul Wafi, S | 1 |
| Abdul Moin, NI | 1 |
| Alias, A | 1 |
| Zakaria, Y | 1 |
| Abu-Bakar, N | 1 |
| Naveed, A | 1 |
| Jilani, K | 1 |
| Siddique, AB | 1 |
| Akbar, M | 1 |
| Riaz, M | 1 |
| Mushtaq, Z | 1 |
| Sikandar, M | 1 |
| Ilyas, S | 1 |
| Bibi, I | 1 |
| Asghar, A | 1 |
| Rasool, G | 1 |
| Irfan, M | 1 |
| Li, XY | 1 |
| Zhao, S | 2 |
| Fan, XH | 1 |
| Chen, KP | 1 |
| Hua, W | 1 |
| Liu, ZM | 1 |
| Xue, XD | 1 |
| Zhou, B | 1 |
| Xing, YL | 1 |
| Chen, MA | 1 |
| Sun, Y | 2 |
| Neradilek, MB | 1 |
| Wu, XT | 1 |
| Huang, W | 1 |
| Cui, Y | 1 |
| Yang, QQ | 1 |
| Li, HW | 1 |
| Zhao, XQ | 1 |
| Hossein Rashidi, B | 1 |
| Tarafdari, A | 1 |
| Ghazimirsaeed, ST | 1 |
| Shahrokh Tehraninezhad, E | 1 |
| Keikha, F | 1 |
| Eslami, B | 1 |
| Ghazimirsaeed, SM | 1 |
| Jafarabadi, M | 1 |
| Silvani, Y | 1 |
| Lovita, AND | 1 |
| Maharani, A | 1 |
| Wiyasa, IWA | 1 |
| Sujuti, H | 1 |
| Ratnawati, R | 1 |
| Raras, TYM | 1 |
| Lemin, AS | 1 |
| Rahman, MM | 1 |
| Pangarah, CA | 1 |
| Kiyu, A | 1 |
| Zeng, C | 2 |
| Du, H | 1 |
| Lin, D | 1 |
| Jalan, D | 1 |
| Rubagumya, F | 1 |
| Hopman, WM | 1 |
| Vanderpuye, V | 1 |
| Lopes, G | 1 |
| Seruga, B | 1 |
| Booth, CM | 1 |
| Berry, S | 1 |
| Hammad, N | 1 |
| Sajo, EA | 1 |
| Okunade, KS | 1 |
| Olorunfemi, G | 1 |
| Rabiu, KA | 1 |
| Anorlu, RI | 1 |
| Xiang, Y | 1 |
| Xu, X | 2 |
| Dong, X | 2 |
| Tang, S | 1 |
| Gao, XC | 1 |
| Wei, CH | 1 |
| Zhang, RG | 1 |
| Cai, Q | 1 |
| He, Y | 2 |
| Tong, F | 1 |
| Dong, JH | 1 |
| Wu, G | 1 |
| Dong, XR | 1 |
| Tang, X | 2 |
| Tao, F | 1 |
| Xiang, W | 1 |
| Zhao, Y | 6 |
| Jin, L | 1 |
| Tao, H | 1 |
| Lei, Y | 1 |
| Gan, H | 1 |
| Huang, Y | 1 |
| Chen, L | 5 |
| Shan, A | 1 |
| Zhao, H | 3 |
| Wu, M | 2 |
| Ma, Q | 1 |
| Wang, J | 4 |
| Zhang, E | 1 |
| Li, Y | 8 |
| Xue, F | 1 |
| Deng, L | 1 |
| Liu, L | 2 |
| Yan, Z | 3 |
| Meng, J | 1 |
| Chen, G | 3 |
| Anastassiadou, M | 1 |
| Bernasconi, G | 1 |
| Brancato, A | 1 |
| Carrasco Cabrera, L | 1 |
| Greco, L | 1 |
| Jarrah, S | 1 |
| Kazocina, A | 1 |
| Leuschner, R | 1 |
| Magrans, JO | 1 |
| Miron, I | 1 |
| Nave, S | 1 |
| Pedersen, R | 1 |
| Reich, H | 1 |
| Rojas, A | 1 |
| Sacchi, A | 1 |
| Santos, M | 1 |
| Theobald, A | 1 |
| Vagenende, B | 1 |
| Verani, A | 1 |
| Du, L | 1 |
| Li, J | 10 |
| Li, P | 1 |
| Jiao, Q | 1 |
| Meng, P | 1 |
| Wang, F | 4 |
| Wang, YS | 1 |
| Wang, C | 5 |
| Hou, J | 1 |
| Zhang, A | 1 |
| Lv, B | 1 |
| Gao, C | 1 |
| Pang, D | 1 |
| Lu, K | 1 |
| Ahmad, NH | 1 |
| Zhu, J | 3 |
| Zhang, L | 9 |
| Zhuang, T | 1 |
| Tu, J | 1 |
| Zhao, Z | 2 |
| Qu, Y | 1 |
| Yao, H | 1 |
| Lee, DF | 1 |
| Shen, J | 3 |
| Wen, L | 1 |
| Huang, G | 2 |
| Xie, X | 1 |
| Zhao, Q | 1 |
| Hu, W | 1 |
| Lu, J | 2 |
| Li, M | 1 |
| Li, W | 3 |
| Wu, W | 2 |
| Du, F | 1 |
| Ji, H | 1 |
| Wan, L | 1 |
| Wen, Q | 1 |
| Cho, CH | 1 |
| Zou, C | 1 |
| Xiao, Z | 2 |
| Su, X | 1 |
| Bi, Z | 1 |
| Su, Q | 1 |
| Huang, H | 2 |
| Wei, Y | 2 |
| Gao, Y | 2 |
| Na, KJ | 1 |
| Choi, H | 1 |
| Oh, HR | 1 |
| Kim, YH | 1 |
| Lee, SB | 1 |
| Jung, YJ | 2 |
| Koh, J | 1 |
| Park, S | 1 |
| Lee, HJ | 1 |
| Jeon, YK | 1 |
| Chung, DH | 1 |
| Paeng, JC | 1 |
| Park, IK | 1 |
| Kang, CH | 1 |
| Cheon, GJ | 1 |
| Kang, KW | 1 |
| Lee, DS | 1 |
| Kim, YT | 1 |
| Pajuelo-Lozano, N | 1 |
| Alcalá, S | 1 |
| Sainz, B | 1 |
| Perona, R | 1 |
| Sanchez-Perez, I | 1 |
| Logotheti, S | 1 |
| Marquardt, S | 1 |
| Gupta, SK | 1 |
| Richter, C | 1 |
| Edelhäuser, BAH | 1 |
| Engelmann, D | 1 |
| Brenmoehl, J | 1 |
| Söhnchen, C | 1 |
| Murr, N | 1 |
| Alpers, M | 1 |
| Singh, KP | 1 |
| Wolkenhauer, O | 1 |
| Heckl, D | 1 |
| Spitschak, A | 1 |
| Pützer, BM | 1 |
| Liao, Y | 1 |
| Cheng, J | 1 |
| Kong, X | 1 |
| Zhang, M | 5 |
| Yang, T | 2 |
| Dong, Y | 2 |
| Yuan, Z | 2 |
| Cao, J | 1 |
| Luo, Z | 1 |
| Mei, Z | 1 |
| Yao, Y | 1 |
| Liang, C | 1 |
| Song, Y | 1 |
| Yu, K | 1 |
| Zhu, C | 1 |
| Huang, Z | 1 |
| Qian, J | 1 |
| Ge, J | 1 |
| Hu, J | 3 |
| Wang, H | 5 |
| Mi, Y | 1 |
| Kong, H | 2 |
| Xi, D | 1 |
| Yan, W | 1 |
| Luo, X | 2 |
| Ning, Q | 1 |
| Chang, X | 2 |
| Wang, Q | 4 |
| Rathore, MG | 1 |
| Reddy, K | 1 |
| Chen, H | 2 |
| Shin, SH | 1 |
| Ma, WY | 1 |
| Bode, AM | 1 |
| Dong, Z | 1 |
| Mu, W | 1 |
| Liu, C | 4 |
| Gao, F | 1 |
| Qi, Y | 1 |
| Lu, H | 2 |
| Cai, X | 1 |
| Ji, RY | 1 |
| Tian, J | 2 |
| Shi, Y | 2 |
| Ying, S | 1 |
| Tan, M | 1 |
| Feng, G | 1 |
| Kuang, Y | 1 |
| Chen, D | 1 |
| Zhu, ZQ | 1 |
| Tang, HX | 1 |
| Shi, ZE | 1 |
| Liu, Q | 5 |
| Mu, J | 1 |
| Cong, Z | 1 |
| Chen, S | 3 |
| Fu, D | 1 |
| Li, Z | 3 |
| Celestrin, CP | 1 |
| Rocha, GZ | 1 |
| Stein, AM | 1 |
| Guadagnini, D | 1 |
| Tadelle, RM | 1 |
| Saad, MJA | 1 |
| Oliveira, AG | 1 |
| Bianconi, V | 1 |
| Bronzo, P | 1 |
| Banach, M | 1 |
| Sahebkar, A | 1 |
| Mannarino, MR | 1 |
| Pirro, M | 1 |
| Patsourakos, NG | 1 |
| Kouvari, M | 1 |
| Kotidis, A | 1 |
| Kalantzi, KI | 1 |
| Tsoumani, ME | 1 |
| Anastasiadis, F | 1 |
| Andronikos, P | 1 |
| Aslanidou, T | 1 |
| Efraimidis, P | 1 |
| Georgiopoulos, A | 1 |
| Gerakiou, K | 1 |
| Grigoriadou-Skouta, E | 1 |
| Grigoropoulos, P | 1 |
| Hatzopoulos, D | 1 |
| Kartalis, A | 1 |
| Lyras, A | 1 |
| Markatos, G | 1 |
| Mikrogeorgiou, A | 1 |
| Myroforou, I | 1 |
| Orkopoulos, A | 1 |
| Pavlidis, P | 1 |
| Petras, C | 1 |
| Riga, M | 1 |
| Skouloudi, M | 1 |
| Smyrnioudis, N | 1 |
| Thomaidis, K | 1 |
| Tsikouri, GE | 1 |
| Tsikouris, EI | 1 |
| Zisimos, K | 1 |
| Vavoulis, P | 1 |
| Vitali, MG | 1 |
| Vitsas, G | 1 |
| Vogiatzidis, C | 1 |
| Chantanis, S | 1 |
| Fousas, S | 1 |
| Panagiotakos, DB | 1 |
| Tselepis, AD | 1 |
| Jungen, C | 1 |
| Alken, FA | 1 |
| Eickholt, C | 1 |
| Scherschel, K | 1 |
| Kuklik, P | 1 |
| Klatt, N | 1 |
| Schwarzl, J | 1 |
| Moser, J | 1 |
| Jularic, M | 1 |
| Akbulak, RO | 1 |
| Schaeffer, B | 1 |
| Willems, S | 1 |
| Meyer, C | 1 |
| Nowak, JK | 1 |
| Szczepanik, M | 1 |
| Trypuć, M | 1 |
| Pogorzelski, A | 1 |
| Bobkowski, W | 1 |
| Grytczuk, M | 1 |
| Minarowska, A | 1 |
| Wójciak, R | 1 |
| Walkowiak, J | 1 |
| Lu, Y | 1 |
| Xi, J | 1 |
| Chen, W | 2 |
| Zhang, F | 1 |
| Wei, H | 2 |
| Gurzu, S | 1 |
| Jung, I | 1 |
| Sugimura, H | 2 |
| Stefan-van Staden, RI | 1 |
| Yamada, H | 1 |
| Natsume, H | 1 |
| Iwashita, Y | 1 |
| Szodorai, R | 1 |
| Szederjesi, J | 1 |
| Yari, D | 1 |
| Ehsanbakhsh, Z | 1 |
| Validad, MH | 1 |
| Langroudi, FH | 1 |
| Esfandiari, H | 1 |
| Prager, A | 1 |
| Hassanpour, K | 1 |
| Kurup, SP | 1 |
| Mets-Halgrimson, R | 1 |
| Yoon, H | 1 |
| Zeid, JL | 1 |
| Mets, MB | 1 |
| Rahmani, B | 1 |
| Araujo-Castillo, RV | 1 |
| Culquichicón, C | 1 |
| Solis Condor, R | 1 |
| Efendi, F | 1 |
| Sebayang, SK | 1 |
| Astutik, E | 1 |
| Hadisuyatmana, S | 1 |
| Has, EMM | 1 |
| Kuswanto, H | 1 |
| Foroutan, T | 1 |
| Ahmadi, F | 1 |
| Moayer, F | 1 |
| Khalvati, S | 1 |
| Zhang, Q | 2 |
| Lyu, Y | 1 |
| Huang, J | 2 |
| Yu, N | 1 |
| Wen, Z | 1 |
| Hou, H | 1 |
| Zhao, T | 1 |
| Gupta, A | 1 |
| Khosla, N | 1 |
| Govindasamy, V | 1 |
| Saini, A | 1 |
| Annapurna, K | 1 |
| Dhakate, SR | 1 |
| Akkaya, Ö | 1 |
| Chandgude, AL | 1 |
| Dömling, A | 1 |
| Harnett, J | 1 |
| Oakes, K | 1 |
| Carè, J | 1 |
| Leach, M | 1 |
| Brown, D | 1 |
| Cramer, H | 1 |
| Pinder, TA | 1 |
| Steel, A | 1 |
| Anheyer, D | 1 |
| Cantu, J | 1 |
| Valle, J | 1 |
| Flores, K | 1 |
| Gonzalez, D | 1 |
| Valdes, C | 1 |
| Lopez, J | 1 |
| Padilla, V | 1 |
| Alcoutlabi, M | 1 |
| Parsons, J | 1 |
| Núñez, K | 1 |
| Hamed, M | 1 |
| Fort, D | 1 |
| Bruce, D | 1 |
| Thevenot, P | 1 |
| Cohen, A | 1 |
| Weber, P | 1 |
| Menezes, AMB | 1 |
| Gonçalves, H | 1 |
| Perez-Padilla, R | 1 |
| Jarvis, D | 1 |
| de Oliveira, PD | 1 |
| Wehrmeister, FC | 1 |
| Mir, S | 1 |
| Wong, J | 1 |
| Ryan, CM | 1 |
| Bellingham, G | 1 |
| Waseem, R | 1 |
| Eckert, DJ | 1 |
| Chung, F | 1 |
| Hegde, H | 1 |
| Shimpi, N | 1 |
| Panny, A | 1 |
| Glurich, I | 1 |
| Christie, P | 1 |
| Acharya, A | 1 |
| English, KL | 1 |
| Downs, M | 1 |
| Goetchius, E | 1 |
| Buxton, R | 1 |
| Ryder, JW | 1 |
| Ploutz-Snyder, R | 1 |
| Guilliams, M | 1 |
| Scott, JM | 1 |
| Ploutz-Snyder, LL | 1 |
| Martens, C | 1 |
| Goplen, FK | 1 |
| Aasen, T | 1 |
| Gjestad, R | 1 |
| Nordfalk, KF | 1 |
| Nordahl, SHG | 1 |
| Inoue, T | 1 |
| Soshi, S | 1 |
| Kubota, M | 1 |
| Marumo, K | 1 |
| Mortensen, NP | 1 |
| Caffaro, MM | 1 |
| Patel, PR | 2 |
| Uddin, MJ | 1 |
| Aravamudhan, S | 1 |
| Sumner, SJ | 1 |
| Fennell, TR | 1 |
| Gal, RL | 1 |
| Cohen, NJ | 1 |
| Kruger, D | 1 |
| Beck, RW | 1 |
| Bergenstal, RM | 1 |
| Calhoun, P | 1 |
| Cushman, T | 1 |
| Haban, A | 1 |
| Hood, K | 1 |
| Johnson, ML | 1 |
| McArthur, T | 1 |
| Olson, BA | 1 |
| Weinstock, RS | 1 |
| Oser, SM | 1 |
| Oser, TK | 1 |
| Bugielski, B | 1 |
| Strayer, H | 1 |
| Aleppo, G | 1 |
| Maruyama, H | 1 |
| Hirayama, K | 1 |
| Yamashita, M | 1 |
| Ohgi, K | 1 |
| Tsujimoto, R | 1 |
| Takayasu, M | 1 |
| Shimohata, H | 1 |
| Kobayashi, M | 1 |
| Buscagan, TM | 1 |
| Rees, DC | 1 |
| Jaborek, JR | 1 |
| Zerby, HN | 1 |
| Wick, MP | 1 |
| Fluharty, FL | 1 |
| Moeller, SJ | 1 |
| Razavi, P | 1 |
| Dickler, MN | 1 |
| Shah, PD | 1 |
| Toy, W | 1 |
| Brown, DN | 1 |
| Won, HH | 1 |
| Li, BT | 1 |
| Shen, R | 1 |
| Vasan, N | 1 |
| Modi, S | 1 |
| Jhaveri, K | 1 |
| Caravella, BA | 1 |
| Patil, S | 1 |
| Selenica, P | 1 |
| Zamora, S | 1 |
| Cowan, AM | 1 |
| Comen, E | 1 |
| Covey, A | 1 |
| Berger, MF | 1 |
| Hudis, CA | 1 |
| Norton, L | 1 |
| Nagy, RJ | 1 |
| Odegaard, JI | 1 |
| Lanman, RB | 1 |
| Solit, DB | 1 |
| Robson, ME | 1 |
| Lacouture, ME | 1 |
| Brogi, E | 1 |
| Reis-Filho, JS | 1 |
| Moynahan, ME | 1 |
| Scaltriti, M | 1 |
| Chandarlapaty, S | 1 |
| Papouskova, K | 1 |
| Moravcova, M | 1 |
| Masrati, G | 1 |
| Ben-Tal, N | 1 |
| Sychrova, H | 1 |
| Zimmermannova, O | 1 |
| Fang, J | 1 |
| Luo, T | 2 |
| Su, H | 1 |
| Tsetseris, L | 1 |
| Anthopoulos, TD | 1 |
| Liu, SF | 1 |
| Zhao, K | 1 |
| Sacan, O | 1 |
| Turkyilmaz, IB | 1 |
| Bayrak, BB | 1 |
| Mutlu, O | 1 |
| Akev, N | 1 |
| Yanardag, R | 1 |
| Gruber, S | 1 |
| Kamnoedboon, P | 1 |
| Özcan, M | 1 |
| Srinivasan, M | 1 |
| Jo, YH | 1 |
| Oh, HK | 1 |
| Jeong, SY | 1 |
| Lee, BG | 1 |
| Zheng, J | 2 |
| Guan, H | 1 |
| Li, D | 4 |
| Tan, H | 1 |
| Maji, TK | 1 |
| J R, A | 1 |
| Mukherjee, S | 1 |
| Alexander, R | 1 |
| Mondal, A | 1 |
| Das, S | 1 |
| Sharma, RK | 1 |
| Chakraborty, NK | 1 |
| Dasgupta, K | 1 |
| Sharma, AMR | 1 |
| Hawaldar, R | 1 |
| Pandey, M | 1 |
| Naik, A | 1 |
| Majumdar, K | 1 |
| Pal, SK | 1 |
| Adarsh, KV | 1 |
| Ray, SK | 1 |
| Karmakar, D | 1 |
| Ma, Y | 2 |
| Gao, W | 1 |
| Ma, S | 1 |
| Zhou, T | 2 |
| Wu, T | 1 |
| Ye, C | 1 |
| He, X | 1 |
| Jiang, F | 2 |
| Yuan, D | 1 |
| Chen, Q | 1 |
| Hong, M | 1 |
| Chen, K | 1 |
| Hussain, M | 1 |
| Razi, SS | 1 |
| Yildiz, EA | 1 |
| Zhao, J | 2 |
| Yaglioglu, HG | 1 |
| Donato, MD | 1 |
| Jiang, J | 1 |
| Jamil, MI | 1 |
| Zhan, X | 1 |
| Chen, F | 1 |
| Cheng, D | 1 |
| Wu, CT | 1 |
| Utsunomiya, T | 1 |
| Ichii, T | 1 |
| Fujinami, S | 1 |
| Nakajima, K | 1 |
| Sanchez, DM | 1 |
| Raucci, U | 1 |
| Ferreras, KN | 1 |
| Martínez, TJ | 1 |
| Mordi, NA | 1 |
| Mordi, IR | 1 |
| Singh, JS | 1 |
| McCrimmon, RJ | 1 |
| Struthers, AD | 1 |
| Lang, CC | 1 |
| Wang, XW | 1 |
| Yuan, LJ | 1 |
| Chen, WF | 1 |
| Luo, R | 2 |
| Yang, K | 1 |
| Amarasiri, SS | 1 |
| Attanayake, AP | 1 |
| Arawwawala, LDAM | 1 |
| Jayatilaka, KAPW | 1 |
| Mudduwa, LKB | 1 |
| Ogunsuyi, O | 2 |
| Akanni, O | 1 |
| Alabi, O | 1 |
| Alimba, C | 1 |
| Adaramoye, O | 1 |
| Cambier, S | 1 |
| Eswara, S | 1 |
| Gutleb, AC | 1 |
| Bakare, A | 1 |
| Gu, Z | 1 |
| Cong, J | 1 |
| Pellegrini, M | 1 |
| Palmieri, S | 1 |
| Ricci, A | 1 |
| Serio, A | 1 |
| Paparella, A | 1 |
| Lo Sterzo, C | 1 |
| Jadeja, SD | 1 |
| Vaishnav, J | 1 |
| Mansuri, MS | 1 |
| Shah, C | 1 |
| Mayatra, JM | 1 |
| Shah, A | 1 |
| Begum, R | 1 |
| Lian, Y | 1 |
| Wan, T | 1 |
| Schultz-Lebahn, A | 1 |
| Skipper, MT | 1 |
| Hvas, AM | 1 |
| Larsen, OH | 1 |
| Hijazi, Z | 1 |
| Granger, CB | 1 |
| Hohnloser, SH | 1 |
| Westerbergh, J | 1 |
| Lindbäck, J | 1 |
| Alexander, JH | 1 |
| Keltai, M | 1 |
| Parkhomenko, A | 1 |
| López-Sendón, JL | 1 |
| Lopes, RD | 1 |
| Siegbahn, A | 1 |
| Wallentin, L | 1 |
| El-Tarabany, MS | 1 |
| Saleh, AA | 1 |
| El-Araby, IE | 1 |
| El-Magd, MA | 1 |
| van Ginkel, MPH | 1 |
| Schijven, MP | 1 |
| van Grevenstein, WMU | 1 |
| Schreuder, HWR | 1 |
| Pereira, EDM | 1 |
| da Silva, J | 1 |
| Carvalho, PDS | 1 |
| Grivicich, I | 1 |
| Picada, JN | 1 |
| Salgado Júnior, IB | 1 |
| Vasques, GJ | 1 |
| Pereira, MADS | 1 |
| Reginatto, FH | 1 |
| Ferraz, ABF | 1 |
| Vasilenko, EA | 1 |
| Gorshkova, EN | 1 |
| Astrakhantseva, IV | 1 |
| Drutskaya, MS | 1 |
| Tillib, SV | 1 |
| Nedospasov, SA | 1 |
| Mokhonov, VV | 1 |
| Nam, YW | 1 |
| Cui, M | 1 |
| Orfali, R | 1 |
| Viegas, A | 1 |
| Nguyen, M | 1 |
| Mohammed, EHM | 1 |
| Zoghebi, KA | 1 |
| Rahighi, S | 1 |
| Parang, K | 1 |
| Patterson, KC | 1 |
| Kahanovitch, U | 1 |
| Gonçalves, CM | 1 |
| Hablitz, JJ | 1 |
| Staruschenko, A | 1 |
| Mulkey, DK | 1 |
| Olsen, ML | 1 |
| Gu, L | 1 |
| Mukhtar, A | 1 |
| Wu, K | 2 |
| Zhang, YY | 1 |
| Lu, DZ | 1 |
| Dong, W | 1 |
| Bi, WJ | 1 |
| Feng, XJ | 1 |
| Wen, LM | 1 |
| Sun, H | 2 |
| Qi, MC | 1 |
| Chang, CC | 1 |
| Dinh, TK | 1 |
| Lee, YA | 1 |
| Wang, FN | 1 |
| Sung, YC | 1 |
| Yu, PL | 1 |
| Chiu, SC | 1 |
| Shih, YC | 1 |
| Wu, CY | 1 |
| Huang, YD | 1 |
| Lu, TT | 1 |
| Wan, D | 1 |
| Sakizadeh, J | 1 |
| Cline, JP | 1 |
| Snyder, MA | 1 |
| Kiely, CJ | 1 |
| McIntosh, S | 1 |
| Cao, JW | 1 |
| Zhao, CK | 1 |
| Yang, R | 1 |
| Zhang, QY | 1 |
| Chen, KJ | 2 |
| He, Z | 1 |
| Chen, B | 1 |
| Du, X | 1 |
| Moore, J | 1 |
| Blank, BR | 1 |
| Eksterowicz, J | 1 |
| Sutimantanapi, D | 1 |
| Yuen, N | 1 |
| Metzger, T | 1 |
| Chan, B | 1 |
| Huang, T | 1 |
| Duong, F | 1 |
| Kong, W | 1 |
| Chang, JH | 1 |
| Sun, J | 1 |
| Zavorotinskaya, T | 1 |
| Ye, Q | 1 |
| Junttila, MR | 1 |
| Ndubaku, C | 1 |
| Friedman, LS | 1 |
| Fantin, VR | 1 |
| Sun, D | 1 |
| Fei, P | 1 |
| Xie, Q | 1 |
| Jiang, Y | 1 |
| Feng, H | 1 |
| Chang, Y | 1 |
| Kang, H | 1 |
| Xing, M | 1 |
| Shao, Z | 2 |
| Yuan, C | 1 |
| Wu, Y | 2 |
| Allan, R | 1 |
| Canham, K | 1 |
| Wallace, R | 1 |
| Singh, D | 1 |
| Ward, J | 1 |
| Cooper, A | 1 |
| Newcomb, C | 1 |
| Nammour, S | 1 |
| El Mobadder, M | 1 |
| Maalouf, E | 1 |
| Namour, M | 1 |
| Namour, A | 1 |
| Rey, G | 1 |
| Matamba, P | 1 |
| Matys, J | 1 |
| Zeinoun, T | 1 |
| Grzech-Leśniak, K | 1 |
| Segabinazi Peserico, C | 1 |
| Garozi, L | 1 |
| Zagatto, AM | 1 |
| Machado, FA | 1 |
| Hirth, JM | 1 |
| Dinehart, EE | 1 |
| Lin, YL | 1 |
| Kuo, YF | 1 |
| Nouri, SS | 1 |
| Ritchie, C | 1 |
| Volow, A | 1 |
| Li, B | 2 |
| McSpadden, S | 1 |
| Dearman, K | 1 |
| Kotwal, A | 1 |
| Sudore, RL | 1 |
| Ward, L | 1 |
| Thakur, A | 1 |
| Kondadasula, SV | 1 |
| Ji, K | 1 |
| Schalk, DL | 1 |
| Bliemeister, E | 1 |
| Ung, J | 1 |
| Aboukameel, A | 1 |
| Casarez, E | 1 |
| Sloane, BF | 1 |
| Lum, LG | 1 |
| Xiao, M | 1 |
| Feng, X | 2 |
| Gao, R | 2 |
| Du, B | 1 |
| Brooks, T | 1 |
| Zwirner, J | 1 |
| Hammer, N | 1 |
| Ondruschka, B | 1 |
| Jermy, M | 1 |
| Luengo, A | 1 |
| Marzo, I | 1 |
| Reback, M | 1 |
| Daubit, IM | 1 |
| Fernández-Moreira, V | 1 |
| Metzler-Nolte, N | 1 |
| Gimeno, MC | 1 |
| Tonchev, I | 1 |
| Heberman, D | 1 |
| Peretz, A | 1 |
| Medvedovsky, AT | 1 |
| Gotsman, I | 1 |
| Rashi, Y | 1 |
| Poles, L | 1 |
| Goland, S | 1 |
| Perlman, GY | 1 |
| Danenberg, HD | 1 |
| Beeri, R | 1 |
| Shuvy, M | 1 |
| Yang, D | 2 |
| Sarapulova, A | 1 |
| Pang, Q | 1 |
| Meng, Y | 1 |
| Wei, L | 1 |
| Ehrenberg, H | 1 |
| Kim, CC | 1 |
| Jeong, SH | 1 |
| Oh, KH | 1 |
| Nam, KT | 1 |
| Sun, JY | 1 |
| Ning, J | 1 |
| Duan, Z | 1 |
| Kershaw, SV | 1 |
| Rogach, AL | 1 |
| Gao, Z | 1 |
| Wang, T | 2 |
| Cao, T | 1 |
| Guo, L | 2 |
| Fu, Y | 1 |
| Seeger, ZL | 1 |
| Izgorodina, EI | 1 |
| Hue, S | 1 |
| Beldi-Ferchiou, A | 1 |
| Bendib, I | 1 |
| Surenaud, M | 1 |
| Fourati, S | 1 |
| Frapard, T | 1 |
| Rivoal, S | 1 |
| Razazi, K | 1 |
| Carteaux, G | 1 |
| Delfau-Larue, MH | 1 |
| Mekontso-Dessap, A | 1 |
| Audureau, E | 1 |
| de Prost, N | 1 |
| Gao, SS | 1 |
| Duangthip, D | 1 |
| Lo, ECM | 1 |
| Chu, CH | 1 |
| Roberts, W | 1 |
| Rosenheck, RA | 1 |
| Miyake, T | 1 |
| Kimoto, E | 1 |
| Mathialagan, S | 1 |
| Horlbogen, LM | 1 |
| Ramanathan, R | 1 |
| Wood, LS | 1 |
| Johnson, JG | 1 |
| Le, VH | 1 |
| Vourvahis, M | 1 |
| Rodrigues, AD | 1 |
| Muto, C | 1 |
| Furihata, K | 1 |
| Sugiyama, Y | 1 |
| Kusuhara, H | 1 |
| Gong, Q | 1 |
| Song, W | 1 |
| Cao, P | 1 |
| Gu, S | 1 |
| Zhou, G | 1 |
| Toma, C | 1 |
| Khandhar, S | 1 |
| Zalewski, AM | 1 |
| D'Auria, SJ | 1 |
| Tu, TM | 1 |
| Jaber, WA | 1 |
| Cho, J | 2 |
| Suwandaratne, NS | 1 |
| Razek, S | 1 |
| Choi, YH | 1 |
| Piper, LFJ | 1 |
| Watson, DF | 1 |
| Banerjee, S | 1 |
| Xie, S | 1 |
| Lindsay, AP | 1 |
| Bates, FS | 1 |
| Lodge, TP | 1 |
| Chapovetsky, A | 1 |
| Liu, JJ | 1 |
| Welborn, M | 1 |
| Luna, JM | 1 |
| Do, T | 1 |
| Haiges, R | 1 |
| Miller Iii, TF | 1 |
| Marinescu, SC | 1 |
| Lopez, SA | 1 |
| Compter, I | 1 |
| Eekers, DBP | 1 |
| Hoeben, A | 1 |
| Rouschop, KMA | 1 |
| Reymen, B | 1 |
| Ackermans, L | 1 |
| Beckervordersantforth, J | 1 |
| Bauer, NJC | 1 |
| Anten, MM | 1 |
| Wesseling, P | 1 |
| Postma, AA | 1 |
| De Ruysscher, D | 1 |
| Lambin, P | 1 |
| Qiang, L | 1 |
| Cui, YH | 1 |
| He, YY | 1 |
| Kumar, SK | 1 |
| Jacobus, SJ | 1 |
| Cohen, AD | 1 |
| Weiss, M | 1 |
| Callander, N | 1 |
| Singh, AK | 1 |
| Parker, TL | 1 |
| Menter, A | 1 |
| Parsons, B | 1 |
| Kumar, P | 1 |
| Kapoor, P | 1 |
| Rosenberg, A | 1 |
| Zonder, JA | 1 |
| Faber, E | 1 |
| Lonial, S | 1 |
| Anderson, KC | 1 |
| Richardson, PG | 1 |
| Orlowski, RZ | 1 |
| Wagner, LI | 1 |
| Rajkumar, SV | 1 |
| Hou, G | 1 |
| Xie, H | 1 |
| Sun, Z | 2 |
| Fang, Z | 1 |
| Dunstand-Guzmán, E | 1 |
| Hallal-Calleros, C | 1 |
| Hernández-Velázquez, VM | 1 |
| Canales-Vargas, EJ | 1 |
| Domínguez-Roldan, R | 1 |
| Pedernera, M | 1 |
| Peña-Chora, G | 1 |
| Flores-Pérez, I | 1 |
| Kim, MJ | 2 |
| Han, C | 1 |
| White, K | 1 |
| Park, HJ | 1 |
| Ding, D | 1 |
| Boyd, K | 1 |
| Rothenberger, C | 1 |
| Bose, U | 1 |
| Carmichael, P | 1 |
| Linser, PJ | 1 |
| Tanokura, M | 1 |
| Salvi, R | 1 |
| Someya, S | 1 |
| Samuni, A | 1 |
| Goldstein, S | 1 |
| Divya, KP | 1 |
| Dharuman, V | 1 |
| Feng, J | 2 |
| Qian, Y | 3 |
| Cheng, Q | 1 |
| Ren, X | 1 |
| Wei, Q | 1 |
| Guo, J | 1 |
| Situ, B | 1 |
| An, T | 1 |
| Zheng, L | 1 |
| Augusto, S | 1 |
| Ratola, N | 1 |
| Tarín-Carrasco, P | 1 |
| Jiménez-Guerrero, P | 1 |
| Turco, M | 1 |
| Schuhmacher, M | 1 |
| Costa, S | 1 |
| Teixeira, JP | 1 |
| Costa, C | 1 |
| Syed, A | 1 |
| Marraiki, N | 1 |
| Al-Rashed, S | 1 |
| Elgorban, AM | 1 |
| Yassin, MT | 1 |
| Chankhanittha, T | 1 |
| Nanan, S | 1 |
| Sorokina, KN | 1 |
| Samoylova, YV | 1 |
| Gromov, NV | 1 |
| Ogorodnikova, OL | 1 |
| Parmon, VN | 1 |
| Ye, J | 1 |
| Liao, W | 1 |
| Zhang, P | 1 |
| Nabi, M | 1 |
| Cai, Y | 2 |
| Li, F | 1 |
| Alsbou, EM | 1 |
| Omari, KW | 1 |
| Adeosun, WA | 1 |
| Asiri, AM | 1 |
| Marwani, HM | 1 |
| Barral, M | 1 |
| Jemal-Turki, A | 1 |
| Beuvon, F | 1 |
| Soyer, P | 1 |
| Camparo, P | 1 |
| Cornud, F | 1 |
| Atwater, BD | 1 |
| Jones, WS | 1 |
| Loring, Z | 1 |
| Friedman, DJ | 1 |
| Namburath, M | 1 |
| Papirio, S | 1 |
| Moscariello, C | 1 |
| Di Costanzo, N | 1 |
| Pirozzi, F | 1 |
| Alappat, BJ | 1 |
| Sreekrishnan, TR | 1 |
| Volpin, F | 1 |
| Woo, YC | 1 |
| Kim, H | 1 |
| Freguia, S | 1 |
| Jeong, N | 1 |
| Choi, JS | 1 |
| Phuntsho, S | 1 |
| Shon, HK | 1 |
| Domínguez-Zambrano, E | 1 |
| Pedraza-Chaverri, J | 1 |
| López-Santos, AL | 1 |
| Medina-Campos, ON | 1 |
| Cruz-Rivera, C | 1 |
| Bueno-Hernández, F | 1 |
| Espinosa-Cuevas, A | 1 |
| Bulavaitė, A | 1 |
| Dalgediene, I | 1 |
| Michailoviene, V | 1 |
| Pleckaityte, M | 1 |
| Sauerbier, P | 1 |
| Köhler, R | 1 |
| Renner, G | 1 |
| Militz, H | 1 |
| Du, RW | 1 |
| Bu, WG | 1 |
| de Oliveira, AM | 1 |
| de Freitas, AFS | 1 |
| Costa, MDS | 1 |
| Torres, MKDS | 1 |
| Castro, YAA | 1 |
| Almeida, AMR | 1 |
| Paiva, PMG | 1 |
| Carvalho, BM | 1 |
| Napoleão, TH | 1 |
| Vangaveti, S | 1 |
| Das, P | 1 |
| Kumar, VL | 3 |
| Katsiki, N | 1 |
| Ferrannini, E | 1 |
| Van Nostrand, JL | 1 |
| Hellberg, K | 1 |
| Luo, EC | 1 |
| Van Nostrand, EL | 1 |
| Dayn, A | 1 |
| Yu, J | 1 |
| Shokhirev, MN | 1 |
| Dayn, Y | 1 |
| Yeo, GW | 1 |
| Shaw, RJ | 1 |
| Guo, H | 1 |
| Zhang, C | 2 |
| Deng, Q | 1 |
| Leng, Q | 1 |
| Werida, R | 1 |
| Kabel, M | 1 |
| Omran, G | 1 |
| Shokry, A | 1 |
| Mostafa, T | 1 |
| Lv, C | 2 |
| Gao, K | 2 |
| Mao, L | 1 |
| Ji, D | 1 |
| Yin, JY | 1 |
| Li, DF | 1 |
| Zhu, CT | 1 |
| Ye, JP | 1 |
| Pan, YQ | 1 |
| van den Bosch, MHJ | 1 |
| Conart, JB | 1 |
| Blot, G | 1 |
| Augustin, S | 1 |
| Millet-Puel, G | 1 |
| Roubeix, C | 1 |
| Beguier, F | 1 |
| Charles-Messance, H | 1 |
| Touhami, S | 1 |
| Sahel, JA | 1 |
| Berrod, JP | 1 |
| Léveillard, T | 1 |
| Guillonneau, X | 1 |
| Delarasse, C | 1 |
| Sennlaub, F | 1 |
| Chang, JE | 1 |
| Choi, MS | 2 |
| Huan, Z | 1 |
| Xu, J | 1 |
| Ghasempour, G | 1 |
| Aliabadi, M | 2 |
| Hashemnia, SMR | 1 |
| Emamgholipour, S | 1 |
| Didari, T | 1 |
| Hassani, S | 1 |
| Baeeri, M | 1 |
| Navaei-Nigjeh, M | 1 |
| Rahimifard, M | 1 |
| Haghi-Aminjan, H | 1 |
| Nejad, SM | 1 |
| Hassan, FI | 1 |
| Mojtahedzadeh, M | 1 |
| Abdollahi, M | 1 |
| Bojja, SL | 1 |
| Anand, S | 1 |
| Bhatia, A | 1 |
| Joshi, R | 1 |
| Minz, RW | 1 |
| Karbalaee-Hasani, A | 1 |
| Khadive, T | 1 |
| Eskandari, M | 1 |
| Shahidi, S | 1 |
| Mosavi, M | 1 |
| Nejadebrahimi, Z | 1 |
| Khalkhali, L | 1 |
| Sangdari, A | 1 |
| Mohammadi, D | 1 |
| Soltani, A | 1 |
| Khodabandehloo, H | 1 |
| Hosseini, H | 1 |
| Koushki, M | 1 |
| Guo, Y | 2 |
| Shi, J | 1 |
| Hong, L | 1 |
| Chen, M | 2 |
| Yuan, X | 1 |
| Jiang, S | 2 |
| El-Mahdy, NA | 1 |
| El-Sayad, ME | 1 |
| El-Kadem, AH | 1 |
| Abu-Risha, SE | 1 |
| Diaz, A | 1 |
| Muñoz-Arenas, G | 1 |
| Venegas, B | 1 |
| Vázquez-Roque, R | 1 |
| Flores, G | 1 |
| Guevara, J | 1 |
| Gonzalez-Vergara, E | 1 |
| Treviño, S | 1 |
| Li, L | 3 |
| Gao, L | 1 |
| Huan, Y | 1 |
| Lei, L | 1 |
| Cao, H | 2 |
| Gao, A | 1 |
| Shen, Z | 2 |
| Mitrovic, B | 1 |
| Gluvic, Z | 1 |
| Macut, D | 1 |
| Obradovic, M | 1 |
| Sudar-Milovanovic, E | 1 |
| Soskic, S | 1 |
| Stajic, D | 1 |
| Isenovic, ER | 1 |
| Xu, T | 1 |
| Liang, Y | 1 |
| Mao, Y | 1 |
| Loor, JJ | 1 |
| Yang, Z | 1 |
| Kar, E | 1 |
| Alataş, Ö | 1 |
| Şahıntürk, V | 1 |
| Öz, S | 1 |
| Su, YJ | 2 |
| Wang, PW | 1 |
| Weng, SW | 1 |
| Abd El-Hameed, AM | 1 |
| Yousef, AI | 1 |
| Abd El-Twab, SM | 1 |
| El-Shahawy, AAG | 1 |
| Abdel-Moneim, A | 1 |
| Patel, F | 1 |
| Parwani, K | 1 |
| Patel, D | 1 |
| Mandal, P | 1 |
| Docrat, TF | 1 |
| Nagiah, S | 1 |
| Chuturgoon, AA | 1 |
| Lin, CY | 1 |
| Wu, CH | 1 |
| Hsu, CY | 1 |
| Chen, TH | 1 |
| Lin, MS | 1 |
| Lin, YS | 2 |
| El-Baz, AM | 1 |
| Shata, A | 1 |
| Hassan, HM | 1 |
| El-Sokkary, MMA | 1 |
| Khodir, AE | 1 |
| Mostafa, TM | 1 |
| Hegazy, SK | 1 |
| Elnaidany, SS | 1 |
| Shehabeldin, WA | 1 |
| Sawan, ES | 1 |
| Gokulakrishnan, K | 1 |
| Pandey, GK | 1 |
| Sathishkumar, C | 1 |
| Sundararajan, S | 1 |
| Durairaj, P | 1 |
| Manickam, N | 1 |
| Mohan, V | 1 |
| Balasubramanyam, M | 1 |
| Slaughter, VL | 1 |
| Rumsey, JW | 1 |
| Boone, R | 1 |
| Malik, D | 1 |
| Sriram, NN | 1 |
| Long, CJ | 1 |
| McAleer, CW | 1 |
| Lambert, S | 1 |
| Shuler, ML | 1 |
| Hickman, JJ | 1 |
| Zou, W | 1 |
| Gu, X | 1 |
| Yan, N | 1 |
| Yan, R | 1 |
| Jia, S | 1 |
| Xu, A | 1 |
| Lee, J | 2 |
| Xu, P | 1 |
| Asgharzadeh, F | 1 |
| Barneh, F | 1 |
| Fakhraie, M | 1 |
| Adel Barkhordar, SL | 1 |
| Shabani, M | 1 |
| Soleimani, A | 1 |
| Rahmani, F | 1 |
| Ariakia, F | 1 |
| Mehraban, S | 1 |
| Avan, A | 1 |
| Hashemzehi, M | 1 |
| Arjmand, MH | 1 |
| Behnam-Rassouli, R | 1 |
| Jaberi, N | 1 |
| Sayyed-Hosseinian, SH | 1 |
| Ferns, GA | 1 |
| Ryzhikov, M | 1 |
| Jafari, M | 1 |
| Khazaei, M | 2 |
| Hassanian, SM | 1 |
| Ran, Y | 1 |
| Geng, L | 1 |
| Fu, CN | 1 |
| Gao, WS | 1 |
| Song, SS | 1 |
| Yue, SW | 1 |
| Qu, YJ | 1 |
| Luo, G | 1 |
| Liu, W | 2 |
| Fan, C | 1 |
| Shirooie, S | 1 |
| Khaledi, E | 1 |
| Dehpour, AR | 2 |
| Noori, T | 1 |
| Sadeghi, F | 1 |
| Sobarzo-Sánchez, E | 1 |
| Horiuchi, T | 1 |
| Sakata, N | 1 |
| Narumi, Y | 1 |
| Kimura, T | 1 |
| Hayashi, T | 2 |
| Nagano, K | 1 |
| Nishibori, M | 1 |
| Tsukita, S | 1 |
| Yamada, T | 1 |
| Katagiri, H | 1 |
| Shirakawa, R | 1 |
| Horiuchi, H | 1 |
| Hristova, M | 1 |
| Schuiveling, M | 2 |
| Vazirpanah, N | 2 |
| Radstake, TRDJ | 2 |
| Zimmermann, M | 2 |
| Broen, JCA | 2 |
| Qi, B | 1 |
| Hu, L | 2 |
| Shang, L | 1 |
| Liu, N | 1 |
| Wen, N | 1 |
| Hong, Y | 1 |
| Fang, D | 1 |
| Maniar, K | 1 |
| Moideen, A | 1 |
| Bhattacharyya, R | 1 |
| Banerjee, D | 1 |
| Pastor-Villaescusa, B | 1 |
| Cañete, MD | 1 |
| Caballero-Villarraso, J | 1 |
| Hoyos, R | 1 |
| Latorre, M | 1 |
| Vázquez-Cobela, R | 1 |
| Plaza-Díaz, J | 1 |
| Maldonado, J | 1 |
| Bueno, G | 1 |
| Leis, R | 1 |
| Gil, Á | 1 |
| Cañete, R | 1 |
| Aguilera, CM | 1 |
| Pandey, A | 2 |
| Verma, S | 2 |
| Araújo, AA | 1 |
| Pereira, ASBF | 1 |
| Medeiros, CACX | 1 |
| Brito, GAC | 1 |
| Leitão, RFC | 1 |
| Araújo, LS | 1 |
| Guedes, PMM | 1 |
| Hiyari, S | 1 |
| Pirih, FQ | 1 |
| Araújo Júnior, RF | 1 |
| Choi, RY | 1 |
| Ham, JR | 1 |
| Lee, HI | 1 |
| Cho, HW | 1 |
| Park, SK | 2 |
| Seo, KI | 1 |
| Lee, MK | 1 |
| Jing, Y | 1 |
| Wu, F | 1 |
| Li, R | 1 |
| Hollander, MC | 1 |
| Latour, LL | 1 |
| Ishii, H | 1 |
| Min, Y | 1 |
| Ray-Choudhury, A | 1 |
| Munasinghe, J | 1 |
| Merchant, AS | 1 |
| Lin, PC | 1 |
| Hallenbeck, J | 1 |
| Boehm, M | 1 |
| Liao, S | 1 |
| Zhong, W | 1 |
| Feng, Y | 1 |
| Miłkowska-Dymanowska, J | 1 |
| Białas, AJ | 1 |
| Makowska, J | 1 |
| Wardzynska, A | 1 |
| Górski, P | 1 |
| Piotrowski, WJ | 1 |
| Tavenier, A | 1 |
| Deng, W | 1 |
| Leishman, E | 1 |
| Bradshaw, HB | 1 |
| Dey, SK | 1 |
| Liu, G | 1 |
| Bei, J | 1 |
| Liang, L | 1 |
| Yu, G | 1 |
| Allin, KH | 1 |
| Tremaroli, V | 1 |
| Caesar, R | 1 |
| Jensen, BAH | 1 |
| Damgaard, MTF | 1 |
| Bahl, MI | 1 |
| Licht, TR | 1 |
| Hansen, TH | 1 |
| Nielsen, T | 1 |
| Dantoft, TM | 1 |
| Linneberg, A | 1 |
| Jørgensen, T | 1 |
| Vestergaard, H | 1 |
| Kristiansen, K | 1 |
| Franks, PW | 1 |
| Hansen, T | 1 |
| Bäckhed, F | 1 |
| Pedersen, O | 1 |
| Yi, H | 1 |
| Huang, C | 1 |
| Cao, Q | 1 |
| Pollock, CA | 1 |
| Chen, XM | 2 |
| Sekino, N | 1 |
| Kano, M | 1 |
| Matsumoto, Y | 1 |
| Sakata, H | 1 |
| Akutsu, Y | 1 |
| Hanari, N | 1 |
| Murakami, K | 1 |
| Toyozumi, T | 1 |
| Takahashi, M | 1 |
| Otsuka, R | 1 |
| Yokoyama, M | 1 |
| Shiraishi, T | 1 |
| Okada, K | 1 |
| Hoshino, I | 1 |
| Iida, K | 1 |
| Akimoto, AK | 1 |
| Matsubara, H | 1 |
| Jupp, PW | 1 |
| de Souza Teixeira, AA | 1 |
| Souza, CO | 1 |
| Biondo, LA | 1 |
| Sanches Silveira, L | 1 |
| Lima, EA | 1 |
| Batatinha, HA | 1 |
| Araujo, AP | 1 |
| Alves, MJ | 1 |
| Hirabara, SM | 1 |
| Curi, R | 1 |
| Neto, JCR | 1 |
| Yuan, H | 1 |
| Qu, J | 1 |
| Yu, B | 1 |
| Sun, S | 1 |
| Ren, W | 1 |
| Garvey, WT | 1 |
| Van Gaal, L | 1 |
| Leiter, LA | 1 |
| Vijapurkar, U | 1 |
| List, J | 1 |
| Cuddihy, R | 1 |
| Ren, J | 1 |
| Davies, MJ | 1 |
| Han, J | 1 |
| Edwards, P | 1 |
| Gao, H | 1 |
| Yu, FS | 1 |
| Qiao, X | 1 |
| Menegazzo, L | 1 |
| Scattolini, V | 1 |
| Cappellari, R | 1 |
| Bonora, BM | 1 |
| Albiero, M | 1 |
| Bortolozzi, M | 1 |
| Romanato, F | 1 |
| Ceolotto, G | 1 |
| Vigili de Kreutzeberg, S | 1 |
| Avogaro, A | 1 |
| Fadini, GP | 1 |
| Tao, L | 1 |
| Cao, Y | 1 |
| Morita, N | 1 |
| Hosaka, T | 1 |
| Kitahara, A | 1 |
| Murashima, T | 1 |
| Onuma, H | 1 |
| Sumitani, Y | 1 |
| Takahashi, K | 1 |
| Tanaka, T | 1 |
| Kondo, T | 1 |
| Ishida, H | 1 |
| Denis, GV | 1 |
| Sebastiani, P | 1 |
| Bertrand, KA | 1 |
| Strissel, KJ | 1 |
| Tran, AH | 1 |
| Slama, J | 1 |
| Medina, ND | 1 |
| Andrieu, G | 1 |
| Palmer, JR | 1 |
| Moulton, CD | 1 |
| Hopkins, CWP | 1 |
| Ismail, K | 1 |
| Stahl, D | 1 |
| Hall, DT | 1 |
| Griss, T | 1 |
| Ma, JF | 1 |
| Sanchez, BJ | 1 |
| Sadek, J | 1 |
| Tremblay, AMK | 1 |
| Mubaid, S | 1 |
| Omer, A | 1 |
| Ford, RJ | 1 |
| Bedard, N | 1 |
| Pause, A | 1 |
| Wing, SS | 1 |
| Di Marco, S | 1 |
| Steinberg, GR | 1 |
| Jones, RG | 1 |
| Gallouzi, IE | 1 |
| Tian, R | 1 |
| Dai, J | 2 |
| Jiang, R | 1 |
| Afshari, K | 1 |
| Dehdashtian, A | 1 |
| Haddadi, NS | 1 |
| Haj-Mirzaian, A | 1 |
| Iranmehr, A | 1 |
| Ebrahimi, MA | 1 |
| Tavangar, SM | 1 |
| Faghir-Ghanesefat, H | 1 |
| Mohammadi, F | 1 |
| Rahimi, N | 1 |
| Javidan, AN | 1 |
| Shan, T | 1 |
| Rajaei, E | 1 |
| Haybar, H | 1 |
| Mowla, K | 1 |
| Zayeri, ZD | 1 |
| Zhu, S | 1 |
| Tian, X | 1 |
| Ye, Z | 1 |
| Zhai, D | 1 |
| Zhu, Z | 1 |
| Wei, D | 1 |
| Zhu, Q | 1 |
| Saka Herrán, C | 1 |
| Jané-Salas, E | 1 |
| Estrugo Devesa, A | 1 |
| López-López, J | 1 |
| Al-Hashem, F | 1 |
| Al-Humayed, S | 1 |
| Amin, SN | 1 |
| Mansy, SS | 1 |
| Hassan, S | 1 |
| Abdel-Salam, LO | 1 |
| Ellatif, MA | 1 |
| Alfaifi, M | 1 |
| Wang, SY | 1 |
| Cai, GY | 1 |
| Al-Trad, B | 1 |
| Alkhateeb, H | 1 |
| Alsmadi, W | 1 |
| Al-Zoubi, M | 1 |
| Ba, W | 1 |
| Yin, G | 1 |
| Yang, J | 1 |
| Chi, S | 1 |
| Novita, BD | 1 |
| Soediono, EI | 1 |
| Nugraha, J | 1 |
| de Oliveira, S | 1 |
| Houseright, RA | 1 |
| Graves, AL | 1 |
| Golenberg, N | 1 |
| Korte, BG | 1 |
| Miskolci, V | 1 |
| Huttenlocher, A | 1 |
| Zhang, ZJ | 1 |
| Yuan, J | 1 |
| Bi, Y | 1 |
| Ottria, A | 1 |
| van der Linden, M | 1 |
| Wichers, CGK | 1 |
| van Lochem, E | 1 |
| Phipps-Green, A | 1 |
| Merriman, T | 1 |
| Jansen, M | 1 |
| Savchenko, LG | 1 |
| Digtiar, NI | 1 |
| Selikhova, LG | 1 |
| Kaidasheva, EI | 1 |
| Shlykova, OA | 1 |
| Vesnina, LE | 1 |
| Kaidashev, IP | 1 |
| Li, YL | 1 |
| Li, XQ | 1 |
| Wang, YD | 1 |
| Shen, C | 1 |
| Zhao, CY | 1 |
| Inayat, H | 1 |
| Azim, MK | 1 |
| Baloch, AA | 1 |
| Peng, XW | 1 |
| Zhou, HH | 1 |
| Hu, R | 1 |
| Zhou, Z | 2 |
| Culig, Z | 1 |
| Ge, CX | 1 |
| Xu, MX | 1 |
| Qin, YT | 1 |
| Gu, TT | 1 |
| Lou, DS | 1 |
| Hu, LF | 1 |
| Wang, BC | 1 |
| Tan, J | 1 |
| Xue, J | 1 |
| Liu, P | 1 |
| Sha, L | 1 |
| Lei, H | 1 |
| Manzoor, S | 1 |
| Ganie, MA | 1 |
| Amin, S | 1 |
| Shah, ZA | 1 |
| Bhat, IA | 1 |
| Yousuf, SD | 1 |
| Jeelani, H | 1 |
| Kawa, IA | 1 |
| Fatima, Q | 1 |
| Rashid, F | 1 |
| Karam, HM | 1 |
| Radwan, RR | 1 |
| Moiseeva, O | 1 |
| Deschênes-Simard, X | 1 |
| St-Germain, E | 1 |
| Igelmann, S | 1 |
| Huot, G | 1 |
| Cadar, AE | 1 |
| Bourdeau, V | 1 |
| Ferbeyre, G | 1 |
| Desai, N | 2 |
| Roman, A | 1 |
| Rochelson, B | 1 |
| Gupta, M | 2 |
| Xue, X | 1 |
| Chatterjee, PK | 2 |
| Tam Tam, H | 1 |
| Metz, CN | 2 |
| Andrews, M | 2 |
| Soto, N | 2 |
| Arredondo, M | 1 |
| Heyer, EJ | 1 |
| Mergeche, JL | 1 |
| Bruce, SS | 1 |
| Connolly, ES | 1 |
| Derosa, G | 4 |
| Franzetti, IG | 3 |
| Querci, F | 3 |
| Carbone, A | 1 |
| Ciccarelli, L | 2 |
| Piccinni, MN | 2 |
| Fogari, E | 3 |
| Maffioli, P | 4 |
| Shin, NR | 1 |
| Lee, JC | 1 |
| Lee, HY | 1 |
| Kim, MS | 1 |
| Whon, TW | 1 |
| Lee, MS | 1 |
| Bae, JW | 1 |
| Salman, ZK | 1 |
| Refaat, R | 1 |
| Selima, E | 1 |
| El Sarha, A | 1 |
| Ismail, MA | 1 |
| Martin-Montalvo, A | 1 |
| Mercken, EM | 1 |
| Mitchell, SJ | 1 |
| Palacios, HH | 1 |
| Mote, PL | 1 |
| Scheibye-Knudsen, M | 1 |
| Gomes, AP | 1 |
| Ward, TM | 1 |
| Minor, RK | 1 |
| Blouin, MJ | 1 |
| Schwab, M | 1 |
| Pollak, M | 1 |
| Yu, Y | 1 |
| Becker, KG | 1 |
| Bohr, VA | 1 |
| Ingram, DK | 1 |
| Sinclair, DA | 1 |
| Wolf, NS | 1 |
| Spindler, SR | 1 |
| Bernier, M | 1 |
| de Cabo, R | 1 |
| Russe, OQ | 1 |
| Möser, CV | 1 |
| Kynast, KL | 1 |
| King, TS | 1 |
| Stephan, H | 1 |
| Geisslinger, G | 1 |
| Niederberger, E | 1 |
| Ciaraldi, TP | 1 |
| Aroda, V | 1 |
| Mudaliar, SR | 1 |
| Henry, RR | 1 |
| Ortega, FJ | 1 |
| Moreno-Navarrete, JM | 1 |
| Mayas, D | 1 |
| Serino, M | 1 |
| Rodriguez-Hermosa, JI | 1 |
| Ricart, W | 1 |
| Luche, E | 1 |
| Burcelin, R | 1 |
| Tinahones, FJ | 1 |
| Frühbeck, G | 1 |
| Mingrone, G | 1 |
| Fernández-Real, JM | 1 |
| Lin, CF | 1 |
| Young, KC | 1 |
| Bai, CH | 1 |
| Yu, BC | 1 |
| Ma, CT | 1 |
| Chien, YC | 1 |
| Su, HC | 1 |
| Wang, HY | 1 |
| Liao, CS | 1 |
| Lai, HW | 1 |
| Tsao, CW | 1 |
| Kim, D | 1 |
| Lee, JE | 1 |
| Lee, AS | 1 |
| Lee, S | 1 |
| Kim, SH | 1 |
| Park, BH | 1 |
| Kim, W | 1 |
| Kang, KP | 1 |
| Zhao, ZQ | 1 |
| Li, LY | 1 |
| Tian, FS | 1 |
| Zheng, XL | 1 |
| Xiong, HL | 1 |
| Sun, LT | 1 |
| Karatas, A | 1 |
| Özlü, T | 1 |
| Erdem, A | 1 |
| Calixto, MC | 1 |
| Lintomen, L | 1 |
| André, DM | 1 |
| Leiria, LO | 1 |
| Ferreira, D | 1 |
| Lellis-Santos, C | 1 |
| Anhê, GF | 1 |
| Bordin, S | 1 |
| Landgraf, RG | 1 |
| Kotani, H | 1 |
| Yamaguchi, T | 1 |
| Taguchi, K | 1 |
| Iida, M | 1 |
| Ina, K | 1 |
| Maeda, M | 1 |
| Kuzuya, M | 1 |
| Hattori, Y | 1 |
| Ignarro, LJ | 1 |
| Yue, W | 1 |
| Yang, CS | 1 |
| DiPaola, RS | 1 |
| Tan, XL | 1 |
| Woo, SL | 1 |
| Xu, H | 2 |
| Guo, X | 1 |
| Guo, T | 1 |
| Botchlett, R | 1 |
| Qi, T | 1 |
| Pei, Y | 1 |
| An, X | 1 |
| Huo, Y | 1 |
| Ito, K | 1 |
| Mercado, N | 1 |
| Bułdak, Ł | 1 |
| Łabuzek, K | 1 |
| Bułdak, RJ | 1 |
| Kozłowski, M | 1 |
| Machnik, G | 1 |
| Liber, S | 1 |
| Suchy, D | 1 |
| Duława-Bułdak, A | 1 |
| Kim, J | 1 |
| Kwak, HJ | 1 |
| Cha, JY | 1 |
| Jeong, YS | 1 |
| Rhee, SD | 1 |
| Kim, KR | 1 |
| Cheon, HG | 1 |
| Cansby, E | 1 |
| Nerstedt, A | 1 |
| Amrutkar, M | 1 |
| Durán, EN | 1 |
| Smith, U | 1 |
| Mahlapuu, M | 1 |
| Edsfeldt, A | 1 |
| Gonçalves, I | 1 |
| Grufman, H | 1 |
| Nitulescu, M | 1 |
| Dunér, P | 1 |
| Bengtsson, E | 1 |
| Mollet, IG | 1 |
| Persson, A | 1 |
| Nilsson, M | 1 |
| Orho-Melander, M | 1 |
| Melander, O | 1 |
| Björkbacka, H | 1 |
| Nilsson, J | 1 |
| Du, C | 1 |
| Zheng, Q | 1 |
| Peng, L | 1 |
| Zhu, XC | 1 |
| Jiang, T | 1 |
| Zhang, QQ | 1 |
| Cao, L | 1 |
| Tan, MS | 1 |
| Wang, HF | 1 |
| Ding, ZZ | 1 |
| Tan, L | 1 |
| Yu, JT | 1 |
| Han, CS | 1 |
| Herrin, MA | 1 |
| Pitruzzello, MC | 1 |
| Mulla, MJ | 1 |
| Werner, EF | 1 |
| Pettker, CM | 1 |
| Flannery, CA | 1 |
| Abrahams, VM | 1 |
| Naderpoor, N | 1 |
| Shorakae, S | 1 |
| Joham, A | 1 |
| Boyle, J | 1 |
| De Courten, B | 1 |
| Teede, HJ | 1 |
| Arredondo-Olguín, M | 1 |
| Jeve, YB | 1 |
| Konje, JC | 1 |
| Doshani, A | 1 |
| Liu, SN | 1 |
| Sun, SJ | 1 |
| Hou, SC | 1 |
| Shen, ZF | 1 |
| Saisho, Y | 1 |
| Lefaucheur, R | 1 |
| Bourre, B | 1 |
| Ozkul-Wermester, O | 1 |
| Maltête, D | 1 |
| Wallon, D | 1 |
| Aljada, A | 2 |
| Zechner, D | 1 |
| Radecke, T | 1 |
| Amme, J | 1 |
| Bürtin, F | 1 |
| Albert, AC | 1 |
| Partecke, LI | 1 |
| Vollmar, B | 1 |
| Noureddin, M | 1 |
| Rinella, ME | 1 |
| Zeb, MH | 1 |
| Baruah, A | 1 |
| Kossak, SK | 1 |
| Buttar, NS | 1 |
| Oxenkrug, GF | 1 |
| Xu, W | 1 |
| Deng, YY | 1 |
| Maharjan, P | 1 |
| Gao, S | 1 |
| Tian, Y | 1 |
| Zhuo, X | 1 |
| Zhou, J | 1 |
| Kover, KL | 1 |
| Heruth, DP | 1 |
| Watkins, DJ | 1 |
| Moore, WV | 1 |
| Jackson, K | 1 |
| Zang, M | 1 |
| Clements, MA | 1 |
| Gong, X | 1 |
| Duan, R | 1 |
| Ao, JE | 1 |
| Ai, Q | 1 |
| Ge, P | 1 |
| Lin, L | 1 |
| Fukumura, D | 1 |
| Incio, J | 1 |
| Shankaraiah, RC | 1 |
| Jain, RK | 1 |
| García-Heredia, A | 1 |
| Riera-Borrull, M | 1 |
| Fort-Gallifa, I | 1 |
| Luciano-Mateo, F | 1 |
| Cabré, N | 1 |
| Hernández-Aguilera, A | 1 |
| Joven, J | 1 |
| Camps, J | 1 |
| Li, A | 2 |
| Qiu, Z | 1 |
| Qi, LW | 1 |
| Kou, J | 1 |
| Liu, B | 2 |
| Huang, F | 1 |
| Chen, MJ | 1 |
| Ho, HN | 1 |
| Matassa, DS | 1 |
| Amoroso, MR | 1 |
| Avolio, R | 1 |
| Arzeni, D | 1 |
| Procaccini, C | 1 |
| Faicchia, D | 1 |
| Maddalena, F | 1 |
| Simeon, V | 1 |
| Agliarulo, I | 1 |
| Zanini, E | 1 |
| Mazzoccoli, C | 1 |
| Recchi, C | 1 |
| Stronach, E | 1 |
| Marone, G | 1 |
| Gabra, H | 1 |
| Matarese, G | 1 |
| Landriscina, M | 1 |
| Esposito, F | 1 |
| Yao, T | 1 |
| Zhao, W | 1 |
| Hou, T | 1 |
| Zhang, N | 1 |
| Hsieh, PS | 1 |
| Tiwari, V | 1 |
| Rawat, JK | 1 |
| Devi, U | 1 |
| Yadav, RK | 1 |
| Roy, S | 1 |
| Gautam, S | 1 |
| Saraf, SA | 1 |
| Kumar, V | 1 |
| Ansari, N | 1 |
| Saeedan, AS | 1 |
| Kaithwas, G | 1 |
| van Vught, LA | 1 |
| Scicluna, BP | 1 |
| Hoogendijk, AJ | 1 |
| Wiewel, MA | 1 |
| Klein Klouwenberg, PM | 1 |
| Cremer, OL | 1 |
| Horn, J | 1 |
| Nürnberg, P | 1 |
| Bonten, MM | 1 |
| Schultz, MJ | 1 |
| van der Poll, T | 1 |
| Cho, JG | 1 |
| Song, JJ | 1 |
| Choi, J | 1 |
| Im, GJ | 1 |
| Jung, HH | 1 |
| Chae, SW | 1 |
| Sathyapalan, T | 1 |
| Javed, Z | 1 |
| Kilpatrick, ES | 1 |
| Coady, AM | 1 |
| Atkin, SL | 1 |
| Pecikoza, UB | 1 |
| Tomić, MA | 1 |
| Micov, AM | 1 |
| Stepanović-Petrović, RM | 1 |
| Pan, Y | 1 |
| Jiang, L | 1 |
| Qian, C | 1 |
| Song, C | 1 |
| Ye, W | 1 |
| Ramos, EH | 1 |
| Wong, BC | 1 |
| Belsham, DD | 1 |
| Chung, MM | 1 |
| Nicol, CJ | 1 |
| Cheng, YC | 1 |
| Lin, KH | 1 |
| Chen, YL | 1 |
| Pei, D | 1 |
| Lin, CH | 1 |
| Shih, YN | 1 |
| Yen, CH | 1 |
| Chen, SJ | 1 |
| Huang, RN | 1 |
| Chiang, MC | 1 |
| Farah, R | 1 |
| Shurtz-Swirski, R | 1 |
| Lapin, O | 1 |
| Braga, MB | 1 |
| Yener, S | 1 |
| Comlekci, A | 1 |
| Akinci, B | 1 |
| Demir, T | 1 |
| Yuksel, F | 1 |
| Ozcan, MA | 1 |
| Bayraktar, F | 1 |
| Yesil, S | 1 |
| Hartemann-Heurtier, A | 1 |
| Halbron, M | 1 |
| Golmard, JL | 1 |
| Jacqueminet, S | 1 |
| Bastard, JP | 1 |
| Rouault, C | 1 |
| Ayed, A | 1 |
| Pieroni, L | 1 |
| Clément, K | 1 |
| Grimaldi, A | 1 |
| Salvadeo, SA | 2 |
| Ferrari, I | 2 |
| Ragonesi, PD | 1 |
| Gadaleta, G | 1 |
| D'Angelo, A | 2 |
| Cicero, AF | 2 |
| Koniari, K | 1 |
| Antoniades, C | 1 |
| Papageorgiou, N | 1 |
| Miliou, A | 1 |
| Noutsou, M | 1 |
| Nikolopoulou, A | 1 |
| Marinou, K | 1 |
| Stefanadi, E | 1 |
| Charakida, M | 1 |
| Kamboli, AM | 1 |
| Stefanadis, C | 1 |
| Shwarts, V | 1 |
| Xavier, DO | 1 |
| Amaral, LS | 1 |
| Gomes, MA | 1 |
| Rocha, MA | 1 |
| Campos, PR | 1 |
| Cota, BD | 1 |
| Tafuri, LS | 1 |
| Paiva, AM | 1 |
| Silva, JH | 1 |
| Andrade, SP | 1 |
| Belo, AV | 1 |
| Mereu, R | 1 |
| Gravina, A | 1 |
| Palumbo, I | 1 |
| Randazzo, S | 1 |
| Tan, BK | 1 |
| Adya, R | 1 |
| Shan, X | 1 |
| Aghilla, M | 1 |
| Lehnert, H | 1 |
| Keay, SD | 1 |
| Randeva, HS | 1 |
| Riethoven, JJ | 1 |
| Xia, Y | 1 |
| Miner, J | 1 |
| Fromm, M | 1 |
| Perez, A | 1 |
| Jacks, R | 1 |
| Arora, V | 1 |
| Spanheimer, R | 1 |
| Chakraborty, A | 1 |
| Chowdhury, S | 1 |
| Bhattacharyya, M | 1 |
| Sena, CM | 1 |
| Matafome, P | 1 |
| Louro, T | 1 |
| Nunes, E | 1 |
| Fernandes, R | 1 |
| Seiça, RM | 1 |
| Grisouard, J | 1 |
| Timper, K | 1 |
| Bouillet, E | 1 |
| Radimerski, T | 1 |
| Dembinski, K | 1 |
| Frey, DM | 1 |
| Peterli, R | 1 |
| Zulewski, H | 1 |
| Keller, U | 1 |
| Müller, B | 1 |
| Schwanstecher, C | 1 |
| Schwanstecher, M | 1 |
| Schöndorf, T | 1 |
| Musholt, PB | 1 |
| Hohberg, C | 1 |
| Forst, T | 1 |
| Lehmann, U | 1 |
| Fuchs, W | 1 |
| Löbig, M | 1 |
| Müller, J | 1 |
| Pfützner, A | 1 |
| Salminen, A | 1 |
| Kaarniranta, K | 1 |
| Haapasalo, A | 1 |
| Soininen, H | 1 |
| Hiltunen, M | 1 |
| Putignano, P | 1 |
| Bossi, AC | 1 |
| Bonaventura, A | 1 |
| Guazzini, B | 1 |
| Testori, G | 1 |
| González, O | 1 |
| Tobia, C | 1 |
| Ebersole, J | 1 |
| Novak, MJ | 1 |
| Sobel, BE | 1 |
| Hardison, RM | 1 |
| Genuth, S | 1 |
| Brooks, MM | 1 |
| McBane, RD | 1 |
| Schneider, DJ | 1 |
| Pratley, RE | 1 |
| Huber, K | 1 |
| Wolk, R | 1 |
| Krishnaswami, A | 1 |
| Frye, RL | 1 |
| Tsai, SJ | 1 |
| Lin, MW | 1 |
| Yang, CT | 1 |
| Huang, MF | 1 |
| Wu, MH | 1 |
| Khan, HB | 1 |
| Vinayagam, KS | 1 |
| Moorthy, BT | 1 |
| Palanivelu, S | 1 |
| Panchanatham, S | 1 |
| Subramaniam, N | 1 |
| Sherman, MH | 1 |
| Rao, R | 1 |
| Wilson, C | 1 |
| Coulter, S | 1 |
| Atkins, AR | 1 |
| Evans, RM | 1 |
| Liddle, C | 1 |
| Downes, M | 1 |
| Gómez-Díaz, RA | 1 |
| Talavera, JO | 1 |
| Pool, EC | 1 |
| Ortiz-Navarrete, FV | 1 |
| Solórzano-Santos, F | 1 |
| Mondragón-González, R | 1 |
| Valladares-Salgado, A | 1 |
| Cruz, M | 1 |
| Aguilar-Salinas, CA | 1 |
| Wacher, NH | 1 |
| Klempfner, R | 1 |
| Leor, J | 1 |
| Tenenbaum, A | 1 |
| Fisman, EZ | 1 |
| Goldenberg, I | 1 |
| Rizzo, MR | 1 |
| Barbieri, M | 1 |
| Marfella, R | 1 |
| Paolisso, G | 1 |
| Yao, F | 1 |
| Ji, GY | 1 |
| Albini, A | 1 |
| Tosetti, F | 1 |
| Li, VW | 1 |
| Noonan, DM | 1 |
| Li, WW | 1 |
| Kim, SA | 1 |
| Choi, HC | 1 |
| Yu, S | 1 |
| Li, MZ | 1 |
| Lin, P | 1 |
| Huang, QX | 1 |
| Hou, WK | 1 |
| Mahmood, K | 1 |
| Naeem, M | 1 |
| Rahimnajjad, NA | 1 |
| Hirsch, HA | 1 |
| Iliopoulos, D | 1 |
| Struhl, K | 1 |
| Genovese, S | 1 |
| De Berardis, G | 1 |
| Nicolucci, A | 1 |
| Mannucci, E | 1 |
| Evangelista, V | 1 |
| Totani, L | 1 |
| Pellegrini, F | 1 |
| Ceriello, A | 1 |
| Després, JP | 1 |
| Dandona, P | 1 |
| Chaudhuri, A | 1 |
| Mohanty, P | 1 |
| Haffner, S | 1 |
| Temprosa, M | 1 |
| Crandall, J | 1 |
| Fowler, S | 1 |
| Goldberg, R | 1 |
| Horton, E | 1 |
| Marcovina, S | 1 |
| Mather, K | 1 |
| Orchard, T | 1 |
| Ratner, R | 1 |
| Barrett-Connor, E | 1 |
| Athyros, VG | 1 |
| Elisaf, M | 1 |
| Mikhailidis, DP | 1 |
| Bhatia, V | 1 |
| Bergheim, I | 1 |
| Luyendyk, JP | 1 |
| Steele, C | 1 |
| Russell, GK | 1 |
| Roth, RA | 1 |
| Arteel, GE | 1 |
| Diamanti-Kandarakis, E | 1 |
| Paterakis, T | 1 |
| Alexandraki, K | 1 |
| Piperi, C | 1 |
| Aessopos, A | 1 |
| Katsikis, I | 1 |
| Katsilambros, N | 1 |
| Kreatsas, G | 1 |
| Panidis, D | 1 |
| Varma, V | 2 |
| Yao-Borengasser, A | 2 |
| Rasouli, N | 2 |
| Bodles, AM | 2 |
| Phanavanh, B | 2 |
| Lee, MJ | 2 |
| Starks, T | 2 |
| Kern, LM | 2 |
| Spencer, HJ | 2 |
| McGehee, RE | 2 |
| Fried, SK | 2 |
| Stocker, DJ | 1 |
| Taylor, AJ | 1 |
| Langley, RW | 1 |
| Jezior, MR | 1 |
| Vigersky, RA | 1 |
| Takemura, Y | 1 |
| Osuga, Y | 1 |
| Yoshino, O | 1 |
| Hasegawa, A | 1 |
| Hirata, T | 1 |
| Hirota, Y | 1 |
| Nose, E | 1 |
| Morimoto, C | 1 |
| Harada, M | 1 |
| Koga, K | 1 |
| Tajima, T | 1 |
| Yano, T | 1 |
| Taketani, Y | 1 |
| Rashidi, AA | 1 |
| Bulcão, C | 1 |
| Ribeiro-Filho, FF | 1 |
| Sañudo, A | 1 |
| Roberta Ferreira, SG | 1 |
| He, CT | 1 |
| Wu, LY | 1 |
| Kelly, AS | 1 |
| Thelen, AM | 1 |
| Kaiser, DR | 1 |
| Gonzalez-Campoy, JM | 1 |
| Bank, AJ | 1 |
| García-Moll, X | 1 |
| Gómez-García, A | 1 |
| Martínez Torres, G | 1 |
| Ortega-Pierres, LE | 1 |
| Rodríguez-Ayala, E | 1 |
| Alvarez-Aguilar, C | 1 |
| Verstraete, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Sitagliptin in Relatives of Patients With Type 1 Diabetes Mellitus, at High Risk of Developing the Disease[NCT05219409] | Phase 2/Phase 3 | 70 participants (Anticipated) | Interventional | 2023-07-31 | Not yet recruiting | ||
| Prevention of Metabolic Complications of Glucocorticoid Excess - a Randomised, Doubleblind,Placebo Controlled Study[NCT01319994] | Phase 2/Phase 3 | 57 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| The Effect of Adding Vildagliptin Versus Glimepiride to Metformin on Markers of Inflammation, Thrombosis, and Atherosclerosis in Diabetic Patients With Symptomatic Coronary Artery Diseases[NCT03693560] | Phase 4 | 80 participants (Actual) | Interventional | 2018-10-08 | Completed | ||
| Intravitreous CytokinE Level in pAtient With retiNal Detachment[NCT03318588] | 74 participants (Actual) | Observational | 2017-11-15 | Completed | |||
| Investigating the Impact of p53 and SIRT1 in the Development of Type 2 DM Through the Treatment of Prediabetic Individuals by Either Nigetella Salivata or Metformin[NCT03925714] | Phase 3 | 90 participants (Anticipated) | Interventional | 2019-04-01 | Recruiting | ||
| A Randomized, Double-Blind, 3-Arm Parallel-Group, 2-Year (104-Week), Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-28431754 Compared With Glimepiride in the Treatment of Subjects With Type 2 Diabetes Mellitus Not Optimally Co[NCT00968812] | Phase 3 | 1,452 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| Diabetes Diagnosis, Management, Prevention and Education in Guinea-Bissau[NCT05591339] | Phase 4 | 200 participants (Anticipated) | Interventional | 2023-03-01 | Not yet recruiting | ||
| Effect of Augmentation of Cerebral Blood Flow on Neuropsychometric Performance After Carotid Endarterectomy in Type II Diabetic Patients[NCT00597545] | 10 participants (Actual) | Interventional | 2007-03-31 | Terminated (stopped due to Half of DM patients had EEG changes and therefore were excluded.) | |||
| Neurologic and Neuropsychometric Outcome in Patients Undergoing Carotid Endarterectomy[NCT00597883] | 585 participants (Actual) | Observational | 2003-03-31 | Completed | |||
| Metformin for Treatment of Psoriasis Combined With Disorders of Glucose and Lipid Metabolism: A Double-Blind, Randomized, Placebo-Controlled Study[NCT03629639] | Phase 4 | 80 participants (Anticipated) | Interventional | 2018-09-01 | Not yet recruiting | ||
| A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The Prime Study[NCT03031821] | Phase 3 | 168 participants (Actual) | Interventional | 2018-07-12 | Terminated (stopped due to Manufacturer discontinued the production of study drugs.) | ||
| Gut-Brain-axis: Targets for Improvement of Cognition in the Elderly[NCT04841668] | 136 participants (Anticipated) | Observational | 2021-04-10 | Recruiting | |||
| A Multi-center, Prospective, Cohort Study to Elucidate the Effects of Metformin Treatment on Steroid Hormones and Social Behavior. Linking Autistic Behaviorial Symptoms to Changes in Steroid Hormone Availability[NCT04930471] | 45 participants (Anticipated) | Observational | 2021-06-30 | Not yet recruiting | |||
| Effects of Metformin and Combination of Metformin and Pioglitazone on Plasma Interleukin-6 and Interleukin-8 Levels in Polycystic Ovarian Syndrome[NCT03117517] | Early Phase 1 | 106 participants (Actual) | Interventional | 2017-03-20 | Completed | ||
| Effect of Metformin and Combination of Olive Oil Plus Nutritional Supplements on Inflammatory Markers IL-6 and IL-8 in PCOS.[NCT05952349] | Phase 2 | 88 participants (Anticipated) | Interventional | 2023-07-01 | Recruiting | ||
| Metformin Administration Effect Over Systemic Inflammation Serum Markers in HIV Positive Prediabetic Patients[NCT03774108] | Phase 4 | 40 participants (Actual) | Interventional | 2018-12-15 | Active, not recruiting | ||
| Effect of Metformin on Chronic Pain After Thoracic Surgery in Diabetic Patients[NCT04089813] | 200 participants (Anticipated) | Observational | 2019-09-10 | Not yet recruiting | |||
| Evolution of Abdominal Adipose Tissue Distribution in Type 2 Diabetic Patients Treated During 6 Months With Pioglitazone or Insulin, in Association With Metformin or Sulfonylurea.[NCT00159211] | 28 participants (Actual) | Interventional | 2005-05-31 | Terminated (stopped due to inclusion was finished) | |||
| Dipeptidyl Peptidase-4 Inhibition and Narrow-band Ultraviolet-B Light in Psoriasis (DINUP): A Randomised Clinical Trial[NCT02347501] | Phase 2 | 118 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.[NCT01991197] | Phase 2 | 20 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| A Phase 3b, Double-Blind, Randomized Study to Determine the Efficacy and Safety of Pioglitazone HCl and Metformin HCl Fixed-Dose Combination Therapy Compared to Pioglitazone HCl Monotherapy and to Metformin HCl Monotherapy in the Treatment of Subjects Wit[NCT00727857] | Phase 3 | 600 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| The Possible Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer[NCT05590117] | Early Phase 1 | 48 participants (Anticipated) | Interventional | 2022-10-11 | Enrolling by invitation | ||
| A Double-blind, Randomized, Placebo-controlled, Parallel Design Study to Evaluate the Effects of the Cardio Formulation on Oxidized LDL in Individuals Who Are Overweight to Mildly Obese and Otherwise Healthy[NCT04317287] | 9 participants (Actual) | Interventional | 2019-12-10 | Terminated (stopped due to COVID-19 Pandemic) | |||
| Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes[NCT00006305] | Phase 3 | 2,368 participants (Actual) | Interventional | 2000-09-30 | Completed | ||
| Metformin Decreases Plasma Resistin Concentrations in Pediatric Patients With Impaired Glucose Tolerance: A Placebo-controlled Randomized Clinical Trial[NCT01394887] | Phase 2/Phase 3 | 52 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| DPP-4 Inhibitors in Patients With Type 2 Diabetes and Acute Myocardial Infarction:Effects on Platelet Function[NCT02377388] | Phase 3 | 74 participants (Actual) | Interventional | 2017-02-07 | Completed | ||
| Phase 4 Study of the Effects of Pravastatin on Cholesterol Levels, Inflammation and Cognition in Schizophrenia[NCT01082588] | Phase 4 | 60 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance[NCT00108615] | Phase 4 | 48 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Phase II Randomized Study of Neoadjuvant Metformin Plus Letrozole vs Placebo Plus Letrozole for ER-positive Postmenopausal Breast Cancer[NCT01589367] | Phase 2 | 208 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
change in visceral/subcutaneous fat (NCT01319994)
Timeframe: 3 months minus baseline
| Intervention | ratio (Mean) |
|---|---|
| Metformin | 0.08 |
| Placebo | -0.03 |
The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance and beta (β)-cell function. HOMA2-IR is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin resistance which is the reciprocal of insulin sensitivity (%S)(100/%S) as a percentage of a normal reference population (normal young adults). HOMA2-IR is calculated using the HOMA model: www.dtu.ox.ac.uk/homacalculator/ (NCT01319994)
Timeframe: 3 months minus baseline
| Intervention | HOMA score (Mean) |
|---|---|
| Metformin | 0.22 |
| Placebo | 2.35 |
The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 104 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in the LS mean change. (NCT00968812)
Timeframe: Baseline, Week 104
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Canagliflozin 100 mg | -0.65 |
| Canagliflozin 300 mg | -0.74 |
| Glimepiride | -0.55 |
The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 52 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in the LS mean change. (NCT00968812)
Timeframe: Day 1 (Baseline) and Week 52
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Canagliflozin 100 mg | -0.82 |
| Canagliflozin 300 mg | -0.93 |
| Glimepiride | -0.81 |
The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 52 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in the LS mean percent change. (NCT00968812)
Timeframe: Day 1 (Baseline) and Week 52
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Canagliflozin 100 mg | -4.2 |
| Canagliflozin 300 mg | -4.7 |
| Glimepiride | 1.0 |
The table below shows the percentage of patients who experienced at least 1 documented hypoglycemic event from Baseline to Week 52 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in percentages. (NCT00968812)
Timeframe: Day 1 (Baseline) and Week 52
| Intervention | Percentage of patients (Number) |
|---|---|
| Canagliflozin 100 mg | 5.6 |
| Canagliflozin 300 mg | 4.9 |
| Glimepiride | 34.2 |
Battery of neuropsychometric tests to evaluate a variety of cognitive functions. (NCT00597545)
Timeframe: Post-operatively at 1 day
| Intervention | participants (Number) |
|---|---|
| Conventional Shunt | 1 |
| Prophylactic Shunt | 2 |
IL-6 and IL-8 levels by ELISA method using commercially available kits. (NCT03117517)
Timeframe: Baseline and after 3 Months
| Intervention | pg/ml (Geometric Mean) | |||
|---|---|---|---|---|
| IL-6 levels at baseline | IL-6 levels after 3 months of treatment | IL-8 Llevels at baseline | IL-8 Llevels after treatment | |
| Metformin | 14.60 | 12.65 | 61.92 | 32.70 |
| Metformin, Pioglitazone | 14.12 | 11.12 | 41.86 | 22.00 |
Serum level of LH was measure at baseline and after 3 months of treatment (NCT03117517)
Timeframe: Baseine and after 3 Months
| Intervention | mIU/ml (Geometric Mean) | |
|---|---|---|
| LH level at baseline | LH level after treatment | |
| Metformin | 5.79 | 4.92 |
| Metformin, Pioglitazone | 6.625 | 5.16 |
Insulin resistance was measure by calculating HOMA-IR from the data of insulin and sugar levels. (NCT03117517)
Timeframe: Baseline and after 3 months
| Intervention | unitless (Mean) | |
|---|---|---|
| HOMA-IR at baseline | HOMA-IR after treatment | |
| Metformin | 7.19 | 3.97 |
| Metformin, Pioglitazone | 6.22 | 3.84 |
High sensitivity C-reactive protein (range 0 - no maximum) (NCT01991197)
Timeframe: 16 weeks
| Intervention | µg/ml (Median) |
|---|---|
| Sitagliptin | 0 |
| Gliclazide | 8.4 |
The change in glucose from baseline to 16 weeks (NCT01991197)
Timeframe: 16 weeks
| Intervention | mmol/L (Median) |
|---|---|
| Sitagliptin | -0.2 |
| Gliclazide | -0.1 |
The change in systolic blood pressure from baseline to 16 weeks measured in kg (NCT01991197)
Timeframe: 16 weeks
| Intervention | mmHg (Median) |
|---|---|
| Sitagliptin | 4 |
| Gliclazide | -9 |
The change in total cholesterol from baseline to 16 weeks (NCT01991197)
Timeframe: 16 weeks
| Intervention | mmol/L (Median) |
|---|---|
| Sitagliptin | 0.1 |
| Gliclazide | -0.1 |
Psoriasis area and severity index 0-72, higher score worse outcome (NCT01991197)
Timeframe: baseline and 32 weeks
| Intervention | score on a scale (Median) |
|---|---|
| Sitagliptin | 3 |
| Gliclazide | 1.8 |
Psoriasis area and severity index (0-72), higher scores worse outcome (NCT01991197)
Timeframe: 16 weeks
| Intervention | score on a scale (Median) |
|---|---|
| Sitagliptin | 9.5 |
| Gliclazide | 9.4 |
The change in weight from baseline to 16 weeks measured in kg (NCT01991197)
Timeframe: 16 weeks
| Intervention | kg (Median) |
|---|---|
| Sitagliptin | -0.5 |
| Gliclazide | -0.6 |
Dipeptidyl peptidase-4 levels levels in skin (0-no maximum) (NCT01991197)
Timeframe: 16 weeks
| Intervention | dCt (Median) |
|---|---|
| Gliclazide | -1.12 |
| Sitagliptin | 0 |
Interleukin 17 levels in skin (0-no maximum) (NCT01991197)
Timeframe: 16 weeks
| Intervention | dCt (Median) |
|---|---|
| Sitagliptin | 3.41 |
| Gliclazide | 2.09 |
"Secondary outcomes:~The change in serum concentrations of the cytokine interleukin-17 (IL-17) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks
| Intervention | pg/ml (Median) |
|---|---|
| Sitagliptin | 0 |
| Gliclazide | 0 |
"Secondary outcomes:~The change in serum concentrations of the cytokine interleukin-23 (IL-23) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks
| Intervention | pg/ml (Median) |
|---|---|
| Sitagliptin | 0 |
| Gliclazide | 0 |
"Secondary outcomes:~The change in serum concentrations of the adipokine leptin Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks
| Intervention | pg/ml (Median) |
|---|---|
| Sitagliptin | -0.07 |
| Gliclazide | 0.43 |
"Secondary outcomes:~The change in serum concentrations of the cytokines tumour necrosis factor alpha (TNFα) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks
| Intervention | pg/ml (Median) |
|---|---|
| Sitagliptin | 0 |
| Gliclazide | 0 |
"Dosage: Sitagliptin: 100mg daily, or 50mg daily for participants with moderate kidney disease Gliclazide: 80-320 mg daily.~Secondary outcomes: the number participants with adverse events." (NCT01991197)
Timeframe: 32 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Sitagliptin | 6 |
| Gliclazide | 10 |
"Dermatology life quality index (a skin related quality of life measure) (0-10), higher score worse outcome EQ-5D Euroqol 5 item quality of life index comprising 5 dimensions mobility, self-care, usual activities, pain, anxiety. An index can be derived from these 5 dimensions by conversion with a table of scores. The maximum score of 1 indicates the best health state and minimum score indicating the worst health outcome -0.594.~HADS Hospital anxiety and depression scale 0-16 for anxiety and 0-16 for depression, higher score worse outcome HAQ-8 Stanford 8 item disability scale. Scoring is from 0 (without any difficulty) to 3 (unable to do). The 8 scores from the 8 sections are summed and divided by 8. The result is the disability index (range 0-3 with 25 possible values). A" (NCT01991197)
Timeframe: 16 weeks
| Intervention | score on a scale (Median) | ||||
|---|---|---|---|---|---|
| DLQI | HAQ-8 | HADS Anxiety | HADS Depression | EQ-5D | |
| Gliclazide | -1.0 | 0.0 | 0 | 0 | -0.2 |
| Sitagliptin | 0.0 | 0.0 | -1 | 0 | 0 |
"Secondary outcomes:~d. number or participants who acheived a greater than 50% reduction in PASI from baseline (PASI-50); e. number of participants who achieved PASI-75 and PASI-90." (NCT01991197)
Timeframe: 16 weeks
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| PASI 50 | PASI 75 | PASI 90 | |
| Gliclazide | 1 | 0 | 0 |
| Sitagliptin | 1 | 0 | 0 |
The change between Adiponectin collected at final visit or week 24 and Adiponectin collected at baseline. (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | mcg/ml (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | 7.8 |
| Pioglitazone 15 mg BID | 9.2 |
| Metformin 850 mg BID | -0.3 |
The change between the Fasting Insulin value collected at final visit or week 24 and Fasting Insulin collected at baseline. (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | μIU/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | -3.91 |
| Pioglitazone 15 mg BID | -3.18 |
| Metformin 850 mg BID | -0.98 |
The change between the value of Fasting Plasma Glucose collected at final visit or week 24 and Fasting Plasma Glucose collected at baseline. (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | -39.9 |
| Pioglitazone 15 mg BID | -22.2 |
| Metformin 850 mg BID | -24.8 |
The change between High-Density Lipoprotein Cholesterol collected at final visit or week 24 and High-Density Lipoprotein Cholesterol collected at baseline. (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | 14.20 |
| Pioglitazone 15 mg BID | 9.88 |
| Metformin 850 mg BID | 6.09 |
The change between Homeostasis Model Assessment of Insulin Resistance collected at final visit or week 24 and Homeostasis Model Assessment of Insulin Resistance collected at baseline. Homeostasis Model Assessment measures insulin resistance, calculated by insulin times glucose, divided by a constant (22.5). (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | percent of insulin resistance (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | -2.704 |
| Pioglitazone 15 mg BID | -2.075 |
| Metformin 850 mg BID | -1.085 |
The change between Intermediate-Density Low Density Lipoprotein collected at final visit or week 24 and Intermediate-Density Low Density Lipoprotein collected at baseline (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | nmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | -16.3 |
| Pioglitazone 15 mg BID | -11.0 |
| Metformin 850 mg BID | -17.3 |
The change between Intermediate-Medium High Density Lipoprotein collected at final visit or week 24 and Intermediate-Medium High Density Lipoprotein collected at baseline (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | μmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | 1.34 |
| Pioglitazone 15 mg BID | 1.62 |
| Metformin 850 mg BID | -0.09 |
The change between Large High Density Lipoprotein collected at final visit or week 24 and Large High Density Lipoprotein collected at baseline (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | μmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | 0.70 |
| Pioglitazone 15 mg BID | 1.02 |
| Metformin 850 mg BID | 0.52 |
The change between Large Low Density Lipoprotein collected at final visit or week 24 and Large Low Density Lipoprotein collected at baseline. (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | nmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | 96.0 |
| Pioglitazone 15 mg BID | 115.7 |
| Metformin 850 mg BID | 18.4 |
The change between Large-Chylomicrons Very Low Density Lipoprotein collected at final visit or week 24 and Large-Chylomicrons Very Low Density Lipoprotein collected at baseline (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | nmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | -1.71 |
| Pioglitazone 15 mg BID | -1.97 |
| Metformin 850 mg BID | -1.96 |
The change between Low-Density Lipoprotein Cholesterol collected at final visit or week 24 and Low-Density Lipoprotein Cholesterol collected at baseline. (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | 1.19 |
| Pioglitazone 15 mg BID | 6.08 |
| Metformin 850 mg BID | -1.37 |
The change between High Density Lipoprotein collected at final visit or week 24 and High Density Lipoprotein collected at baseline. (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | μmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | 0.28 |
| Pioglitazone 15 mg BID | -0.80 |
| Metformin 850 mg BID | 0.62 |
The change between High Density Lipoprotein collected at final visit or week 24 and High Density Lipoprotein collected at baseline. (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | nm (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | 0.15 |
| Pioglitazone 15 mg BID | 0.19 |
| Metformin 850 mg BID | 0.11 |
The change between Low Density Lipoprotein particle concentration collected at final visit or week 24 and Low Density Lipoprotein particle concentration collected at baseline. (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | nmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | -240.6 |
| Pioglitazone 15 mg BID | -217.2 |
| Metformin 850 mg BID | -176.4 |
The change between Low Density Lipoprotein collected at final visit or week 24 and Low Density Lipoprotein collected at baseline. (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | nm (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | 0.55 |
| Pioglitazone 15 mg BID | 0.6 |
| Metformin 850 mg BID | 0.2 |
The change between Very Low Density Lipoprotein collected at final visit or week 24 and Very Low Density Lipoprotein collected at baseline. (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | nmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | -2.78 |
| Pioglitazone 15 mg BID | 0.98 |
| Metformin 850 mg BID | -11.30 |
The change between Very Low Density Lipoprotein collected at final visit or week 24 and Very Low Density Lipoprotein collected at baseline. (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | nm (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | -2.64 |
| Pioglitazone 15 mg BID | -3.79 |
| Metformin 850 mg BID | -0.20 |
The change between Medium-Intermediate Very Low Density Lipoprotein collected at final visit or week 24 and Medium-Intermediate Very Low Density Lipoprotein collected at baseline (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | nmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | -4.07 |
| Pioglitazone 15 mg BID | -3.01 |
| Metformin 850 mg BID | -6.48 |
The change between Medium-Small Low Density Lipoprotein collected at final visit or week 24 and Medium-Small Low Density Lipoprotein collected at baseline (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | nmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | -63.8 |
| Pioglitazone 15 mg BID | -66.0 |
| Metformin 850 mg BID | -35.3 |
The change between Small High Density Lipoprotein collected at final visit or week 24 and Small High Density Lipoprotein collected at baseline (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | μmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | -1.78 |
| Pioglitazone 15 mg BID | -3.41 |
| Metformin 850 mg BID | 0.19 |
The change between Small Low Density Lipoprotein collected at final visit or week 24 and Small Low Density Lipoprotein collected at baseline (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | nmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | -319.3 |
| Pioglitazone 15 mg BID | -321.3 |
| Metformin 850 mg BID | -179.0 |
The change between Small Very Low Density Lipoprotein collected at final visit or week 24 and Small Very Low Density Lipoprotein collected at baseline (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | nmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | 3.05 |
| Pioglitazone 15 mg BID | 5.9 |
| Metformin 850 mg BID | -2.86 |
The change between Total Cholesterol collected at final visit or week 24 and Total Cholesterol collected at baseline. (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | 1.06 |
| Pioglitazone 15 mg BID | 4.79 |
| Metformin 850 mg BID | -2.72 |
The change between Triglycerides collected at final visit or week 24 and Triglycerides collected at baseline. (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | -5.95 |
| Pioglitazone 15 mg BID | -5.54 |
| Metformin 850 mg BID | -1.78 |
The change between Very Small Low Density Lipoprotein collected at final visit or week 24 and Very Small Low Density Lipoprotein collected at baseline (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | nmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | -255.5 |
| Pioglitazone 15 mg BID | -255.2 |
| Metformin 850 mg BID | -143.8 |
Measurement for High Sensitivity C-reactive Protein was collected at final visit or week 24 and at baseline. Percent change from baseline is calculated as: [(Week 24 - baseline levels)/baseline]*100 (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | percent (Median) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | -36.7 |
| Pioglitazone 15 mg BID | -34.0 |
| Metformin 850 mg BID | -26.2 |
The change between the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at final visit or week 24 and Glycosylated Hemoglobin collected at baseline. (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | percentage of Glycosylated Hemoglobin (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | -1.83 |
| Pioglitazone 15 mg BID | -0.96 |
| Metformin 850 mg BID | -0.99 |
(NCT00006305)
Timeframe: five years
| Intervention | participants (Number) |
|---|---|
| Revascularization and Insulin Providing (IP) | 80 |
| Revascularization and Insulin Sensitizing (IS) | 75 |
| Medical Therapy and Insulin Providing (IP) | 80 |
| Medical Therapy and Insulin Sensitizing (IS) | 81 |
(NCT00006305)
Timeframe: five years
| Intervention | participants (Number) |
|---|---|
| Revascularization and Insulin Providing (IP) | 145 |
| Revascularization and Insulin Sensitizing (IS) | 121 |
| Medical Therapy and Insulin Providing (IP) | 143 |
| Medical Therapy and Insulin Sensitizing (IS) | 140 |
(NCT01082588)
Timeframe: Baseline, week 12
| Intervention | mg/L (Mean) |
|---|---|
| Pravastatin | 0.8063 |
| Placebo | -0.5136 |
(NCT01082588)
Timeframe: Baseline, week 12
| Intervention | mg/dl (Mean) |
|---|---|
| Pravastatin | -25.565 |
| Placebo | -2.913 |
"The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery measures cognitive functioning within 7 domains: speed of processing, attention/vigilance, working memory (non verbal and verbal), verbal learning, visual learning, reasoning and problem solving and social cognition.~The composite score is calculated by the MATRICS computer program, which equally weights each of the 7 domain scores. The range of composite scores is 20-80. Higher scores indicate higher levels or cognitive functioning, while lower scores indicate lower levels of cognitive functioning." (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | 4.0417 |
| Placebo | 4.125 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 15-105. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -5.625 |
| Placebo | -3.76 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -0.83 |
| Placebo | -0.28 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -2.9583 |
| Placebo | -2.44 |
The Positive and Negative Syndrome Scale (PANSS) is a scale used to rate severity of schizophrenia. All items are summed to calculate the total score. The scale range is 30-210. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -9.416 |
| Placebo | -6.48 |
53 reviews available for metformin and Inflammation
| Article | Year |
|---|---|
Metformin as an anti-inflammatory agent: a short review.
Topics: Animals; Blood Glucose; Clinical Studies as Topic; Humans; Hypoglycemic Agents; Inflammation; Metfor | 2021 |
An update on mode of action of metformin in modulation of meta-inflammation and inflammaging.
Topics: AMP-Activated Protein Kinases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Inflammation; | 2022 |
Role of metformin in inflammation.
Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Diabetes Mellitus, Type 2; Inflamm | 2023 |
Metformin in SARS-CoV-2 infection: A hidden path - from altered inflammation to reduced mortality. A review from the literature.
Topics: COVID-19; Diabetes Mellitus, Type 2; Humans; Inflammation; Metformin; SARS-CoV-2 | 2023 |
Is metformin neuroprotective against diabetes mellitus-induced neurodegeneration? An updated graphical review of molecular basis.
Topics: Diabetes Mellitus; Humans; Inflammation; Metformin; Neuroprotection; Neuroprotective Agents | 2023 |
Novel Approaches to the Management of Diabetes Mellitus in Patients with Coronary Artery Disease.
Topics: Cardiovascular Diseases; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV | 2023 |
Metformin beyond an anti-diabetic agent: A comprehensive and mechanistic review on its effects against natural and chemical toxins.
Topics: Antioxidants; Apoptosis; Humans; Hypoglycemic Agents; Inflammation; Liver; Metformin; Oxidative Stre | 2023 |
Recent Insights Into Mechanisms of β-Cell Lipo- and Glucolipotoxicity in Type 2 Diabetes.
Topics: Animals; Autophagy; Diabetes Mellitus, Type 2; Endoplasmic Reticulum Stress; Fatty Acids, Nonesterif | 2020 |
Anabolic and anticatabolic agents used in burn care: What is known and what is yet to be learned.
Topics: Anabolic Agents; Burns; Clonidine; Growth Hormone-Releasing Hormone; Hormones; Human Growth Hormone; | 2020 |
Targeting immunometabolism as an anti-inflammatory strategy.
Topics: Anti-Inflammatory Agents; Autoimmune Diseases; Dimethyl Fumarate; Glycolysis; Humans; Immunomodulati | 2020 |
Metformin effect on gut microbiota: insights for HIV-related inflammation.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus; Disease Models, Animal; Dysbiosis; Gastrointes | 2020 |
The Bacterium
Topics: Akkermansia; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Dysbiosis; Gram-Negative Bacterial | 2020 |
Shedding Light on the Effects of Calorie Restriction and its Mimetics on Skin Biology.
Topics: Animals; Caloric Restriction; Dermatologic Agents; Fasting; Humans; Inflammation; Metformin; Peroxis | 2020 |
The impact of metformin and aspirin on T-cell mediated inflammation: A systematic review of in vitro and in vivo findings.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Diabetes Mellitu | 2020 |
Metformin and COVID-19: From cellular mechanisms to reduced mortality.
Topics: Aged; Comorbidity; COVID-19; Diabetes Mellitus, Type 2; Hospitalization; Humans; Hypoglycemic Agents | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era?
Topics: Anti-Inflammatory Agents; Comorbidity; COVID-19; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV | 2020 |
Immunomodulatory and Antiviral Activity of Metformin and Its Potential Implications in Treating Coronavirus Disease 2019 and Lung Injury.
Topics: Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatmen | 2020 |
Osteoarthritis year in review 2020: biology.
Topics: Autophagy; Cartilage, Articular; Gastrointestinal Microbiome; Humans; Hypoglycemic Agents; Inflammat | 2021 |
A Molecular Perspective on the Potential Benefits of Metformin for the Treatment of Inflammatory Skin Disorders.
Topics: Acanthosis Nigricans; Acne Vulgaris; Dermatitis, Allergic Contact; Hidradenitis Suppurativa; Humans; | 2020 |
Effect of Metformin on Circulating Levels of Inflammatory Markers in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Humans; Inflammation; Metformin; Randomized Controlled Trials | 2021 |
The intersection of metformin and inflammation.
Topics: Animals; Anti-Inflammatory Agents; Autophagy-Related Proteins; Humans; Inflammation; Inflammation Me | 2021 |
The Role of Mitochondria in Immune-Cell-Mediated Tissue Regeneration and Ageing.
Topics: Adaptive Immunity; Aging; Animals; Antigen-Presenting Cells; B-Lymphocyte Subsets; Cytokines; DNA; D | 2021 |
Metformin, A New Era for an Old Drug in the Treatment of Immune Mediated Disease?
Topics: Animals; Cell Differentiation; Humans; Hypoglycemic Agents; Immune System Diseases; Immunologic Fact | 2018 |
Geroprotectors as a therapeutic strategy for COPD - where are we now?
Topics: Aging; Disease Progression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Me | 2017 |
Repositioning of diabetes treatments for depressive symptoms: A systematic review and meta-analysis of clinical trials.
Topics: Adult; Antidepressive Agents; Blood Glucose; Clinical Trials as Topic; Depression; Diabetes Mellitus | 2018 |
Metformin one in a Million Efficient Medicines for Rheumatoid Arthritis Complications: Inflammation, Osteoblastogenesis, Cardiovascular Disease, Malignancies.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Bone and Bones; Bone Diseases; Cardiovascular | 2019 |
Protective effects of metformin, statins and anti-inflammatory drugs on head and neck cancer: A systematic review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Case-Control Studies; Cohort Studi | 2018 |
Energy restriction in renal protection.
Topics: Aging; Animals; Autophagy; Caloric Restriction; Diet; Energy Metabolism; Female; Humans; Inflammatio | 2018 |
The effect of metformin on biomarkers and survivals for breast cancer- a systematic review and meta-analysis of randomized clinical trials.
Topics: Biomarkers; Blood Glucose; Breast Neoplasms; Female; Gonadal Steroid Hormones; Humans; Hypoglycemic | 2019 |
[Advances on the anti-inflammatory and protective effect of AMPK activators].
Topics: Adiponectin; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Biphenyl Compounds; | 2019 |
Epithelial mesenchymal transition and resistance in endocrine-related cancers.
Topics: Benzopyrans; Breast Neoplasms; Cadherins; Cell Plasticity; Cytokines; Disease Progression; Epidermal | 2019 |
Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment.
Topics: AMP-Activated Protein Kinases; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Repositioning; | 2014 |
STOP accelerating lung aging for the treatment of COPD.
Topics: Aging; Disease Progression; Humans; Inflammation; Lung; Metformin; Oxidative Stress; Pulmonary Disea | 2014 |
Effect of metformin on serum interleukin-6 levels in polycystic ovary syndrome: a systematic review.
Topics: Female; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Interleukin-6; Metformin; Pol | 2014 |
Effect of metformin on serum interleukin-6 levels in polycystic ovary syndrome: a systematic review.
Topics: Female; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Interleukin-6; Metformin; Pol | 2014 |
Effect of metformin on serum interleukin-6 levels in polycystic ovary syndrome: a systematic review.
Topics: Female; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Interleukin-6; Metformin; Pol | 2014 |
Effect of metformin on serum interleukin-6 levels in polycystic ovary syndrome: a systematic review.
Topics: Female; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Interleukin-6; Metformin; Pol | 2014 |
Obesity and polycystic ovary syndrome.
Topics: Adipokines; Bariatric Surgery; Combined Modality Therapy; Comorbidity; Diet, Reducing; Exercise Ther | 2015 |
Placental dysfunction in obese women and antenatal surveillance strategies.
Topics: Diabetes, Gestational; Female; Fetal Development; Humans; Hypoglycemic Agents; Inflammation; Metform | 2015 |
Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect.
Topics: Animals; Anti-Inflammatory Agents; Diabetes Mellitus, Type 2; Glucose; Humans; Hyperglycemia; Hypogl | 2015 |
Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Chemoprevention; Diabetes Mellitus, Type 2; Endoplasmic Reticulum Stress; | 2015 |
Chemoprevention in Barrett's Esophagus: Current Status.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Barrett Esophagus; Bile Acids and Salts; Cy | 2015 |
Obesity and Cancer: An Angiogenic and Inflammatory Link.
Topics: Animals; Drug Resistance, Neoplasm; Humans; Inflammation; Metformin; Neoplasms; Neovascularization, | 2016 |
Hepatic manifestations of women with polycystic ovary syndrome.
Topics: Alanine Transaminase; Androgen Antagonists; Aspartate Aminotransferases; Contraceptives, Oral, Hormo | 2016 |
[Adipose tissue inflammation and atherosclerosis].
Topics: Adipokines; Adipose Tissue; Atherosclerosis; Chemotaxis; Cytokines; Endothelium, Vascular; Humans; H | 2009 |
Targeting type 2 diabetes.
Topics: Adipose Tissue; Caloric Restriction; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; | 2011 |
AMP-activated protein kinase: a potential player in Alzheimer's disease.
Topics: Alzheimer Disease; AMP-Activated Protein Kinases; Amyloid; Animals; Autophagy; Calcium; Enzyme Activ | 2011 |
Caloric restriction and chronic inflammatory diseases.
Topics: Adaptive Immunity; Animals; Biomimetics; Caloric Restriction; Cardiovascular Diseases; Chronic Disea | 2012 |
[AMPK: a novel target controlling inflammation].
Topics: AMP-Activated Protein Kinases; Homeostasis; Inflammation; Metformin; NF-kappa B; Phosphorylation | 2012 |
Cancer prevention by targeting angiogenesis.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; | 2012 |
Metformin: the hidden chronicles of a magic drug.
Topics: Animals; Female; Humans; Hypoglycemic Agents; Inflammation; Male; Metabolic Syndrome; Metformin; Neo | 2013 |
Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes.
Topics: Abdomen; Adipose Tissue; Arteriosclerosis; Blood Glucose; Body Constitution; Cardiovascular Diseases | 2003 |
Endothelial dysfunction, inflammation and diabetes.
Topics: Acarbose; Animals; Cardiovascular Agents; Diabetes Mellitus; Diabetic Angiopathies; Endothelium, Vas | 2004 |
Insulin resistance in polycystic ovarian disease.
Topics: Cardiovascular Diseases; Female; Follicle Stimulating Hormone; Humans; Hypoglycemic Agents; Inflamma | 2005 |
The position of long-term stimulation of the endogenous fibrinolytic system: present achievements and clinical perspectives.
Topics: Adrenocorticotropic Hormone; Anabolic Agents; Androgens; Clofibrate; Coronary Disease; Deamino Argin | 1975 |
44 trials available for metformin and Inflammation
| Article | Year |
|---|---|
Randomized Trial of Metformin With Anti-Tuberculosis Drugs for Early Sputum Conversion in Adults With Pulmonary Tuberculosis.
Topics: Adult; Antitubercular Agents; Female; Humans; Inflammation; Male; Metformin; Mycobacterium tuberculo | 2022 |
Effect of metformin as an add-on therapy on neuregulin-4 levels and vascular-related complications in adolescents with type 1 diabetes: A randomized controlled trial.
Topics: Adolescent; Atherosclerosis; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Carotid Int | 2022 |
Effect of aerobic exercise on inflammatory markers in polycystic ovary syndrome: a randomized controlled trial.
Topics: Biomarkers; C-Reactive Protein; Exercise; Female; Humans; Inflammation; Interleukin-6; Metformin; Po | 2022 |
Metformin versus insulin for gestational diabetes: Adiposity variables and adipocytokines in offspring at age of 9 years.
Topics: Adipokines; Adiponectin; Adiposity; Child; Diabetes, Gestational; Female; Humans; Inflammation; Insu | 2023 |
Disuse-induced muscle fibrosis, cellular senescence, and senescence-associated secretory phenotype in older adults are alleviated during re-ambulation with metformin pre-treatment.
Topics: Cellular Senescence; Collagen; Female; Fibrosis; Humans; Inflammation; Male; Metformin; Muscle, Skel | 2023 |
Effects of acarbose and metformin on the inflammatory state in newly diagnosed type 2 diabetes patients: a one-year randomized clinical study.
Topics: Acarbose; Adult; Aged; Biomarkers; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Humans | 2019 |
Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial.
Topics: Adult; Aged; Autoimmune Diseases; Double-Blind Method; Female; Glucocorticoids; Humans; Hypoglycemic | 2020 |
Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans.
Topics: Aged; Animals; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diet, Atherogenic; Di | 2020 |
Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial.
Topics: Biomarkers; Breast Neoplasms; C-Reactive Protein; Colorectal Neoplasms; Combined Modality Therapy; E | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease.
Topics: Adiponectin; Atherosclerosis; Biomarkers; Blood Glucose; Coronary Artery Disease; Diabetes Mellitus, | 2020 |
Effects of Metformin-Single Therapy on the Level of Inflammatory Markers in Serum of Non-Obese T2DM Patients with NAFLD.
Topics: Adult; Biomarkers; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Human | 2022 |
Nigella sativa as a promising intervention for metabolic and inflammatory disorders in obese prediabetic subjects: A comparative study of Nigella sativa versus both lifestyle modification and metformin.
Topics: Blood Glucose; Humans; Inflammation; Life Style; Metformin; Nigella sativa; Obesity; Plant Preparati | 2021 |
Metformin for Obesity in Prepubertal and Pubertal Children: A Randomized Controlled Trial.
Topics: Adolescent; Biomarkers; Body Mass Index; Cardiovascular Diseases; Child; Double-Blind Method; Female | 2017 |
Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes.
Topics: Adiponectin; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Canagliflozin; Diabetes Mellitus, | 2018 |
The antidiabetic drug metformin blunts NETosis in vitro and reduces circulating NETosis biomarkers in vivo.
Topics: Adult; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Com | 2018 |
Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
Topics: Aged; Arginine; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; C-Peptide; Chimerin Protein | 2013 |
Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment.
Topics: Adult; Biomarkers; Chemokines; Cytokines; Drug Therapy, Combination; Female; Glucose Clamp Technique | 2013 |
Metformin ameliorates the proinflammatory state in patients with carotid artery atherosclerosis through sirtuin 1 induction.
Topics: Aged; Arteriosclerosis; Carotid Artery Diseases; Female; Humans; Inflammation; Male; Metformin; Midd | 2015 |
Endocannabinoid receptor blockade increases vascular endothelial growth factor and inflammatory markers in obese women with polycystic ovary syndrome.
Topics: Biomarkers; Cannabinoid Receptor Antagonists; Cytokines; Female; Humans; Hyperandrogenism; Inflammat | 2017 |
A randomized, controlled trial of the effects of rosiglitazone on adipokines, and inflammatory and fibrinolytic markers in diabetic patients: study design and protocol.
Topics: Adipokines; Adult; Aged; Aged, 80 and over; Biomarkers; Blood Glucose; C-Reactive Protein; Cytokines | 2008 |
Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Pressure; Carboxypeptidase B2; CD40 Ligand; Cholesterol | 2009 |
Effects of bed-time insulin versus pioglitazone on abdominal fat accumulation, inflammation and gene expression in adipose tissue in patients with type 2 diabetes.
Topics: Adipose Tissue; Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, Differentiation, | 2009 |
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Topics: Adiponectin; Blood Glucose; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Diet; Double | 2010 |
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Topics: Adiponectin; Blood Glucose; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Diet; Double | 2010 |
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Topics: Adiponectin; Blood Glucose; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Diet; Double | 2010 |
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Topics: Adiponectin; Blood Glucose; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Diet; Double | 2010 |
Combined effects of atorvastatin and metformin on glucose-induced variations of inflammatory process in patients with diabetes mellitus.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Drug | 2011 |
Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.
Topics: Acarbose; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Fem | 2010 |
Effects of pioglitazone and metformin fixed-dose combination therapy on cardiovascular risk markers of inflammation and lipid profile compared with pioglitazone and metformin monotherapy in patients with type 2 diabetes.
Topics: Adiponectin; Adult; Aged; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus | 2010 |
Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients.
Topics: Adult; C-Reactive Protein; Calcium; Diabetes Mellitus, Type 2; Female; Glycation End Products, Advan | 2011 |
The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study.
Topics: Aged; Biomarkers; Blood Coagulation; Blood Platelets; Body Mass Index; Diabetes Mellitus, Type 2; Fe | 2011 |
Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients.
Topics: Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Exenatide; Femal | 2011 |
Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
Topics: Adult; Biomarkers; C-Reactive Protein; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Co | 2011 |
Interleukin-6 as an early chronic inflammatory marker in polycystic ovary syndrome with insulin receptor substrate-2 polymorphism.
Topics: Adolescent; Adult; Case-Control Studies; Female; Homozygote; Humans; Hypoglycemic Agents; Inflammati | 2011 |
Metformin decreases plasma resistin concentrations in pediatric patients with impaired glucose tolerance: a placebo-controlled randomized clinical trial.
Topics: Adiponectin; Adolescent; Biomarkers; C-Reactive Protein; Child; Child, Preschool; Drug Administratio | 2012 |
Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease.
Topics: Adamantane; Adiponectin; Atherosclerosis; Biomarkers; C-Reactive Protein; Diabetes Mellitus, Type 2; | 2012 |
Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fema | 2012 |
Chemerin and apelin are positively correlated with inflammation in obese type 2 diabetic patients.
Topics: Apelin; Blood Glucose; Body Mass Index; Chemokines; Diabetes Mellitus, Type 2; Dinoprost; Humans; Hy | 2012 |
Effect of pioglitazone versus metformin on cardiovascular risk markers in type 2 diabetes.
Topics: Aged; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cell Adhesion Molecules; Diabetes Mel | 2013 |
Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance.
Topics: Blood Coagulation; Blood Glucose; Body Mass Index; Diabetes Mellitus; Female; Glucose Intolerance; H | 2005 |
Inflammatory markers and the metabolic syndrome.
Topics: Antihypertensive Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Drug | 2005 |
Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin.
Topics: Adult; C-Reactive Protein; Case-Control Studies; Cell Adhesion Molecules; E-Selectin; Female; Humans | 2006 |
A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes.
Topics: Aged; Atherosclerosis; C-Reactive Protein; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease | 2007 |
Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome.
Topics: Adolescent; Adult; Aged; Apolipoproteins B; Biomarkers; Blood Glucose; Body Mass Index; C-Reactive P | 2007 |
Both slow-release and regular-form metformin improve glycemic control without altering plasma visfatin level in patients with type 2 diabetes mellitus.
Topics: Adiponectin; Adult; Aged; Blood Glucose; C-Reactive Protein; Chemistry, Pharmaceutical; Cholesterol; | 2007 |
Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Arginine; Biomarkers; Blood Glucose; Blood Pressure; Brachial Artery; C-Reactive Protei | 2007 |
228 other studies available for metformin and Inflammation
| Article | Year |
|---|---|
Metformin ameliorates maternal high-fat diet-induced maternal dysbiosis and fetal liver apoptosis.
Topics: Administration, Oral; Animals; Apoptosis; Diet, High-Fat; Disease Models, Animal; Drinking Water; Dy | 2021 |
Metformin Attenuates Postinfarction Myocardial Fibrosis and Inflammation in Mice.
Topics: Animals; Fibrosis; Hypoglycemic Agents; Inflammation; Male; Metformin; Mice; Mice, Inbred C57BL; Myo | 2021 |
Metformin selectively dampens the acute inflammatory response through an AMPK-dependent mechanism.
Topics: Adenylate Kinase; Humans; Hypoglycemic Agents; Hypoxia-Inducible Factor 1, alpha Subunit; Inflammati | 2021 |
L-ergothioneine and metformin alleviates liver injury in experimental type-2 diabetic rats via reduction of oxidative stress, inflammation, and hypertriglyceridemia.
Topics: Administration, Oral; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Drug Therapy, Combina | 2021 |
Metformin Protects Against Inflammation, Oxidative Stress to Delay Poly I:C-Induced Aging-Like Phenomena in the Gut of an Annual Fish.
Topics: Aging; AMP-Activated Protein Kinases; Animals; Cytokines; Diabetes Mellitus, Type 2; Female; Inflamm | 2022 |
Metformin alleviates inflammation through suppressing FASN-dependent palmitoylation of Akt.
Topics: 4-Butyrolactone; Animals; Cell Membrane; Colitis; Dextran Sulfate; Down-Regulation; Enzyme Activatio | 2021 |
Ameliorative effect of curcumin and zinc oxide nanoparticles on multiple mechanisms in obese rats with induced type 2 diabetes.
Topics: Animals; Antioxidants; Blood Glucose; Curcumin; Diabetes Mellitus, Experimental; Diabetes Mellitus, | 2021 |
Topics: Acanthaceae; Animals; Atherosclerosis; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; D | 2021 |
Metformin inhibits tumor growth and affects intestinal flora in diabetic tumor-bearing mice.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Correlation of Data; Diabetes Mellitus, Experiment | 2021 |
P53 mediates the protective effects of metformin in inflamed lung endothelial cells.
Topics: Animals; Cardiac Myosins; Cattle; Endothelial Cells; Gene Expression Regulation; Hypoglycemic Agents | 2021 |
Metformin attenuates LPS-induced neuronal injury and cognitive impairments by blocking NF-κB pathway.
Topics: Animals; Cognition; Cognitive Dysfunction; Hippocampus; Inflammation; Lipopolysaccharides; Male; Met | 2021 |
Metformin effect in models of inflammation is associated with activation of ATP-dependent potassium channels and inhibition of tumor necrosis factor-α production.
Topics: Adenosine Triphosphate; Animals; Carrageenan; Diabetes Mellitus, Type 2; Disease Models, Animal; Ede | 2022 |
Impaired metabolic effects of metformin in men with early-onset androgenic alopecia.
Topics: Alopecia; Biological Availability; Blood Glucose; Diabetes Mellitus, Type 2; Drug Monitoring; Humans | 2022 |
Metformin regulates macrophage polarization via the Shh signaling pathway to improve pulmonary vascular development in bronchopulmonary dysplasia.
Topics: Animals; Bronchopulmonary Dysplasia; Cell Polarity; Hedgehog Proteins; Hyperoxia; Inflammation; Lung | 2022 |
Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome.
Topics: Adult; Benzhydryl Compounds; Body Weight; C-Reactive Protein; Cholesterol, HDL; Diabetes Mellitus, T | 2021 |
Metformin prevents methylglyoxal-induced apoptosis by suppressing oxidative stress in vitro and in vivo.
Topics: Animals; Apoptosis; Heme Oxygenase-1; Human Umbilical Vein Endothelial Cells; Humans; Inflammation; | 2022 |
Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes.
Topics: COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus; Hospitalization; Humans; Hypoglycemic Agents; | 2022 |
Glutathione-modified macrophage-derived cell membranes encapsulated metformin nanogels for the treatment of spinal cord injury.
Topics: Animals; Cell Membrane; Glutathione; Inflammation; Macrophages; Metformin; Nanogels; Rats; Rats, Spr | 2022 |
Metformin prevents endothelial oxidative stress and microvascular insulin resistance during obesity development in male rats.
Topics: Animals; Glucose; Inflammation; Insulin; Insulin Resistance; Male; Metformin; Muscle, Skeletal; Obes | 2022 |
Metformin attenuated sepsis-associated liver injury and inflammatory response in aged mice.
Topics: Aging; Animals; Inflammation; Lipopolysaccharides; Liver; Liver Diseases; Male; Metformin; Mice; Mic | 2022 |
Urolithin A Attenuates Diabetes-Associated Cognitive Impairment by Ameliorating Intestinal Barrier Dysfunction via N-glycan Biosynthesis Pathway.
Topics: Animals; Cognitive Dysfunction; Coumarins; Diabetes Mellitus, Type 2; Diet, High-Fat; Inflammation; | 2022 |
A pH-responsive hyaluronic acid hydrogel for regulating the inflammation and remodeling of the ECM in diabetic wounds.
Topics: Animals; Diabetes Mellitus, Experimental; Hyaluronic Acid; Hydrogels; Hydrogen-Ion Concentration; In | 2022 |
Metformin improves renal injury of MRL/lpr lupus-prone mice via the AMPK/STAT3 pathway.
Topics: AMP-Activated Protein Kinases; Animals; Humans; Inflammation; Kidney; Lipopolysaccharides; Lupus Ery | 2022 |
Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; | 2022 |
Effects of metformin, letrozole and atorvastatin on inflammation and apoptosis in experimental peritoneal and ovarian endometriosis in the rat.
Topics: Animals; Apoptosis; Atorvastatin; bcl-2-Associated X Protein; Endometriosis; Female; Humans; Inflamm | 2022 |
PDIA4, a novel ER stress chaperone, modulates adiponectin expression and inflammation in adipose tissue.
Topics: Adiponectin; Adipose Tissue; Animals; Cytokines; Endoplasmic Reticulum Stress; Glucose; Humans; Infl | 2022 |
Dose-dependent immunomodulatory effects of metformin on human neonatal monocyte-derived macrophages.
Topics: Animals; Anti-Inflammatory Agents; Humans; Inflammation; Macrophages; Metformin; Monocytes; Rats | 2022 |
Combining the HSP90 inhibitor TAS-116 with metformin effectively degrades the NLRP3 and attenuates inflammasome activation in rats: A new management paradigm for ulcerative colitis.
Topics: Animals; Benzamides; Colitis, Ulcerative; Dextran Sulfate; Inflammasomes; Inflammation; Metformin; M | 2022 |
Thyroid Antibody Titers and Hypothalamic-Pituitary-Thyroid Axis Activity in Levothyroxine-Treated Women With Autoimmune Subclinical Hypothyroidism Receiving Atorvastatin or Metformin.
Topics: Atorvastatin; C-Reactive Protein; Female; Hashimoto Disease; Humans; Hydroxymethylglutaryl-CoA Reduc | 2022 |
Rapamycin/metformin co-treatment normalizes insulin sensitivity and reduces complications of metabolic syndrome in type 2 diabetic mice.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fatty Liver; Hyperglycemia; Hyp | 2022 |
Gentiopicroside alleviates cardiac inflammation and fibrosis in T2DM rats through targeting Smad3 phosphorylation.
Topics: Animals; Anti-Inflammatory Agents; Blood Glucose; Diabetes Mellitus, Type 2; Fibrosis; Heart Failure | 2022 |
Maternal Treatment with Metformin Persistently Ameliorates High-Fat Diet-Induced Metabolic Symptoms and Modulates Gut Microbiota in Rat Offspring.
Topics: Animals; Diet, High-Fat; Female; Gastrointestinal Microbiome; Humans; Inflammation; Male; Maternal N | 2022 |
Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Benzhydryl Compounds; Biomarkers; Cholesterol; Chol | 2022 |
Sex-specific effects of maternal metformin intervention during glucose-intolerant obese pregnancy on body composition and metabolic health in aged mouse offspring.
Topics: Adult; Animals; Body Composition; Child; Diabetes Mellitus, Type 2; Diabetes, Gestational; Diet, Hig | 2022 |
Anti-Inflammatory Properties of Metformin During Cultivation of Primary Rat Astrocytes in a Medium with High Glucose Concentration.
Topics: Animals; Anti-Inflammatory Agents; Astrocytes; Cells, Cultured; Chromatography, Liquid; Cyclooxygena | 2022 |
Early effects of LPS-induced neuroinflammation on the rat hippocampal glycolytic pathway.
Topics: Animals; Cytokines; Glucose; Glutamates; Hippocampus; Inflammasomes; Inflammation; Lactates; Lipopol | 2022 |
Tert-butylhydroquinone abrogates fructose-induced insulin resistance in rats via mitigation of oxidant stress, NFkB-mediated inflammation in the liver but not the skeletal muscle of high fructose drinking rats.
Topics: Animals; Fructose; Inflammation; Insulin Resistance; Liver; Male; Metabolic Syndrome; Metformin; Mus | 2022 |
Metformin improves tendon degeneration by blocking translocation of HMGB1 and suppressing tendon inflammation and senescence in aging mice.
Topics: Aging; Animals; Cellular Senescence; HMGB1 Protein; Inflammation; Metformin; Mice; Tendons | 2023 |
Metformin ameliorates 5-fluorouracil-induced intestinalinjury by inhibiting cellular senescence, inflammation, and oxidative stress.
Topics: Animals; Cellular Senescence; Fluorouracil; Inflammation; Male; Metformin; Mice; Mice, Inbred BALB C | 2022 |
Chlorogenic acid improves glucose tolerance, lipid metabolism, inflammation and microbiota composition in diabetic db/db mice.
Topics: Animals; Chlorogenic Acid; Diabetes Mellitus; Glucose; Inflammation; Insulin Resistance; Lipid Metab | 2022 |
Chlorogenic acid improves glucose tolerance, lipid metabolism, inflammation and microbiota composition in diabetic db/db mice.
Topics: Animals; Chlorogenic Acid; Diabetes Mellitus; Glucose; Inflammation; Insulin Resistance; Lipid Metab | 2022 |
Chlorogenic acid improves glucose tolerance, lipid metabolism, inflammation and microbiota composition in diabetic db/db mice.
Topics: Animals; Chlorogenic Acid; Diabetes Mellitus; Glucose; Inflammation; Insulin Resistance; Lipid Metab | 2022 |
Chlorogenic acid improves glucose tolerance, lipid metabolism, inflammation and microbiota composition in diabetic db/db mice.
Topics: Animals; Chlorogenic Acid; Diabetes Mellitus; Glucose; Inflammation; Insulin Resistance; Lipid Metab | 2022 |
Melatonin and metformin ameliorated trastuzumab-induced cardiotoxicity through the modulation of mitochondrial function and dynamics without reducing its anticancer efficacy.
Topics: Animals; Cardiotoxicity; Inflammation; Male; Melatonin; Metformin; Mitochondria; Rats; Rats, Wistar; | 2023 |
Melatonin and metformin ameliorated trastuzumab-induced cardiotoxicity through the modulation of mitochondrial function and dynamics without reducing its anticancer efficacy.
Topics: Animals; Cardiotoxicity; Inflammation; Male; Melatonin; Metformin; Mitochondria; Rats; Rats, Wistar; | 2023 |
Melatonin and metformin ameliorated trastuzumab-induced cardiotoxicity through the modulation of mitochondrial function and dynamics without reducing its anticancer efficacy.
Topics: Animals; Cardiotoxicity; Inflammation; Male; Melatonin; Metformin; Mitochondria; Rats; Rats, Wistar; | 2023 |
Melatonin and metformin ameliorated trastuzumab-induced cardiotoxicity through the modulation of mitochondrial function and dynamics without reducing its anticancer efficacy.
Topics: Animals; Cardiotoxicity; Inflammation; Male; Melatonin; Metformin; Mitochondria; Rats; Rats, Wistar; | 2023 |
Metformin Attenuates Inflammation and Fibrosis in Thyroid-Associated Ophthalmopathy.
Topics: AMP-Activated Protein Kinases; Fibrosis; Graves Ophthalmopathy; Humans; Inflammation; Metformin | 2022 |
PDIA4, a new endoplasmic reticulum stress protein, modulates insulin resistance and inflammation in skeletal muscle.
Topics: Animals; Cytokines; Endoplasmic Reticulum Stress; Humans; Inflammation; Insulin Resistance; Metformi | 2022 |
Metformin-chlorogenic acid combination reduces skeletal muscle inflammation in c57BL/6 mice on high-fat diets.
Topics: Adipose Tissue; Animals; Chlorogenic Acid; Diet, High-Fat; Inflammation; Insulin Resistance; Metform | 2023 |
Effect of metformin on sepsis-associated acute lung injury and gut microbiota in aged rats with sepsis.
Topics: Acute Lung Injury; Animals; Escherichia coli; Gastrointestinal Microbiome; Inflammation; Interleukin | 2023 |
Metformin Suppresses Thioacetamide-Induced Chronic Kidney Disease in Association with the Upregulation of AMPK and Downregulation of Oxidative Stress and Inflammation as Well as Dyslipidemia and Hypertension.
Topics: AMP-Activated Protein Kinases; Animals; Down-Regulation; Dyslipidemias; Fibrosis; Hypertension; Infl | 2023 |
The combination of metformin with morin alleviates hepatic steatosis via modulating hepatic lipid metabolism, hepatic inflammation, brown adipose tissue thermogenesis, and white adipose tissue browning in high-fat diet-fed mice.
Topics: Adipose Tissue, Brown; Adipose Tissue, White; Animals; Diet, High-Fat; Inflammation; Lipid Metabolis | 2023 |
Combination therapy of metformin and p-coumaric acid mitigates metabolic dysfunction associated with obesity and nonalcoholic fatty liver disease in high-fat diet obese C57BL/6 mice.
Topics: Animals; Diet, High-Fat; Inflammation; Liver; Metformin; Mice; Mice, Inbred C57BL; Non-alcoholic Fat | 2023 |
A druggable copper-signalling pathway that drives inflammation.
Topics: Animals; Cell Plasticity; Copper; Epigenesis, Genetic; Hydrogen Peroxide; Inflammation; Macrophage A | 2023 |
Metformin Treatment of Hidradenitis Suppurativa: Effect on Metabolic Parameters, Inflammation, Cardiovascular Risk Biomarkers, and Immune Mediators.
Topics: Adipokines; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Case-Control Studies; Heart Dis | 2023 |
The F/B ratio as a biomarker for inflammation in COVID-19 and T2D: Impact of metformin.
Topics: Bacteroidetes; Biomarkers; C-Reactive Protein; COVID-19; Diabetes Mellitus, Type 2; Firmicutes; Huma | 2023 |
Metformin Counteracts the Deleterious Effects of Methylglyoxal on Ovalbumin-Induced Airway Eosinophilic Inflammation and Remodeling.
Topics: Airway Remodeling; Animals; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Inflammation; Lung | 2023 |
Molecular insights of anti-diabetic compounds and its hyaluronic acid conjugates against aldose reductase enzyme through molecular modeling and simulations study-a novel treatment option for inflammatory diabetes.
Topics: Aldehyde Reductase; Diabetes Mellitus, Type 2; Humans; Hyaluronic Acid; Inflammation; Insulin Resist | 2023 |
Gallic acid and metformin co-administration reduce oxidative stress, apoptosis and inflammation via Fas/caspase-3 and NF-κB signaling pathways in thioacetamide-induced acute hepatic encephalopathy in rats.
Topics: Animals; Apoptosis; Caspase 3; Gallic Acid; Hepatic Encephalopathy; Inflammation; Metformin; NF-kapp | 2023 |
Hyaluronic acid-graphene oxide quantum dots nanoconjugate as dual purpose drug delivery and therapeutic agent in meta-inflammation.
Topics: Animals; Antioxidants; Cytokines; Diabetes Mellitus, Type 2; Hyaluronic Acid; Inflammation; Metformi | 2023 |
Dapagliflozin and metformin in combination ameliorates diabetic nephropathy by suppressing oxidative stress, inflammation, and apoptosis and activating autophagy in diabetic rats.
Topics: Animals; Apoptosis; Autophagy; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic | 2024 |
Metformin potentiates immunosuppressant activity and adipogenic differentiation of human umbilical cord-mesenchymal stem cells.
Topics: Cell Differentiation; Cells, Cultured; Culture Media, Conditioned; Humans; Immunosuppressive Agents; | 2023 |
Protective role of metformin in preeclampsia via the regulation of NF-κB/sFlt-1 and Nrf2/HO-1 signaling pathways by activating AMPK.
Topics: AMP-Activated Protein Kinases; Female; Humans; Inflammation; Lipopolysaccharides; Metformin; NF-E2-R | 2023 |
The Effects of Probiotic
Topics: Animals; Antioxidants; Bacillus; Cholesterol; Dexamethasone; Inflammation; Metformin; Probiotics; Ra | 2023 |
Enhanced fatty acid oxidation through metformin and baicalin as therapy for COVID-19 and associated inflammatory states in lung and kidney.
Topics: AMP-Activated Protein Kinases; Animals; COVID-19; Fatty Acids; Fibrosis; Humans; Inflammation; Kidne | 2023 |
Inflammatory macrophages reprogram to immunosuppression by reducing mitochondrial translation.
Topics: Animals; Humans; Immunosuppression Therapy; Inflammation; Macrophages; Metformin; Mice; Myeloid Cell | 2023 |
Amelioration of perivascular adipose inflammation reverses vascular dysfunction in a model of nonobese prediabetic metabolic challenge: potential role of antidiabetic drugs.
Topics: Adipose Tissue; Animals; Disease Models, Animal; Feeding Behavior; Hypoglycemic Agents; Inflammation | 2019 |
Sitagliptin favorably modulates immune-relevant pathways in human beta cells.
Topics: Cell Line; Diabetes Mellitus, Type 2; Gene Expression; Glucagon-Like Peptide 1; Glycated Hemoglobin; | 2019 |
Possible involvement of metformin in downregulation of neuroinflammation and associated behavioural changes in mice.
Topics: Animals; Antioxidants; Brain; Cytokines; Disease Models, Animal; Down-Regulation; Glutathione; Infla | 2019 |
Amelioration of metabolic syndrome by metformin associates with reduced indices of low-grade inflammation independently of the gut microbiota.
Topics: Ampicillin; Animals; Anti-Bacterial Agents; Diet, High-Fat; Fatty Liver; Gastrointestinal Microbiome | 2019 |
Cardioprotective role of metformin against sodium arsenite-induced oxidative stress, inflammation, and apoptosis.
Topics: Animals; Antioxidants; Apoptosis; Arsenites; Biomarkers; Cardiotonic Agents; Enzymes; Heart; Inflamm | 2020 |
Metformin decreases LPS-induced inflammatory response in rabbit annulus fibrosus stem/progenitor cells by blocking HMGB1 release.
Topics: Animals; Annulus Fibrosus; Anti-Inflammatory Agents; Cellular Senescence; HMGB1 Protein; Inflammatio | 2019 |
Combined effects of metformin and photobiomodulation improve the proliferation phase of wound healing in type 2 diabetic rats.
Topics: Animals; Blood Glucose; Cell Proliferation; Combined Modality Therapy; Diabetes Mellitus, Experiment | 2020 |
Metformin Reduces Lipotoxicity-Induced Meta-Inflammation in
Topics: Adenylate Kinase; Animals; Cells, Cultured; Diet, High-Fat; Inflammation; Inositol 1,4,5-Trisphospha | 2019 |
Effects of metformin on lipopolysaccharide-induced depressive-like behavior in mice and its mechanisms.
Topics: Animals; Behavior, Animal; Depression; Inflammation; Lipopolysaccharides; Male; Metformin; Mice; Mic | 2020 |
Metformin: the white knight fighting corticosteroid side-effects.
Topics: Adrenal Cortex Hormones; Double-Blind Method; Glucocorticoids; Humans; Inflammation; Metformin | 2020 |
Metformin Reduces Aging-Related Leaky Gut and Improves Cognitive Function by Beneficially Modulating Gut Microbiome/Goblet Cell/Mucin Axis.
Topics: Aging; Animals; Cognition; Diet, High-Fat; Disease Models, Animal; Dysbiosis; Gastrointestinal Micro | 2020 |
Protective effect of metformin against rotenone-induced parkinsonism in mice.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dopaminergic Neurons; Endoplasmic Reticulum Chape | 2020 |
Starvation and antimetabolic therapy promote cytokine release and recruitment of immune cells.
Topics: Activating Transcription Factor 4; Antimetabolites; Cell Death; Deoxyglucose; Epithelial Cells; Gene | 2020 |
Exenatide ameliorates experimental non-alcoholic fatty liver in rats via suppression of toll-like receptor 4/NFκB signaling: Comparison to metformin.
Topics: Animals; Body Weight; Diet, High-Fat; Disease Progression; Dose-Response Relationship, Drug; Exenati | 2020 |
Effects of Metformin on Life Span, Cognitive Ability, and Inflammatory Response in a Short-Lived Fish.
Topics: Animals; beta-Galactosidase; Biomarkers; Cognition; Cyprinodontiformes; Cytokines; Diet; Inflammatio | 2020 |
NLRP3 inflammasome drives inflammation in high fructose fed diabetic rat liver: Effect of resveratrol and metformin.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fructose; Hypoglycemic Agents; | 2020 |
CD4
Topics: Aged; Aging; Autophagy; CD4-Positive T-Lymphocytes; Cytokines; Humans; Inflammation; Metformin; Mito | 2020 |
Metformin Enhances Autophagy and Normalizes Mitochondrial Function to Alleviate Aging-Associated Inflammation.
Topics: Adult; Aging; Autophagy; Humans; Hypoglycemic Agents; Inflammation; Metformin; Middle Aged; Mitochon | 2020 |
Metformin pretreatment suppresses alterations to the articular cartilage ultrastructure and knee joint tissue damage secondary to type 2 diabetes mellitus in rats.
Topics: Animals; Cartilage, Articular; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Hypoglyce | 2020 |
Metabolic benefits of annatto-extracted tocotrienol on glucose homeostasis, inflammation, and gut microbiome.
Topics: Adipokines; Adipose Tissue, White; Animals; Bacteria; Bixaceae; Blood Glucose; Body Weight; Caroteno | 2020 |
Metformin and SARS-CoV-2: mechanistic lessons on air pollution to weather the cytokine/thrombotic storm in COVID-19.
Topics: Aged; Betacoronavirus; Calcium Release Activated Calcium Channels; Coronavirus Infections; COVID-19; | 2020 |
Metformin protects against ischaemic myocardial injury by alleviating autophagy-ROS-NLRP3-mediated inflammatory response in macrophages.
Topics: Adenosine Triphosphate; Animals; Autophagy; DNA, Mitochondrial; Female; Hemodynamics; Hydrogen Perox | 2020 |
Metformin loaded phosphatidylserine nanoliposomes improve memory deficit and reduce neuroinflammation in streptozotocin-induced Alzheimer's disease model.
Topics: Alzheimer Disease; Animals; Cytokines; Disease Models, Animal; Hippocampus; Inflammation; Liposomes; | 2020 |
Role of TRPV1/TRPV3 channels in olanzapine-induced metabolic alteration: Possible involvement in hypothalamic energy-sensing, appetite regulation, inflammation and mesolimbic pathway.
Topics: Animals; Appetite Regulation; Capsaicin; Coloring Agents; Energy Metabolism; Female; Furans; Gene Ex | 2020 |
The possible role of progranulin on anti-inflammatory effects of metformin in temporal lobe epilepsy.
Topics: Animals; Anti-Inflammatory Agents; Cytokines; Disease Models, Animal; Epilepsy, Temporal Lobe; Glial | 2020 |
Peanut skin extract ameliorates the symptoms of type 2 diabetes mellitus in mice by alleviating inflammation and maintaining gut microbiota homeostasis.
Topics: Animals; Anti-Inflammatory Agents; Arachis; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; E | 2020 |
Metformin reduces saturated fatty acid-induced lipid accumulation and inflammatory response by restoration of autophagic flux in endothelial cells.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Carnitine O-Palmitoyltransferase; Endothelium, Va | 2020 |
Metformin suppresses inflammation and apoptosis of myocardiocytes by inhibiting autophagy in a model of ischemia-reperfusion injury.
Topics: Animals; Apoptosis; Autophagy; Drug Evaluation, Preclinical; Hypoglycemic Agents; Inflammation; Male | 2020 |
Metformin improves depressive-like symptoms in mice via inhibition of peripheral and central NF-κB-NLRP3 inflammation activation.
Topics: Animals; Inflammation; Interleukin-1beta; Metformin; Mice; NF-kappa B; NLR Family, Pyrin Domain-Cont | 2020 |
Pilosocereus gounellei (Cactaceae) stem extract decreases insulin resistance, inflammation, oxidative stress, and cardio-metabolic risk in diet-induced obese mice.
Topics: Animals; Cactaceae; Cardiovascular Diseases; Cytokines; Diet, High-Fat; Hyperglycemia; Inflammation; | 2021 |
Metformin and silymarin afford protection in cyclosporine A induced hepatorenal toxicity in rat by modulating redox status and inflammation.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cyclosporine; Inflammation; Kidney Diseases; Male; | 2021 |
AMPK regulation of Raptor and TSC2 mediate metformin effects on transcriptional control of anabolism and inflammation.
Topics: AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Gene Expr | 2020 |
Next steps in mechanisms of inflammaging.
Topics: Aged; Aging; Autophagy; Humans; Inflammation; Metformin; Mitochondria; Reactive Oxygen Species | 2020 |
Therapeutic effect of metformin on inflammation and apoptosis after spinal cord injury in rats through the Wnt/β-catenin signaling pathway.
Topics: Animals; Apoptosis; Inflammation; Male; Metformin; Neuroprotective Agents; Rats, Sprague-Dawley; Spi | 2020 |
Metformin alleviates high glucose-induced ER stress and inflammation by inhibiting the interaction between caveolin1 and AMPKα in rat astrocytes.
Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Astrocytes; Caveolin 1; Cells, Cul | 2021 |
Metformin ameliorates olanzapine-induced insulin resistance via suppressing macrophage infiltration and inflammatory responses in rats.
Topics: Adipose Tissue; Animals; Anti-Inflammatory Agents; Blood Glucose; Cytokines; Disease Models, Animal; | 2021 |
Effects of inflammatory and anti-inflammatory environments on the macrophage mitochondrial function.
Topics: Animals; Citric Acid Cycle; Inflammation; Interleukin-10; Interleukin-6; Lipopolysaccharides; Macrop | 2020 |
Insulin inhibits inflammation-induced cone death in retinal detachment.
Topics: Adult; Animals; Cell Death; Eye Proteins; Female; Glucose; Humans; Hypoglycemic Agents; Inflammation | 2020 |
Metformin protects chondrocytes against IL-1β induced injury by regulation of the AMPK/NF-κ B signaling pathway.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Cell Line; Cell Survival; Cells, Cultured; Chondr | 2020 |
Combination of metformin and chlorogenic acid attenuates hepatic steatosis and inflammation in high-fat diet fed mice.
Topics: Animals; Anti-Inflammatory Agents; Chlorogenic Acid; Diet, High-Fat; Glucose Intolerance; Hypoglycem | 2021 |
Short-term Effects of Metformin on Cardiac and Peripheral Blood Cells Following Cecal Ligation and Puncture-induced Sepsis.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Biomarkers; Blood Cells; Cecum; Disease Models, Ani | 2021 |
Metformin ameliorates the status epilepticus- induced hippocampal pathology through possible mTOR modulation.
Topics: Animals; Anti-Inflammatory Agents; Cytokines; Disease Models, Animal; Dose-Response Relationship, Dr | 2021 |
Metformin alleviates allergic airway inflammation and increases Treg cells in obese asthma.
Topics: Animals; Anti-Inflammatory Agents; Asthma; Body Weight; Bronchoalveolar Lavage Fluid; CD4 Lymphocyte | 2021 |
Metformin alleviates inflammation in oxazolone induced ulcerative colitis in rats: plausible role of sphingosine kinase 1/sphingosine 1 phosphate signaling pathway.
Topics: Animals; Colitis, Ulcerative; Colon; Inflammation; Lysophospholipids; Male; Metformin; Oxazolone; Ph | 2021 |
Metforminium Decavanadate (MetfDeca) Treatment Ameliorates Hippocampal Neurodegeneration and Recognition Memory in a Metabolic Syndrome Model.
Topics: Animals; Catalase; Drug Combinations; Hippocampus; Inflammation; Male; Memory; Metabolic Syndrome; M | 2021 |
Combination of bis (α-furancarboxylato) oxovanadium (IV) and metformin improves hepatic steatosis through down-regulating inflammatory pathways in high-fat diet-induced obese C57BL/6J mice.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diet, | 2021 |
The aberrant expression of CD69 on peripheral T-helper cells in diet-induced inflammation is ameliorated by low-dose aspirin and metformin treatment.
Topics: Animals; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Aspirin; Blood Glucose; Diabetes Mel | 2021 |
Metformin activated AMPK signaling contributes to the alleviation of LPS-induced inflammatory responses in bovine mammary epithelial cells.
Topics: AMP-Activated Protein Kinases; Animals; Cattle; Cells, Cultured; Epithelial Cells; Female; Inflammat | 2021 |
Effects of metformin on lipopolysaccharide induced inflammation by activating fibroblast growth factor 21.
Topics: Animals; Fibroblast Growth Factors; Inflammation; Lipopolysaccharides; Liver; Male; Metformin; Rats; | 2022 |
Hepatoprotective Effects of Polydatin-Loaded Chitosan Nanoparticles in Diabetic Rats: Modulation of Glucose Metabolism, Oxidative Stress, and Inflammation Biomarkers.
Topics: Animals; Chitosan; Diabetes Mellitus, Experimental; Glucose; Glucosides; Inflammation; Lipid Peroxid | 2021 |
Metformin and Probiotics Interplay in Amelioration of Ethanol-Induced Oxidative Stress and Inflammatory Response in an
Topics: Animals; Chemical and Drug Induced Liver Injury; Endoplasmic Reticulum Stress; Ethanol; Hep G2 Cells | 2021 |
Metformin protects against neuroinflammation through integrated mechanisms of miR-141 and the NF-ĸB-mediated inflammasome pathway in a diabetic mouse model.
Topics: Animals; Brain; Computational Biology; Diabetes Mellitus, Experimental; Inflammasomes; Inflammation; | 2021 |
Reduced Mortality Associated With the Use of Metformin Among Patients With Autoimmune Diseases.
Topics: Aged; Anti-Inflammatory Agents; Autoimmune Diseases; Cell Proliferation; Databases, Factual; Diabete | 2021 |
The therapeutic role of lactobacillus and montelukast in combination with metformin in diabetes mellitus complications through modulation of gut microbiota and suppression of oxidative stress.
Topics: Acetates; Animals; Cyclopropanes; Cytochrome P-450 CYP1A2 Inducers; Diabetes Complications; Diabetes | 2021 |
Augmentation of RBP4/STRA6 signaling leads to insulin resistance and inflammation and the plausible therapeutic role of vildagliptin and metformin.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; Animals; Diet, High-Fat; Glucose; Hypoglycemic Agents; Inf | 2021 |
Validation of an adipose-liver human-on-a-chip model of NAFLD for preclinical therapeutic efficacy evaluation.
Topics: Adipocytes; Adipose Tissue, White; Cell Communication; Cells, Cultured; Culture Media; Culture Media | 2021 |
Metformin in Combination with Malvidin Prevents Progression of Non-Alcoholic Fatty Liver Disease via Improving Lipid and Glucose Metabolisms, and Inhibiting Inflammation in Type 2 Diabetes Rats.
Topics: Animals; Anthocyanins; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Progressi | 2021 |
Metformin in combination with genistein ameliorates skeletal muscle inflammation in high-fat diet fed c57BL/6 mice.
Topics: Animals; Diet, High-Fat; Drug Therapy, Combination; Genistein; Glucose Intolerance; Hypolipidemic Ag | 2021 |
Metformin intervention ameliorates AS in ApoE-/- mice through restoring gut dysbiosis and anti-inflammation.
Topics: Animals; Anti-Inflammatory Agents; Apolipoproteins E; Atherosclerosis; Dysbiosis; Fatty Acids, Volat | 2021 |
Potential effect of EGCG on the anti-tumor efficacy of metformin in melanoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Catechin; Cell Line, Tumor; Cell Movement; Cell Nucleus; | 2021 |
Metformin inhibits polyphosphate-induced hyper-permeability and inflammation.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Anti-Inflammatory Agents; Capillary Permeability; Cel | 2021 |
Decreased SFRP5 correlated with excessive metabolic inflammation in polycystic ovary syndrome could be reversed by metformin: implication of its role in dysregulated metabolism.
Topics: Adaptor Proteins, Signal Transducing; Adult; Case-Control Studies; Female; Humans; Inflammation; Met | 2021 |
Obesity increases neuropathic pain via the AMPK-ERK-NOX4 pathway in rats.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Apoptosis; Butadienes; Diet, Hig | 2021 |
Pharmacological activation of SIRT1 by metformin prevented trauma-induced heterotopic ossification through inhibiting macrophage mediated inflammation.
Topics: Animals; Burns; Disease Models, Animal; Humans; Inflammation; Macrophages; Male; Metformin; Mice; Os | 2021 |
The effect of dapsone in testosterone enanthate-induced polycystic ovary syndrome in rat.
Topics: Androgens; Animals; Cytokines; Dapsone; Female; Inflammation; Metformin; Ovary; Polycystic Ovary Syn | 2021 |
Metformin directly binds the alarmin HMGB1 and inhibits its proinflammatory activity.
Topics: Animals; Antibodies, Neutralizing; HMGB1 Protein; Humans; Inflammation; Metformin; Mice; Protein Bin | 2017 |
Pathophysiological explanation of cardiovascular benefits of sodium-glucose cotransporter-2 inhibitors by neurotrophic theory.
Topics: Adipose Tissue; Brain-Derived Neurotrophic Factor; Cardiovascular Diseases; Cytokines; Diabetes Mell | 2017 |
Metformin Attenuates Neurological Deficit after Intracerebral Hemorrhage by Inhibiting Apoptosis, Oxidative Stress and Neuroinflammation in Rats.
Topics: Animals; Antioxidants; Apoptosis; Brain Injuries; Cerebral Hemorrhage; Disease Models, Animal; Infla | 2017 |
Metformin exerts anti-obesity effect via gut microbiome modulation in prediabetics: A hypothesis.
Topics: Animals; Anti-Obesity Agents; Butyrates; Diabetes Mellitus, Type 2; Gastrointestinal Microbiome; Hor | 2017 |
Metformin maintains mucosal integrity in experimental model of colitis by inhibiting oxidative stress and pro-inflammatory signaling.
Topics: Animals; Anti-Inflammatory Agents; Biomarkers; Colitis, Ulcerative; Colon; Cyclooxygenase 2; Disease | 2017 |
Effects of metformin on inflammation, oxidative stress, and bone loss in a rat model of periodontitis.
Topics: Alveolar Bone Loss; Animals; Disease Models, Animal; Gingiva; Glutathione Peroxidase; Glutathione Pe | 2017 |
Scopoletin Supplementation Ameliorates Steatosis and Inflammation in Diabetic Mice.
Topics: Animals; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Diet, High-Fat; Dietary Supple | 2017 |
Metformin improves obesity-associated inflammation by altering macrophages polarization.
Topics: Adenylate Kinase; Adipose Tissue; Animals; Cell Polarity; Cytokines; Diet, High-Fat; Glucose; Inflam | 2018 |
Attenuation of Myeloid-Specific TGFβ Signaling Induces Inflammatory Cerebrovascular Disease and Stroke.
Topics: Animals; Cell Line; Immunosuppressive Agents; Inflammation; Metformin; Methotrexate; Mice; Mice, Inb | 2017 |
Synthesis, Characterization, and Biological Evaluations of 1,3,5-Triazine Derivatives of Metformin Cyclization with Berberine and Magnolol in the Presence of Sodium Methylate.
Topics: Anti-Inflammatory Agents; Berberine; Biphenyl Compounds; Cyclization; Humans; Inflammation; Insulin | 2017 |
Metformin attenuates susceptibility to inflammation-induced preterm birth in mice with higher endocannabinoid levels.
Topics: Amidohydrolases; Animals; Decidua; Endocannabinoids; Female; Hypoglycemic Agents; Inflammation; Lipo | 2018 |
Stachyose Improves Inflammation through Modulating Gut Microbiota of High-Fat Diet/Streptozotocin-Induced Type 2 Diabetes in Rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diet, High-Fat; Gastrointestinal Microbiome; Inflammation; | 2018 |
Aberrant intestinal microbiota in individuals with prediabetes.
Topics: Aged; Animals; Anthropometry; Biomarkers; Blood Glucose; Case-Control Studies; Denmark; Diabetes Mel | 2018 |
Metformin attenuates folic-acid induced renal fibrosis in mice.
Topics: Albuminuria; Animals; Cell Line; Chemokine CCL2; Collagen Type IV; Disease Models, Animal; Extracell | 2018 |
Antitumor effects of metformin are a result of inhibiting nuclear factor kappa B nuclear translocation in esophageal squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Ce | 2018 |
A complex systems approach to cancer prevention.
Topics: beta-Glucans; Decision Support Techniques; Diet; Drug Synergism; Energy Metabolism; Exercise; Glucos | 2018 |
Short-term treatment with metformin reduces hepatic lipid accumulation but induces liver inflammation in obese mice.
Topics: Animals; Cytokines; Diet, High-Fat; Enzyme-Linked Immunosorbent Assay; Hepatocytes; Inflammation; Li | 2018 |
Metformin ameliorates the progression of atherosclerosis via suppressing macrophage infiltration and inflammatory responses in rabbits.
Topics: Animals; Aorta; Atherosclerosis; C-Reactive Protein; Cell Adhesion; Cell Differentiation; Cell Line, | 2018 |
Metformin suppresses retinal angiogenesis and inflammation in vitro and in vivo.
Topics: Animals; Apoptosis; Cell Movement; Cell Proliferation; Cells, Cultured; Endothelial Cells; Humans; H | 2018 |
Neuroprotective effects of metformin on traumatic brain injury in rats associated with NF-κB and MAPK signaling pathway.
Topics: Animals; Brain; Brain Injuries, Traumatic; Disease Models, Animal; Extracellular Signal-Regulated MA | 2018 |
Novel Mechanisms Modulating Palmitate-Induced Inflammatory Factors in Hypertrophied 3T3-L1 Adipocytes by AMPK.
Topics: 3T3-L1 Cells; Adenylate Kinase; Adipocytes; Aminoimidazole Carboxamide; Animals; Chemokine CCL2; Inf | 2018 |
Inflammatory signatures distinguish metabolic health in African American women with obesity.
Topics: Biomarkers; Black or African American; Chemokines; Cytokines; Diabetes Mellitus, Type 2; Female; Gly | 2018 |
The AMPK agonist 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), but not metformin, prevents inflammation-associated cachectic muscle wasting.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinase Kinases; Animals; Cachexia; Cell Line; Enzy | 2018 |
Metformin alleviated endotoxemia-induced acute lung injury via restoring AMPK-dependent suppression of mTOR.
Topics: Acute Lung Injury; AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Cytokines; Endo | 2018 |
Anti-inflammatory effects of Metformin improve the neuropathic pain and locomotor activity in spinal cord injured rats: introduction of an alternative therapy.
Topics: Animals; Central Nervous System Agents; Disease Models, Animal; Hyperalgesia; Inflammation; Locomoti | 2018 |
Metformin Protects against LPS-Induced Intestinal Barrier Dysfunction by Activating AMPK Pathway.
Topics: Administration, Oral; AMP-Activated Protein Kinases; Animals; Disease Models, Animal; Humans; Inflam | 2018 |
Metformin protects bone mass in ultra-high-molecular-weight polyethylene particle-induced osteolysis by regulating osteocyte secretion.
Topics: Adaptor Proteins, Signal Transducing; Adenylate Kinase; Animals; Bone and Bones; Cell Differentiatio | 2019 |
Metformin inhibits mTOR-HIF-1α axis and profibrogenic and inflammatory biomarkers in thioacetamide-induced hepatic tissue alterations.
Topics: Animals; Biomarkers; Chronic Disease; Hepatocytes; Hypoxia-Inducible Factor 1, alpha Subunit; Inflam | 2019 |
Eugenol ameliorates insulin resistance, oxidative stress and inflammation in high fat-diet/streptozotocin-induced diabetic rat.
Topics: AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; | 2019 |
Metformin inhibits pro-inflammatory responses via targeting nuclear factor-κB in HaCaT cells.
Topics: Cells, Cultured; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Inflammation; Metfor | 2019 |
Metformin associated inflammation levels regulation in type 2 diabetes mellitus-tuberculosis coinfection patients - A case report.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Inflammation; Interleukin-10; | 2018 |
Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish.
Topics: Animals; Animals, Genetically Modified; Carcinoma, Hepatocellular; Cell Polarity; Diet, High-Fat; Di | 2019 |
mTOR inhibition by metformin impacts monosodium urate crystal-induced inflammation and cell death in gout: a prelude to a new add-on therapy?
Topics: Cell Death; Cytokines; Gout; Humans; Inflammation; Metformin; Monocytes; Signal Transduction; TOR Se | 2019 |
Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes.
Topics: Actins; Ceruloplasmin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gene Expression | 2019 |
Metformin alleviates inflammatory response in non-alcoholic steatohepatitis by restraining signal transducer and activator of transcription 3-mediated autophagy inhibition in vitro and in vivo.
Topics: Animals; Autophagy; Inflammation; Male; Metformin; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Dis | 2019 |
Analysis of Inflammatory Gene Expression Profile of Peripheral Blood Leukocytes in Type 2 Diabetes.
Topics: Adult; Aged; Aged, 80 and over; Caspase 1; Chemokine CCL5; Diabetes Mellitus, Type 2; Female; Gene E | 2019 |
Metformin shows anti-inflammatory effects in murine macrophages through Dicer/microribonucleic acid-34a-5p and microribonucleic acid-125b-5p.
Topics: Animals; Anti-Inflammatory Agents; Biomarkers; Cytokines; DEAD-box RNA Helicases; Hypoglycemic Agent | 2020 |
Endoplasmic reticulum stress-induced iRhom2 up-regulation promotes macrophage-regulated cardiac inflammation and lipid deposition in high fat diet (HFD)-challenged mice: Intervention of fisetin and metformin.
Topics: Animals; Body Weight; Carrier Proteins; Diet, High-Fat; Echocardiography; Endoplasmic Reticulum Stre | 2019 |
Inulin and metformin ameliorate polycystic ovary syndrome via anti-inflammation and modulating gut microbiota in mice.
Topics: Animals; Anti-Inflammatory Agents; Bacteria; Biomarkers; Cytokines; Dehydroepiandrosterone; Diet, Hi | 2019 |
Oral contraceptive use increases risk of inflammatory and coagulatory disorders in women with Polycystic Ovarian Syndrome: An observational study.
Topics: Adult; Body Mass Index; Coagulation Protein Disorders; Contraceptives, Oral; Ethinyl Estradiol; Fema | 2019 |
Metformin modulates cardiac endothelial dysfunction, oxidative stress and inflammation in irradiated rats: A new perspective of an antidiabetic drug.
Topics: Animals; Catalase; Endothelium, Vascular; Gamma Rays; Heart; Inflammation; Male; Metformin; Myocardi | 2019 |
Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-κB activation.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Culture Media, Conditioned; Cyto | 2013 |
Maternal metformin treatment decreases fetal inflammation in a rat model of obesity and metabolic syndrome.
Topics: Animals; Diet, High-Fat; Dietary Carbohydrates; Female; Fetus; Inflammation; Interleukin-6; Male; Me | 2013 |
[Effect of metformin on the expression of tumor necrosis factor-α, Toll like receptors 2/4 and C reactive protein in obese type-2 diabetic patients].
Topics: Biomarkers; Body Mass Index; C-Reactive Protein; Case-Control Studies; Diabetes Mellitus, Type 2; Hu | 2012 |
Inflammation and cognitive dysfunction in type 2 diabetic carotid endarterectomy patients.
Topics: Aged; Cognition Disorders; Diabetes Mellitus, Type 2; Endarterectomy, Carotid; Glyburide; Humans; Hy | 2013 |
Inflammation and cognitive dysfunction in type 2 diabetic carotid endarterectomy patients.
Topics: Aged; Cognition Disorders; Diabetes Mellitus, Type 2; Endarterectomy, Carotid; Glyburide; Humans; Hy | 2013 |
Inflammation and cognitive dysfunction in type 2 diabetic carotid endarterectomy patients.
Topics: Aged; Cognition Disorders; Diabetes Mellitus, Type 2; Endarterectomy, Carotid; Glyburide; Humans; Hy | 2013 |
Inflammation and cognitive dysfunction in type 2 diabetic carotid endarterectomy patients.
Topics: Aged; Cognition Disorders; Diabetes Mellitus, Type 2; Endarterectomy, Carotid; Glyburide; Humans; Hy | 2013 |
An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice.
Topics: Animals; Biomarkers; Blood Glucose; Diet, High-Fat; Drug Administration Schedule; Flow Cytometry; Ho | 2014 |
The combined effect of metformin and L-cysteine on inflammation, oxidative stress and insulin resistance in streptozotocin-induced type 2 diabetes in rats.
Topics: Animals; Body Weight; C-Reactive Protein; Caspase 3; Chemokine CCL2; Cysteine; Cytochromes c; Diabet | 2013 |
Metformin improves healthspan and lifespan in mice.
Topics: AMP-Activated Protein Kinases; Animals; Antioxidants; Biomarkers; Caloric Restriction; Electron Tran | 2013 |
Metformin improves healthspan and lifespan in mice.
Topics: AMP-Activated Protein Kinases; Animals; Antioxidants; Biomarkers; Caloric Restriction; Electron Tran | 2013 |
Metformin improves healthspan and lifespan in mice.
Topics: AMP-Activated Protein Kinases; Animals; Antioxidants; Biomarkers; Caloric Restriction; Electron Tran | 2013 |
Metformin improves healthspan and lifespan in mice.
Topics: AMP-Activated Protein Kinases; Animals; Antioxidants; Biomarkers; Caloric Restriction; Electron Tran | 2013 |
Metformin improves healthspan and lifespan in mice.
Topics: AMP-Activated Protein Kinases; Animals; Antioxidants; Biomarkers; Caloric Restriction; Electron Tran | 2013 |
Metformin improves healthspan and lifespan in mice.
Topics: AMP-Activated Protein Kinases; Animals; Antioxidants; Biomarkers; Caloric Restriction; Electron Tran | 2013 |
Metformin improves healthspan and lifespan in mice.
Topics: AMP-Activated Protein Kinases; Animals; Antioxidants; Biomarkers; Caloric Restriction; Electron Tran | 2013 |
Metformin improves healthspan and lifespan in mice.
Topics: AMP-Activated Protein Kinases; Animals; Antioxidants; Biomarkers; Caloric Restriction; Electron Tran | 2013 |
Metformin improves healthspan and lifespan in mice.
Topics: AMP-Activated Protein Kinases; Animals; Antioxidants; Biomarkers; Caloric Restriction; Electron Tran | 2013 |
Activation of the AMP-activated protein kinase reduces inflammatory nociception.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Behavior, Animal; Enzyme Activat | 2013 |
Inflammation and insulin resistance exert dual effects on adipose tissue tumor protein 53 expression.
Topics: Adipocytes; Adipogenesis; Adipose Tissue; Analysis of Variance; Animals; Bariatric Surgery; Diet, Hi | 2014 |
Blockade of reactive oxygen species and Akt activation is critical for anti-inflammation and growth inhibition of metformin in phosphatase and tensin homolog-deficient RAW264.7 cells.
Topics: Animals; Cell Line; Cell Proliferation; Enzyme Activation; Gene Knockdown Techniques; Hypoglycemic A | 2013 |
Metformin decreases high-fat diet-induced renal injury by regulating the expression of adipokines and the renal AMP-activated protein kinase/acetyl-CoA carboxylase pathway in mice.
Topics: Acetyl-CoA Carboxylase; Adipokines; AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Glucose | 2013 |
Angiotensin II receptor blocker telmisartan prevents new-onset diabetes in pre-diabetes OLETF rats on a high-fat diet: evidence of anti-diabetes action.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Blood Pr | 2013 |
Reply: To PMID 23659985.
Topics: Animals; Female; Fetus; Inflammation; Male; Metabolic Syndrome; Metformin; Obesity; Pregnancy | 2014 |
Maternal metformin, obesity, and metabolic syndrome: the contribution of autonomic nervous system function.
Topics: Animals; Female; Fetus; Inflammation; Male; Metabolic Syndrome; Metformin; Obesity; Pregnancy | 2014 |
Metformin attenuates the exacerbation of the allergic eosinophilic inflammation in high fat-diet-induced obesity in mice.
Topics: AMP-Activated Protein Kinases; Animals; Asthma; Blotting, Western; Bronchoalveolar Lavage Fluid; Die | 2013 |
Endothelial cellular senescence is inhibited by liver X receptor activation with an additional mechanism for its atheroprotection in diabetes.
Topics: Administration, Oral; Animals; Aorta; Atherosclerosis; Cellular Senescence; Densitometry; Diabetes C | 2014 |
Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity.
Topics: Adipose Tissue; Animals; Diet, High-Fat; Disease Models, Animal; Fatty Liver; Glucose; Glucose Intol | 2014 |
Metformin affects macrophages' phenotype and improves the activity of glutathione peroxidase, superoxide dismutase, catalase and decreases malondialdehyde concentration in a partially AMPK-independent manner in LPS-stimulated human monocytes/macrophages.
Topics: AMP-Activated Protein Kinases; Antioxidants; Atherosclerosis; Catalase; Cytokines; Female; Glutathio | 2014 |
Metformin suppresses lipopolysaccharide (LPS)-induced inflammatory response in murine macrophages via activating transcription factor-3 (ATF-3) induction.
Topics: Activating Transcription Factor 3; AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; | 2014 |
Partial hepatic resistance to IL-6-induced inflammation develops in type 2 diabetic mice, while the anti-inflammatory effect of AMPK is maintained.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Blood | 2014 |
Impaired fibrous repair: a possible contributor to atherosclerotic plaque vulnerability in patients with type II diabetes.
Topics: Aged; Antihypertensive Agents; Carotid Artery Diseases; Cytokines; Diabetes Mellitus, Type 2; Diseas | 2014 |
Chronic Metformin Preconditioning Provides Neuroprotection via Suppression of NF-κB-Mediated Inflammatory Pathway in Rats with Permanent Cerebral Ischemia.
Topics: Acute Disease; Animals; Astrocytes; Brain; Brain Ischemia; Calcium-Binding Proteins; Cytokines; Glia | 2015 |
Glucose and metformin modulate human first trimester trophoblast function: a model and potential therapy for diabetes-associated uteroplacental insufficiency.
Topics: Angiogenesis Inducing Agents; Antigens, CD; Carrier Proteins; Cell Line; Cell Movement; Chemokine CC | 2015 |
Association between ferritin and hepcidin levels and inflammatory status in patients with type 2 diabetes mellitus and obesity.
Topics: Adult; Aged; Body Mass Index; C-Reactive Protein; Case-Control Studies; Diabetes Mellitus, Type 2; F | 2015 |
[Metformin ameliorates β-cell dysfunction by regulating inflammation production, ion and hormone homeostasis of pancreas in diabetic KKAy mice].
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Down-Regulation; Female; Glucose Tolerance | 2014 |
Stroke mimicking relapse in a patient with CLIPPERS syndrome.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Brain Stem; Encephalomye | 2015 |
Lipopolysaccharides-Induced Inflammatory Response in White Blood Cells Is Associated with Alterations in Senescence Mediators: Modulation by Metformin.
Topics: Animals; Anti-Inflammatory Agents; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p16; Disea | 2015 |
Impact of diabetes type II and chronic inflammation on pancreatic cancer.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Cell Death; Cell Line, Tumor; Cell | 2015 |
Increased Plasma Levels of Xanthurenic and Kynurenic Acids in Type 2 Diabetes.
Topics: 3-Hydroxyanthranilic Acid; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agen | 2015 |
New Insight Into Metformin Action: Regulation of ChREBP and FOXO1 Activities in Endothelial Cells.
Topics: Adenylate Kinase; Animals; Aorta; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carri | 2015 |
Metformin suppresses intrahepatic coagulation activation in mice with lipopolysaccharide/D‑galactosamine‑induced fulminant hepatitis.
Topics: Animals; Anti-Inflammatory Agents; Blood Coagulation; Disease Models, Animal; Erythropoietin; Galact | 2015 |
Metformin administration induces hepatotoxic effects in paraoxonase-1-deficient mice.
Topics: Animals; Aryldialkylphosphatase; Fatty Liver; Inflammation; Lipid Peroxides; Liver; Male; Metformin; | 2016 |
The role of metformin and resveratrol in the prevention of hypoxia-inducible factor 1α accumulation and fibrosis in hypoxic adipose tissue.
Topics: 3T3-L1 Cells; Adipose Tissue; Animals; Cells, Cultured; Dose-Response Relationship, Drug; Fibrosis; | 2016 |
Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Survival; Cisplatin; | 2016 |
Metformin preconditioning provide neuroprotection through enhancement of autophagy and suppression of inflammation and apoptosis after spinal cord injury.
Topics: Animals; Apoptosis; Autophagy; Female; Inflammation; Metformin; Neurons; Neuroprotective Agents; NF- | 2016 |
Metformin and resveratrol ameliorate muscle insulin resistance through preventing lipolysis and inflammation in hypoxic adipose tissue.
Topics: 3T3-L1 Cells; Adipose Tissue; Administration, Oral; Animals; Cyclic AMP; Cyclic AMP-Dependent Protei | 2016 |
Additional effect of metformin and celecoxib against lipid dysregulation and adipose tissue inflammation in high-fat fed rats with insulin resistance and fatty liver.
Topics: Adipocytes; Adipokines; Adipose Tissue; AMP-Activated Protein Kinases; Animals; Blood Pressure; Body | 2016 |
Redefining the role of peripheral LPS as a neuroinflammatory agent and evaluating the role of hydrogen sulphide through metformin intervention.
Topics: Animals; Hydrogen Sulfide; Hypoglycemic Agents; Inflammation; Inflammation Mediators; Lipopolysaccha | 2016 |
Association of diabetes and diabetes treatment with the host response in critically ill sepsis patients.
Topics: Aged; Biomarkers; Chemokine CX3CL1; Critical Illness; Diabetes Mellitus; E-Selectin; Female; Humans; | 2016 |
Protective Effect of Metformin against Acute Inflammation and Oxidative Stress in Rat.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents; Carrageenan; Catalase; Diclofenac; Disease Models, | 2016 |
The suppressive effects of metformin on inflammatory response of otitis media model in human middle ear epithelial cells.
Topics: Blotting, Western; Cell Line; Cyclooxygenase 2; Cytokines; Ear, Middle; Epithelial Cells; Humans; Hy | 2016 |
Metformin Synergizes With Conventional and Adjuvant Analgesic Drugs to Reduce Inflammatory Hyperalgesia in Rats.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemotherapy, Adjuvant; Drug Synergism | 2017 |
Metformin reduces morphine tolerance by inhibiting microglial-mediated neuroinflammation.
Topics: AMP-Activated Protein Kinases; Analgesics, Opioid; Animals; Calcium-Binding Proteins; Cell Line, Tra | 2016 |
Beneficial Effects of Metformin and/or Salicylate on Palmitate- or TNFα-Induced Neuroinflammatory Marker and Neuropeptide Gene Regulation in Immortalized NPY/AgRP Neurons.
Topics: Agouti-Related Protein; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Cells, Culture | 2016 |
Metformin activation of AMPK suppresses AGE-induced inflammatory response in hNSCs.
Topics: AMP-Activated Protein Kinases; Apoptosis; Blotting, Western; Cell Proliferation; Cells, Cultured; Gl | 2017 |
Intensification of oxidative stress and inflammation in type 2 diabetes despite antihyperglycemic treatment.
Topics: Adult; Aged; Apoptosis; C-Reactive Protein; Case-Control Studies; CD11b Antigen; Diabetes Mellitus, | 2008 |
Metformin inhibits inflammatory angiogenesis in a murine sponge model.
Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Chemokine CCL2; Chemotaxis, Leukocyte; C | 2010 |
The anti-atherogenic aspect of metformin treatment in insulin resistant women with the polycystic ovary syndrome: role of the newly established pro-inflammatory adipokine Acute-phase Serum Amyloid A; evidence of an adipose tissue-monocyte axis.
Topics: Adipokines; Adipose Tissue; Adult; Animals; Atherosclerosis; Case-Control Studies; Female; Humans; I | 2011 |
Activated AMPK and prostaglandins are involved in the response to conjugated linoleic acid and are sufficient to cause lipid reductions in adipocytes.
Topics: 3T3-L1 Cells; Adipocytes; AMP-Activated Protein Kinases; Animals; Inflammation; Linoleic Acids, Conj | 2011 |
Metformin restores endothelial function in aorta of diabetic rats.
Topics: Animals; Aorta; Biomarkers; Cell Adhesion Molecules; Diabetes Mellitus, Type 2; Endothelium, Vascula | 2011 |
Metformin counters both lipolytic/inflammatory agents-decreased hormone sensitive lipase phosphorylation at Ser-554 and -induced lipolysis in human adipocytes.
Topics: 1-Methyl-3-isobutylxanthine; Adipocytes; Adult; Aged; Colforsin; Female; Humans; Hypoglycemic Agents | 2011 |
Anti-inflammatory and anti-hyperlipidemic effect of Semecarpus anacardium in a high fat diet: STZ-induced type 2 diabetic rat model.
Topics: Animals; Anti-Inflammatory Agents; C-Reactive Protein; Diabetes Mellitus, Experimental; Diabetes Mel | 2013 |
Metformin-mediated Bambi expression in hepatic stellate cells induces prosurvival Wnt/β-catenin signaling.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Apoptosis; beta Catenin; Hepatic | 2012 |
Metformin inhibits inflammatory response via AMPK-PTEN pathway in vascular smooth muscle cells.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Cells, Cultured; Hypoglycemic Agents; Inflammation; M | 2012 |
Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth.
Topics: Animals; Anticarcinogenic Agents; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Transformation | 2013 |
Metformin prevents endotoxin-induced liver injury after partial hepatectomy.
Topics: Animals; Carbohydrate Metabolism; Cytokines; Hepatectomy; Hypoglycemic Agents; Inflammation; Lipopol | 2006 |
Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation.
Topics: Abdominal Fat; Biomarkers; Biopsy; Body Mass Index; Cytokines; Gene Expression; Glucose Intolerance; | 2007 |
Metformin suppresses interleukin (IL)-1beta-induced IL-8 production, aromatase activation, and proliferation of endometriotic stromal cells.
Topics: Adult; Antimetabolites; Aromatase; Biomarkers; Bromodeoxyuridine; Cell Separation; Cell Survival; Ce | 2007 |
Metformin suppresses interleukin (IL)-1beta-induced IL-8 production, aromatase activation, and proliferation of endometriotic stromal cells.
Topics: Adult; Antimetabolites; Aromatase; Biomarkers; Bromodeoxyuridine; Cell Separation; Cell Survival; Ce | 2007 |
Metformin suppresses interleukin (IL)-1beta-induced IL-8 production, aromatase activation, and proliferation of endometriotic stromal cells.
Topics: Adult; Antimetabolites; Aromatase; Biomarkers; Bromodeoxyuridine; Cell Separation; Cell Survival; Ce | 2007 |
Metformin suppresses interleukin (IL)-1beta-induced IL-8 production, aromatase activation, and proliferation of endometriotic stromal cells.
Topics: Adult; Antimetabolites; Aromatase; Biomarkers; Bromodeoxyuridine; Cell Separation; Cell Survival; Ce | 2007 |
Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone.
Topics: Adipose Tissue; Adult; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Biomarkers; Body Mas | 2007 |
[Inflammation, atherosclerosis, classic cardiovascular risk factors, biostatistics, clinical significance. Where are we?].
Topics: Acute Coronary Syndrome; Atherosclerosis; Biometry; Dyslipidemias; Fluorobenzenes; Humans; Hydroxyme | 2007 |
[Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia].
Topics: Analysis of Variance; Dyslipidemias; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutary | 2007 |